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Pediatrics is rapidly evolving, and the diagnostic tools are expanding the spectrum of diagnoses
that can be identified at the bedside. The recent progress identified in pediatrics of the last 20
years is astonishing and has consolidated the concept that children are not “smaller adults” and
indeed, perinatal and pediatric pathology has become an independent subspecialty in pathology with
impressive intersections with fetal medicine, neonatology, and pediatrics. The neonatal intensive care
unit (NICU) as well as the pediatric intensive care unit (PICU) play a major role in modern hospitals.
These sections of the hospital provide sick newborns and children with the highest level of medical care.
Differently from the general medical floors, both units allow intensive nursing care and continuous
monitoring of vital parameters, including heart rate, breathing, and blood pressure. The survival of
premature babies and small for date newborns has increased exponentially in the last few decades.
On the other hand, the immune system, as well as the pulmonary and gastrointestinal organs, remain
difficult to manage. At this age an increased rate of infection has been identified, and gastrointestinal
dysfunction is common [1–6]. Cardiovascular function and sepsis are intimately related and may
trigger early death without NICU or PICU intervention [7]. Although the diagnostic procedures in
newborns are often overlapping with diagnostic algorithms used at older age, they continue to be a
complex and dynamic process which requires a proper investigation of the obstetrical and medical
history, skillful physical examination, appropriate laboratory tests, and imaging studies with or without
pathological examination of tissue biopsies. On the other hand, even with these steps, diagnosis
may remain elusive. The journey from the first appearance of symptom or sign to the final diagnosis
may seem sometimes interminable. Today, new techniques seem to shorten this journey swiftly, and
next-generation sequencing (NGS) will play a major role in the next decade. NGS is becoming more
and more used in clinics other than in academia, although one of the most challenging aspects of
NGS testing may reside in its analytical validity. The field of metabolomics is indeed developing
at a remarkable rate, particularly in pediatrics. Over the last few years, the pre-clinical detection of
pathologies has become more robust and efficient. In electronic libraries, new biomarkers are being
identified for several pathologies in neonatology and pediatrics. Management of pediatric diseases
may become extenuating, and the use of single nucleotide polymorphisms for the improvement of our
approach to some pediatric diagnostic algorithmic failures targeting the interindividual variability
may be considered. Pediatric trial networks provide pediatricians, researchers, and agencies with
new information on how children may respond to drugs and medications. The present Special Issue
collects wet lab research and review articles to highlight some fields of pediatrics that may shape
future directions in the diagnosis and management of some diseases. Pediatric heart failure is a
challenge in neonatology and pediatrics, and quality assurance criteria are key [7–11]. An open-heart
surgery with cardiopulmonary bypass (CPB) remains an interventional procedure accompanied
by a high mortality/morbidity rate. Satriano et al. investigated whether blood concentrations of
glutathione (GSH), a powerful endogenous antioxidant, changed in the perioperative period [12].
In the perioperative period, the increase in GSH may suggest that a compensatory mechanism to
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oxidative damage during surgical procedure takes place. The measurement of the interferon (IFN)
score has been suggested for the screening of monogenic interferonopathies, like the Aicardi–Goutières
syndrome. Moreover, it may be useful to stratify subjects with systemic lupus erythematosus before
receiving IFN-targeted treatments. Pin et al. developed an approach to reduce the inter-laboratory
variability [13]. These authors provide shared strategies for the IFN signature analysis. They allow
different centers to compare data and merge their experiences. Diabetic retinopathy (DR) is a dramatic
and major microvascular complication of diabetes mellitus, and very few studies have evidenced the
magnitude of this disorder in the pediatric population [14]. The International Society for Pediatric
and Adolescent Diabetes (ISPAD) mandates that annual screening for DR should be performed in
patients aged 11 years after diabetes of 2 years’ duration and from 9 years of age with diabetes of 5
years’ duration [15]. Kołodziej et al. studied the width of individual retinal layers in patients with
type 1 diabetes (T1DM) correlating their data with markers of diabetes metabolic control applying the
optical coherence tomography (OCT) study performed using a high definition OCT Cirrus 5000 [16].
The authors found a positive correlation between center thickness and spectral-domain for average
glycemia and temporal CT with age at examination, suggesting that selected parameters may be
applied as potential markers of preclinical phase of DR in patients with T1DM. Allen and Gupta
highlight the current and nearest futuristic perspective of “artificial pancreas” suggesting that soon
such a system may not require any manual patient input allowing patients to eat throughout the day
without entering any blood sugars or counting carbohydrates [17]. Such a device may be commercially
available as technology continues to advance in this direction using artificial intelligence. Sarcoidosis is
an inflammatory syndrome of non-necrotizing granulomatous type with multisystemic manifestations,
and its occurrence in pediatrics is not an isolated finding any longer. Few cases have been reported
of this intriguing disease in children and youth [18]. Chiu et al. revised this topic in detail in
this issue [19]. These authors focused on early-onset sarcoidosis, high-risk sarcoidosis, and atypical
sarcoid-related diseases. Blau syndrome and early-onset sarcoidosis occur in children younger than five
years manifesting with extra-thoracic findings but usually without lymphadenopathy and pulmonary
involvement. Endoscopic bronchial ultrasound (EBUS) and transbronchial fine-needle aspiration
(TBNA) sampling of intrathoracic lymph nodes and lung may provide good diagnostic yield and
excellent patient safety profile in childhood. Respiratory syncytial virus (RSV) bronchiolitis remains
an important cause of morbidity in early infancy. RSV belongs to the species of Orthopneumovirus.
The human RSV (HRSV) infects 60% of infants during their first RSV season, and usually all children
show an infection record with this virus by 2–3 years of age [20]. Among the infants infected with RSV,
2–3% will develop bronchiolitis, necessitating hospitalization [21]. RSV bronchiolitis is a major cause
of infection and hospitalization in infancy and childhood worldwide. Palivizumab can be employed to
prevent this infection in preterm babies, infants with certain congenital heart defects (CHD), infants
affected with bronchopulmonary dysplasia (BPD), and infants with congenital malformations of the
airway. HRSV bronchiolitis is treated with supportive care, including oxygen therapy, continuous
positive airway pressure (CPAP) or nasal high flow oxygen, as required. Rodriguez-Gonzalez et al.
identified that left ventricular myocardial dysfunction (LVMD) might occur in healthy infants with
HRSV bronchiolitis who develop severe disease and need to be treated at the PICU [22]. N-terminal
pro-B-type natriuretic peptide (NT-proBNP) seems to increase the accuracy of traditional clinical
markers in predicting the outcomes. Duvekot et al. report a rare event complicating a common
adenotonsillectomy. Subcutaneous and mediastinal emphysema followed by group A beta-hemolytic
streptococci mediastinitis occurred in a young child, reminding us the life-threatening complications of
such surgical procedure [23]. Primary indications for adenotonsillectomy are obstructive sleep apnea
(OSA) and recurrent pharyngotonsillitis. Although there is evidence-based medicine supporting
the use of such surgical procedures on children affected with OSA that is mainly derived on sleep
studies, quality of life, and child behavior, it seems that the impact of surgery on recurrent sore
throat symptoms is less well delineated. It has been indicated that children younger than three years
and children with OSA of moderate to severe degree, as well as infants affected with significant
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comorbidities should be admitted for overnight observation. In most patients, simple analgesia is
adequate postoperatively, while codeine is contraindicated due to cases of postoperative death as
consequence of respiratory suppression. Pain and postoperative hemorrhage (2–4%) are the most
common complications, but bleeding can be life-threatening, nevertheless the mortality rate remains
small but substantial (1:30,000) [24]. Besides tonsillar enlargement, salivary gland enlargement is a
condition which enters in the differential diagnosis of head and neck (H&N) masses. Branchial cysts,
sialadenosis, and inflammation of the salivary glands are often seen in childhood and youth, but
H&N malignant pathologies also need to be taken into consideration. Sergi et al. critically review
the diagnostic features of a pediatric mass of the H&N region [25]. Somatosensory evoked potentials
(SSEPs) are crucial in assessing the functional integrity of the neural pathways and for predicting the
outcome of perinatal injuries. Barkhuizen et al. studied the translational potential of SSEPs together
with sensory function in rodents with perinatal hypoxic-ischemic events [26]. No group differences in
the amplitude or latency of the evoked potentials of the preceding sensory response were seen, but
nevertheless this method of study is intriguing for the functional recovery. Das and van Landeghem
revise the clinicopathological spectrum of bilirubin encephalopathy/kernicterus, which is relatively rare
but continues to occur despite universal newborn screening, particularly in middle and low income
countries [27]. The authors illustrate the array of clinicopathological findings, and the procedures
of diagnostic testing reported to be key in the context of bilirubin encephalopathy and kernicterus.
Khan and Sergi report on sialidosis, which is a rare, autosomal recessive inherited disorder, caused by
α-N-acetyl neuraminidase deficiency resulting from a mutation in the neuraminidase gene (NEU1)
and accompanied by cerebral and extra-cerebral manifestations combining the underlying molecular
biology, the clinical features, and the morphological patterns of this disorder [28].
Finally, the attention should be drawn to the frontispiece of this book. It is a photograph of a
famous sculpture of Horatio Greenough (6 September 1805–18 December 1852). He was an American
sculptor who was best known for his two United States government commissions, “The Rescue” and
“George Washington”, among others. Before graduating from Harvard, Horatio Greenough sailed to
Italy, Rome, to study art. There, the sculptor created many busts. In 1833, he realized “The Ascension
of a Child Conducted by an Infant Angel” in marble. The gift to the Museum of Fine Arts in Boston,
Massachusetts, United States of America, is a marvelous and touching piece of art and may combine
the most elysian characteristics of all Greenough’s sculpture. Both the child and the angel are animated
by a deep serenity, which may deeply contrast to the austere Hadrian’s words engraved in the sculpture
support (Animula, vagula, blandula - Hospes comesque corporis - Quae nunc abibis in loca Pallidula, rigida,
nudula - Nec, ut soles, dabis iocos? Little, suave, and wanderer soul, guest and partner of the body -
Where are you off to now? Somewhere without color, severe, and empty - Never will you participate
in gags as usual). Publius Aelius Hadrianus Augustus was a Roman emperor from 117 to 138 A.D.,
who died at the age of 62 years following a long and restless reign. Suffering from hypertension and
coronary atherosclerosis in the last years of his life, he probably died of congestive heart failure as
extensively reported by Dio Cassius and the Historia Augusta records [29]. This suffering has probably
shaped some of his scripts. The “Ascension of a Child Conducted by an Infant Angel” conveys
an astonishingly gentle, warm, and attractive message of peacefulness, hope, and spirituality in an
age of high infant mortality. In 1911, Newmayer wrote that the country which first recognizes its
responsibilities to the child would be given the appreciation of the world as being the leading civilized
nation [30]. At this time, the United States lagged in the child’s health and welfare, and the infant
mortality rate (IMR) positioned the United States as ranked in the 18th position out of 30 countries, with
a rate of 135 deaths per 1000 live births. Following the European example, US public health leaders
started a national campaign to reduce infant mortality, and, in 1912, the US Children’s Bureau (USCB)
was founded (Brosco 1999). Federal and state programs multiplied and, progressively, pediatricians
and children’s hospitals also surfaced as the ideal supply of healthcare for children. The improvement
of nutrition and treatment of rickets were also crucial and the results of these efforts during the last
century have been impressive in all states consolidating the concept of pediatric healthcare in other
3
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countries, such as Canada, as well [31]. Digitalization of the imaging in radiology and pathology is a
reality in several healthcare institutions worldwide [32,33]. Advances in medical diagnosis and therapy
with the implementation of new technologies will be the basis for the future of pediatric healthcare,
personalized pediatrics, and quality assurance and controls in the 21st century.
Conflicts of Interest: The author declares no conflict of interest.
References
1. Sergi, C.; Hager, T.; Hager, J. Congenital Segmental Intestinal Dilatation: A 25-Year Review with Long-Term
Follow-up at the Medical University of Innsbruck, Austria. AJP Rep. 2019, 9, e218–e225. [CrossRef] [PubMed]
2. Sergi, C.M.; Caluseriu, O.; McColl, H.; Eisenstat, D.D. Hirschsprung’s disease: Clinical dysmorphology,
genes, micro-RNAs, and future perspectives. Pediatr. Res. 2017, 81, 177–191. [CrossRef] [PubMed]
3. Takawira, C.; D’Agostini, S.; Shenouda, S.; Persad, R.; Sergi, C. Laboratory procedures update on Hirschsprung
disease. J. Pediatr. Gastroenterol. Nutr. 2015, 60, 598–605. [CrossRef] [PubMed]
4. Pelletier, J.S.; LaBossiere, J.; Dicken, B.; Gill, R.S.; Sergi, C.; Tahbaz, N.; Bigam, D.; Cheung, P.Y. Low-dose
vasopressin improves cardiac function in newborn piglets with acute hypoxia-reoxygenation. Shock 2013, 40,
320–326. [CrossRef]
5. Cheung, D.C.; Gill, R.S.; Liu, J.Q.; Manouchehri, N.; Sergi, C.; Bigam, D.; Cheung, P.Y.; Dicken, B.J. Vasopressin
improves systemic hemodynamics without compromising mesenteric perfusion in the resuscitation of
asphyxiated newborn piglets: A dose-response study. Intensive Care Med. 2012, 38, 491–498. [CrossRef]
6. Dicken, B.J.; Sergi, C.; Rescorla, F.J.; Breckler, F.; Sigalet, D. Medical management of motility disorders in
patients with intestinal failure: A focus on necrotizing enterocolitis, gastroschisis, and intestinal atresia.
J. Pediatr. Surg. 2011, 46, 1618–1630. [CrossRef]
7. Sergi, C.; Shen, F.; Lim, D.W.; Liu, W.; Zhang, M.; Chiu, B.; Anand, V.; Sun, Z. Cardiovascular dysfunction in
sepsis at the dawn of emerging mediators. Biomed. Pharmacother. 2017, 95, 153–160. [CrossRef]
8. Sergi, C.M. Sudden cardiac death and ethnicity. CMAJ 2019, 191, E1254. [CrossRef]
9. Sergi, C. Customer Care in Pediatric Cardiac Transplant Pathology: Basic Concepts and Critical Analysis in
the Setting of Precision Medicine. Ann. Clin. Lab. Sci. 2019, 49, 682–685.
10. Hsu, Y.H.; Yogasundaram, H.; Parajuli, N.; Valtuille, L.; Sergi, C.; Oudit, G.Y. MELAS syndrome and
cardiomyopathy: Linking mitochondrial function to heart failure pathogenesis. Heart Fail. Rev. 2016, 21,
103–116. [CrossRef]
11. Sergi, C. Promptly reporting of critical laboratory values in pediatrics: A work in progress. World J. Clin.
Pediatr. 2018, 7, 105–110. [CrossRef] [PubMed]
12. Satriano, A.; Franchini, S.; Lapergola, G.; Pluchinotta, F.; Anastasia, L.; Baryshnikova, E.; Livolti, G.;
Gazzolo, D. Glutathione Blood Concentrations: A Biomarker of Oxidative Damage Protection during
Cardiopulmonary Bypass in Children. Diagnostics 2019, 9, 118. [CrossRef]
13. Pin, A.; Monasta, L.; Taddio, A.; Piscianz, E.; Tommasini, A.; Tesser, A. An Easy and Reliable Strategy for
Making Type I Interferon Signature Analysis Comparable among Research Centers. Diagnostics 2019, 9, 113.
[CrossRef] [PubMed]
14. Wang, S.Y.; Andrews, C.A.; Herman, W.H.; Gardner, T.W.; Stein, J.D. Incidence and Risk Factors for
Developing Diabetic Retinopathy among Youths with Type 1 or Type 2 Diabetes throughout the United
States. Ophthalmology 2017, 124, 424–430. [CrossRef] [PubMed]
15. Donaghue, K.C.; Wadwa, R.P.; Dimeglio, L.A.; Wong, T.Y.; Chiarelli, F.; Marcovecchio, M.L.; Salem, M.;
Raza, J.; Hofman, P.L.; Craig, M.E.; et al. ISPAD Clinical Practice Consensus Guidelines 2014. Microvascular
and macrovascular complications in children and adolescents. Pediatr. Diabetes 2014, 15, 257–269. [CrossRef]
16. Kolodziej, M.; Waszczykowska, A.; Korzeniewska-Dyl, I.; Pyziak-Skupien, A.; Walczak, K.; Moczulski, D.;
Jurowski, P.; Mlynarski, W.; Szadkowska, A.; Zmyslowska, A. The HD-OCT Study May Be Useful in Searching
for Markers of Preclinical Stage of Diabetic Retinopathy in Patients with Type 1 Diabetes. Diagnostics 2019, 9,
105. [CrossRef]
17. Allen, N.; Gupta, A. Current Diabetes Technology: Striving for the Artificial Pancreas. Diagnostics 2019, 9, 31.
[CrossRef]
4
Diagnostics 2019, 9, 201
18. Brunner, J.; Sergi, C.; Muller, T.; Gassner, I.; Prufer, F.; Zimmerhackl, L.B. Juvenile sarcoidosis presenting as
Crohn’s disease. Eur. J. Pediatr. 2006, 165, 398–401. [CrossRef]
19. Chiu, B.; Chan, J.; Das, S.; Alshamma, Z.; Sergi, C. Pediatric Sarcoidosis: A Review with Emphasis on Early
Onset and High-Risk Sarcoidosis and Diagnostic Challenges. Diagnostics 2019, 9, 160. [CrossRef]
20. Glezen, W.P.; Taber, L.H.; Frank, A.L.; Kasel, J.A. Risk of primary infection and reinfection with respiratory
syncytial virus. Am. J. Dis. Child. 1986, 140, 543–546. [CrossRef]
21. Hall, C.B.; Weinberg, G.A.; Iwane, M.K.; Blumkin, A.K.; Edwards, K.M.; Staat, M.A.; Auinger, P.; Griffin, M.R.;
Poehling, K.A.; Erdman, D.; et al. The burden of respiratory syncytial virus infection in young children. N.
Engl. J. Med. 2009, 360, 588–598. [CrossRef] [PubMed]
22. Rodriguez-Gonzalez, M.; Perez-Reviriego, A.A.; Castellano-Martinez, A.; Lubian-Lopez, S.;
Benavente-Fernandez, I. Left Ventricular Dysfunction and Plasmatic NT-proBNP Are Associated with
Adverse Evolution in Respiratory Syncytial Virus Bronchiolitis. Diagnostics 2019, 9, 85. [CrossRef] [PubMed]
23. Duvekot, A.; van Heesch, G.; Veder, L. Subcutaneous and Mediastinal Emphysema Followed by Group A
Beta-Hemolytic Streptococci Mediastinitis. A Complicated Course after Adenotonsillectomy: Case Report.
Diagnostics 2019, 9, 11. [CrossRef] [PubMed]
24. Greig, S.R. Current perspectives on the role of tonsillectomy. J. Paediatr. Child. Health 2017, 53, 1065–1070.
[CrossRef]
25. Sergi, C.; Dhiman, A.; Gray, J.A. Fine Needle Aspiration Cytology for Neck Masses in Childhood. An
Illustrative Approach. Diagnostics 2018, 8, 28. [CrossRef]
26. Barkhuizen, M.; Vles, J.S.H.; van Mechelen, R.; Vermeer, M.; Kramer, B.W.; Chedraui, P.; Bergs, P.;
van Kranen-Mastenbroek, V.; Gavilanes, A.W.D. Preterm Perinatal Hypoxia-Ischemia Does not Affect
Somatosensory Evoked Potentials in Adult Rats. Diagnostics 2019, 9, 123. [CrossRef]
27. Das, S.; van Landeghem, F.K.H. Clinicopathological Spectrum of Bilirubin Encephalopathy/Kernicterus.
Diagnostics 2019, 9, 24. [CrossRef]
28. Khan, A.; Sergi, C. Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder.
Diagnostics 2018, 8, 29. [CrossRef]
29. Birley, A. Hadrian: The Restless Emperor; Psychology Press: London, UK, 1997.
30. Newmayer, S.W. The warfare against infant mortality. Ann. Am. Acad. Political Soc. Sci. 1911, 37, 532–542.
[CrossRef]
31. Zhang, M.; Shen, F.; Petryk, A.; Tang, J.; Chen, X.; Sergi, C. “English Disease”: Historical Notes on Rickets,
the Bone-Lung Link and Child Neglect Issues. Nutrients 2016, 8, 722. [CrossRef]
32. Sergi, C.M. Digital Pathology: The Time Is Now to Bridge the Gap between Medicine and Technological
Singularity. In Interactive Multimedia-Multimedia Production and Digital Storytelling; Cvetković, D., Ed.;
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Abstract: Background. Pediatric open-heart surgery with cardiopulmonary bypass (CPB) still remains
a risky interventional procedure at high mortality/morbidity. To date, there are no clinical, laboratory,
and/or monitoring parameters providing useful information on perioperative stress. We therefore
investigated whether blood concentrations of glutathione (GSH), a powerful endogenous antioxidant,
changed in the perioperative period. Methods. We conducted an observational study in 35 congenital
heart disease (CHD) children in whom perioperative standard laboratory and monitoring parameters
and GSH blood levels were assessed at five monitoring time points. Results. GSH showed a pattern
characterized by a progressive increase from pre-surgery up to 24 h after surgery, reaching its highest
peak at the end of CPB. GSH measured at the end of CPB correlated with CPB duration, cross-clamping,
arterial oxygen partial pressure, and with body core temperature. Conclusions. The increase in
GSH levels in the perioperative period suggests a compensatory mechanism to oxidative damage
during surgical procedure. Caution is needed in controlling different CPB phases, especially systemic
reoxygenation in a population that is per se more prone to oxidative stress/damage. The findings may
point the way to detecting the optimal temperature and oxygenation target by biomarker monitoring.
Keywords: GSH; cardiopulmonary bypass; newborn; brain damage; oxidative stress
1. Introduction
Pediatric open-heart surgery with cardiopulmonary bypass (CPB) still remains a risky
interventional procedure at high mortality and morbidity [1]. Hemodynamic and thermal changes
occurring during CPB are known to trigger a cascade of events (i.e., ischemia-reperfusion injury,
surgical procedure, endothelial dysfunction, activation of complement, coagulation, and inflammatory
processes) that can lead to tissue damage [2].
The assessment of proinflammatory cytokines and intracellular biomarkers has been recently
proposed in order to offer useful information on tissue stress in the perioperative period [3]. In this
regard, it has been shown that glutathione (GSH) is essential for vascular and cardiac function and
determines cell survival [4–7]. Moreover, in humans and in animal heart failure models, exacerbated
tumor necrosis factor and soluble tumor necrosis factor receptor-1 expression was related to systemic
and cardiac GSH deficiency supporting the notion of GSH’s role in the defense against oxidative
stress [4,5,8–10].
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GSH has been detected in different biological fluids and it has been suggested that its presence
provides a good source of this protective antioxidant for newborns. GSH performs several important
physiological functions, such as (a) inactivation of oxygen-derived highly reactive species [10,11];
(b) detoxification of various types of xenobiotics and carcinogens [10,12]; (c) maintenance of the
oxidative status of other antioxidants, such as ascorbic acid and α-tocopherol [13]; and (d) cell immune
response improvement by activation of lymphocytes [14]. In this light, GSH in adults undergoing
surgical repair with CPB has been shown to increase, reflecting a cellular defense mechanism against
oxidative damage during reperfusion [15]. Conversely, data on GSH concentrations in children,
affected by congenital heart disease (CHD) and undergoing cardiac surgery, are still lacking or are
a matter of debate. Reduced GSH levels has been recently shown to play an important role in
inflammatory response [3], whereas changes in GSH blood levels were observed according to different
CPB phases (i.e., controlled anterograde low oxygen warm reperfusion before de-clamping and aortic
cross-clamping release) [15].
Therefore, in the present observational study we investigated whether, in CHD children undergoing
cardiac surgery with CPB, blood concentrations of a powerful endogenous antioxidant, namely GSH,
changed in the perioperative period.
2. Materials and Methods
We conducted an observational study at our third-level referral center for pediatric cardiac
diseases of 35 CHD children without pre-existing neurological disorders or other co-morbidities. CHD
characteristics as well as main interventions and clinical laboratory parameters recorded at admission
into the study are reported in Table 1.
Table 1. Laboratory parameters, main interventions, and general characteristics of the children with
complications of congenital heart disease (CHD) admitted into the study.
CHD (n = 35)
CHD characteristics
Tetralogy of Fallot 15
Transposition of great arteries 6
Tricuspid atresia 8
Total anomalous pulmonary venous return 6
Age (months) 30 ± 8
Weight (kg) 11 ± 2
Gender (F/M) 10/25
Laboratory parameters
Hemoglobin (g/dL) 12.3 ± 1.2
Hematocrit (%) 35.5 ± 2.9
Platelet count (103/mmc) 325 ± 102
Creatinine (mg/dL) 0.43 ± 0.25
Urea (mg/dL) 29 ± 14
LDH (UI/L) 565 ± 206
CK (UI/L) 168 ± 114





CPB (min) 90 ± 66
Filtration (n/total) 19/25
Clamping (min) 46 ± 34
Circulatory arrest (n/total) 2/25
Cooling (◦C) 31.9 ± 3.1
Abbreviations: LDH, lactate dehydrogenase; CK, creatine kinase, CPB, cardiopulmonary bypass.
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Informed and signed consent from parents was obtained, before the patients’ inclusion in the
study, which was approved by the local human investigation committee (N718, EC Policlinico San
Donato Milanese, 12, 12, 2012).
At admission to our unit, all children underwent clinical and standard laboratory and monitoring
parameter recordings and GSH assessment. Blood samples were drawn at five predetermined times
before, during, and after surgery, namely, before the surgical procedure and anesthesia (time 0, T0);
during the surgical procedure after sternotomy and before CPB (time 1, T1); at the end of CPB (time
2, T2); at the end of the surgical procedure (time 3, T3); 24 h after the surgical procedure (time 4, T4).
The following parameters were also recorded: peripheral temperature; nasopharyngeal temperature;
pump flow rate; heart rate (HR) mean arterial systolic and diastolic blood pressure (BP); left and right
atrium BP (LA, RA); pulsed arterial oxygen tension (SaO2); and laboratory parameters such as arterial
blood pH and oxygen (PaO2) and carbon dioxide (PaCO2) partial pressures, bicarbonate (HCO3), base
excess (BE), and hemoglobin (Hb) concentrations, hematocrit rate (Ht), platelet count, and creatinine,
urea, lactate dehydrogenase, creatine kinase, and glucose blood levels.
2.1. Anesthetic Technique
After premedication with midazolam (Ipnovel, Roche, Milan, Italy), 0.5 mg/kg·bw (intramuscular),
induction was achieved with oxygen and 3% sevofluorane (SevoFlo, Zoetis Belgium SA,
Louvain-la-Neuve, Belgium) administered via mask (single-breath induction), followed by intravenous
sufentanil (Fentanest, Pharmacia and Upjohn, Milan, Italy) 1 (g/kg·bw) and vecuronium (Norcuron, NV
organon, Oss, The Netherlands) (0.15 mg/kg·bw). Maintenance was achieved with 3% sevofluorane
(except during CPB) and with additional doses of sufentanil (0.5 g/kg·bw) and vecuronium
(0.1 mg/kg·bw) every 30–40 min. During CPB, in the absence of sevofluorane, additional midazolam at
0.2 mg/kg·bw dosage was given. Sufentanil infusion at 0.25 g/kg·bw was continued in the intensive
care unit for sedation [16].
2.2. Cardiopulmonary Bypass Management
The study population underwent a CPB procedure according to our protocols [16]. CPB was
established after systemic heparinization (3 mg/kg·bw) by standard single-stage aortic and bicaval
cannulation, and maintained via non-pulsatile pump flow with a membrane oxygenator (Dideco
Laboratories, Modena, Italy). Flow velocity was kept at 120–150 mL/kg·bw, and mean arterial
blood pressure at 45 mmHg; hypothermia was attained by core and surface cooling. Three patients
were operated in deep hypothermic circulatory arrest (DHCA) (19 ± 7 min) and the minimum
temperature reached was 25 ◦C. Mean rewarming time was calculated from the final temperature
during hypothermic circulatory arrest to 36.5 ◦C. The pump priming solution was composed of
electrolyte solutions (Normosol-R 250 to 650 mL, Abbott Hospital Products, Abbott Park, IL, USA
or Plasma-Lyte A, Travenol Laboratories, Inc., Deerfield, IL, USA), albumin (25%), heparin 1000 to
5000 units in the total solution, sodium bicarbonate (25–30 mEq/L), and packed red blood cells or fresh
frozen plasma. A standard total circuit prime volume was used, according to body weight, varying
from 400 mL (bw < 4.5 kg), to 600 mL (bw > 4.5 kg and bw < 7.5 kg) and to 700 mL (bw > 7.7 kg).
Packed red blood cells (200 to 500 mL) were transfused as needed to maintain a hematocrit level above
30% during CPB. Protamine (1 mg for each mg of heparin) was administered at the end of CPB. The
α-stat regimen was used, and the PaCO2 maintained between 35 and 40 mmHg, without mathematical
correction for the effects of the temperature, by varying the membrane oxygenator gas flow [16].
Modified ultrafiltration (MUF) was routinely performed before removal of arterial and venous
cannulae. In the CPB circuit, the arterial line was connected to the inlet and the venous line to the
outlet of the ultrafilter. As the patient was separated from the CPB, the clamp was removed from the
inlet of the filter, allowing the blood to flow through the arterial line to the filter (10–15 mL/kg/min)
and, finally, from a venous line to the RA. The filter allows the passage of molecules smaller than
65 kD molecular weight. When it was necessary to maintain the intravascular volume and stabilize the
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hemodynamics, the blood returned via the venous reservoir and the venous cannula to the RA. This
technique was performed until the Ht achieved the target of 35% [17].
2.3. GSH Measurement
Levels of nonproteic thiol groups were measured in 200 μL of blood, in accordance with the
method presented by Hu [18], with partial modifications. This spectrophotometric assay is based on
the reaction of thiol groups with 2,2-dithio-bis-nitrobenzoic acid (DTNB) in absolute ethanol to give a
colored compound absorbing at λ = 412 nm. Since the DTNB method is strongly affected by pH, the
possibility of avoiding acids (trichloroacetic or sulfosalicylic acid) to precipitate proteins represents a
remarkable advantage to ensure the accuracy of the assay. We then carried out the removal of proteins
with an excess of absolute ethanol, followed by centrifugation at 3000g for 10 min at room temperature.
Each value represents the mean ± SD of three experimental determinations for each sample. Results
were expressed as micromoles per milliliter of blood.
2.4. Neurological Follow-up
Neurological examination was performed daily according to Prechtl [19]. Each child was assigned
to one of three diagnostic groups—normal, suspect, abnormal. A child was considered to be abnormal
when one or more of the following neurological syndromes were unequivocally present: (a) increased or
decreased excitability (hyperexcitability syndrome, convulsion, apathy syndrome, coma); (b) increased
or decreased motility (hyperkinesia, hypokinesia); (c) increased or decreased tonus (hypertonia,
hypotonia); (d) asymmetries (peripheral or central); (e) defects of the central nervous system; (f) any
combination of the above. When indications of the presence of a syndrome were non-conclusive or if
only isolated symptoms were present (e.g., mild hypotonia or only a slight tremor), the children were
classified as suspect. Abnormal and suspect cases were excluded from the study.
2.5. Statistical Analysis
For the calculation of sample size, we used GSH changes as the main parameter. As no basic
data are available for a studied population, we assumed a decrease of 0.5 SD in GSH to be clinically
significant. Indeed, considering α = 0.05 and using a two-sided test, we estimated a power of 0.80
recruiting 33 CHD patients. We added n = 2 cases to allow any dropout. The sample size was
calculated by using nQuery Advisor (Statistical Solutions, Saugus, MA, USA), version 5.0. The
Kolmogorov–Smirnov test showed values having a Gaussian distribution, and data were expressed as
the mean (SD). Statistical significance was assessed using one-way ANOVA for repeated measures
(followed by the post-hoc Tukey test for multiple comparisons) and the unpaired t-test when only two
groups were compared. Linear regression analysis was used for correlation between GSH and CPB
and laboratory parameters. Statistical significance was set at p < 0.05.
3. Results
Monitoring and laboratory variables at the predetermined perioperative time points are shown in
Table 2. Clinical parameters recorded during surgery remained within limits regarded as within the
reference ranges during this type of procedure. No significant differences from T0 to T4 (p > 0.05, for
all) were observed regarding hemoglobin concentration; hematocrit rate; arterial blood pH, PaCO2,
HCO3, BE, and SaO2; HR; LA BP; RA BP; systolic and diastolic BP; and glucose blood levels. PaO2
showed a pattern, from T0 to T4, characterized by a significant (p < 0.01, for all) progressive increase in
concentration reaching its highest peak at T2 (p < 0.001) and progressively decreasing at the end of
surgery up to 24 h after the surgical procedure (Table 2).
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Table 2. Laboratory parameters at different monitoring time points (before the surgical procedure,
T0; during the surgical procedure before CPB, T1; at the end of CPB, T2; at the end of the surgical
procedure, T3; 24 h after the surgical procedure, T4) in children admitted into the study. Data are given
as mean ± SD.
Parameters T0 T1 T2 T3 T4
Hemoglobin (g/dL) 11.7 ± 2.2 11.5 ± 2.4 11 ± 2.9 11.1 ± 1.4 11.8 ± 1.5
Hematocrit rate (%) 35.9 ± 3.8 33.8 ± 5.4 32.9 ± 6.3 33.4 ± 4.2 34.5 ± 4.7
pH 7.36 ± 0.10 7.36 ± 0.10 7.38 ± 0.08 7.39 ± 0.08 7.42 ± 0.07
PaCO2 (mmHg) 36.9 ± 6.6 35.4 ± 3.9 34.4 ± 5.5 35.5 ± 5.1 36.2 ± 5.9
PaO2 (mmHg) 101 ± 37 144 ± 78 * 211 ± 101 * 163 ± 96 * 155 ± 86 *
HCO3 (mmol/L) 22.1 ± 3.1 22.2 ± 3.9 21.1 ± 3.2 21.2 ± 1.9 22.2 ± 1.8
BE (mmol/L) 0.2 ± 2.5 −1.8 ± 3.6 −3.0 ± 2.1 −0.5 ± 0.7 1.5 ± 1.5
SaO2 (mmHg) 94.9 ± 8.8 93.8 ± 7.2 97.3 ± 1.8 92.7 ± 2.6 95.3 ± 5.5
Heart rate (bpm) 104 ± 11 113 ± 14 121 ± 14 122 ± 12 125 ± 19
LA BP (mmHg) 8.0 ± 3.9 7.7 ± 4.0 9.2 ± 3.5 9.5 ± 4.2 9.3 ± 4.0
RA BP (mmHg) 9.1 ± 2.2 8.7 ± 1.6 8.8 ± 2.1 9.8 ± 2.3 10 ± 2.8
Systolic BP (mmHg) 88 ± 12 87 ± 17 86 ± 14 95 ± 15 96 ± 13
Diastolic BP (mmHg) 42 ± 11 53 ± 10 54 ± 10 56 ± 10 57 ± 11
Glycaemia (mg/dl) 103 ± 12 118 ± 11 130 ± 19 125 ± 15 119 ± 14
* p < 0.05 vs. T0. Abbreviations: arterial carbon dioxide partial pressure, PaCO2; arterial oxygen partial pressure,
PaO2; arterial bicarbonate level, HCO3; base excess, BE; arterial oxygen saturation, SaO2; left atrium, LA; blood
pressure, BP; right atrium, RA.
No overt neurological injury was observed in surviving patients during the first week after surgery.
In CHD children, GSH blood levels were measurable at all monitoring time points. GSH showed a
pattern characterized by a progressive increase from T0 (before surgery) to T4 (at 24 h after surgery),
reaching its highest peak at T3 (at the end of CPB) and remaining at high levels up to T4 (p < 0.01, for
all) (Figure 1).
Figure 1. GSH concentrations (μM/mL) expressed as median and 5◦–95◦ centiles at different monitoring
time points: before the surgical procedure (T0); during the surgical procedure after sternotomy and
before CPB (T1); at the end of CPB (T2); at the end of the surgical procedure (T3); and at 24 h after the
surgical procedure (T4) in congenital heart disease children. GSH was significantly (*p < 0.01, for all)
higher at T3 and T4 vs. T0 monitoring time points.
No significant differences (p > 0.05, for both) in GSH levels were shown from T0 to T2. Moreover,
in order to evaluate the potential side effects of PaO2 on GSH levels, we calculated the PaO2/GSH ratio.
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The PaO2/GSH pattern was characterized by a significant (p < 0.05, for all) increase from T0 to T3,
whereas no differences (p > 0.05) were found between T0 and T4.
Linear regression analysis showed a significant correlation between GSH levels measured at the
end of CPB (T2). In particular, a positive significant correlation was found with CPB duration (R = 0.72;
p < 0.001), with cross-clamping (R = 0.62, p < 0.001), and with PaO2 (R = 0.53; p = 0.002), whereas
a negative significant correlation was observed with body core temperature (R = −0.49; p = 0.012)
(Figures 2–4).
 
Figure 2. Correlation between GSH concentrations (μM/mL) measured at the end of cardiopulmonary
bypass (CPB) procedure and CPB duration (min). There was a significant positive correlation (R = 0.72;
p < 0.001).
 
Figure 3. Correlation between GSH concentrations (μM/mL) measured at the end of cardiopulmonary
bypass (CPB) procedure and body core temperature (◦C) during CPB. There was a significant negative
correlation (R = −0.49; p = 0.012).
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Figure 4. Correlation between GSH concentrations (μM/mL) measured at the end of cardiopulmonary
bypass (CPB) procedure and cross-clamping duration (min). There was a significant positive correlation
(R = 0.62; p < 0.001).
Moreover, an identical pattern was found when PaO2/GSH was correlated with CPB duration
(R = 0.56; p = 0.004), with cross-clamping (R = 0.51, p < 0.010), and with body core temperature
(R = 0.68; p < 0.001).
4. Discussion
It is widely known that congenital heart diseases are the most frequent malformations, affecting
1–20 infants in 1000 live births [1]. According to CHD characteristics, they may account for up to 15% of
mortality, as well as about 4.8% of short-term and 40–50% of long-term developmental abnormalities at
school age [1,20,21]. However, there are still no conclusive clinical, laboratory, or monitoring parameters
able to provide useful information on perioperative stress [22–25]. In this setting, open-heart surgery
and CPB are commonly accepted to cause harmful effects on whole body organs. Vascular resistance
impairment, intra/postoperative hypoperfusion leading to ischemia reperfusion injury, and systemic
inflammation are known to enhance an oxidative stress reaction in the perioperative period [26].
In the present study, we found that the blood levels of a well-established marker of oxidative stress,
namely GSH, significantly increased during surgical procedure by CPB, remaining constantly elevated
up to 24 h after surgery. Furthermore, GSH levels measured at the end of the CPB procedure positively
correlated with CPB, cross-clamp duration, and PaO2, whereas a negative correlation was observed
with body core temperature. These results are, in part, in agreement with previous observations
in adults and in children [15,27], showing increased GSH levels in the postoperative period and in
the different CPB phases. Discrepancies are in relation to the different monitoring time points, CPB
procedure, and patient recruitment [15].
The finding of elevated GSH levels in the perioperative period warrants further consideration. In
particular, increased GSH levels during CPB procedure are (1) related to enhanced oxidative damage
due to hypoxia or hyperoxia insults during CPB itself [2]; (2) correlated with the complexity of surgical
procedures, especially in those cases requiring DHCA [23]; (3) temperature-dependent due to changes
in the oxygen–hemoglobin dissociation curve, enhancing hemoglobin affinity for oxygen with an
increase in reduced/oxidized glutathione ratio [28]; and, (4) related to the use of hyperoxic anesthesia
that stimulates the production of reactive nitrogen and oxygen species (RNOS) by neutrophils and
mitochondria [29].
Altogether, it is reasonable to conclude that the increased release of GSH into systemic circulation
in CHD children who had undergone open heart surgery can be considered as a compensatory
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mechanism to oxidative damage. The fact is of relevance bearing in mind that GSH is implicated the
most in the protection against oxidative injury in glia, astrocytes, and neurons [30]. The mechanism
through which GSH exerts its antioxidant action is, at this stage, not fully elucidated. One explanation
resides in hypoxia or hyperoxia insults able to trigger the cellular GSH content, increasing the effect of
N-acetylcysteine on repletion of GSH and further increasing key enzyme activities that regulate GSH
production, glutamate cysteine ligase, and glutathione synthase [31,32]. In this light, it is reasonable
to suggest that high GSH levels in blood may be the expression of a cascade of events affecting the
glutathione/glutathione-oxidized ratio, which is hypoxia or hyperoxia mediated. Of note, high GSH
levels in systemic circulation enhance its antioxidant capacity, thus reducing the proteins’ defense
mechanisms by oxidative damage. Another explanation resides in therapeutic strategies performed in
the perioperative period such as transfusions (red blood cells, platelets), which contribute to redox
imbalance being an important source of RNOS [33,34]. Finally, the possibility that therapeutic strategies
such as anesthesia and fluid balance management can somewhat affect GSH levels must be taken
into account. The fact is of relevance bearing in mind that (i) perioperative therapeutic strategies
performed did not contain any thiol group, and (ii) fluid management was not responsible for any
hemodilution/concentration phenomenon. Since no significant differences in Hb and Ht rate were
observed at monitoring time points, these findings argue against the hypothesis.
In the present study, we also found that GSH increases in the perioperative period as PaO2 peaks.
Therefore, in order to limit the potential influence of oxygenation on GSH levels, we calculated the
PaO2/GSH ratio. The PaO2/GSH ratio pattern increased during surgery up to the end of the procedure
when it started to decrease, being superimposable to preoperative levels. The PaO2/GSH ratio showed
a positive correlation with CPB duration, cross-clamping, and body core temperature.
The finding of a correlation between GSH and PaO2 deserves further consideration. In particular,
increased GSH has shown the following: (i) in animal models, controlled normoxic reoxygenation
limited brain injury [35]; (ii) in CHD children, lipid peroxidation increased and antioxidant reserve
capacity decreased, being maintained by endogenous radical scavengers such as GSH [35–40]; and
(iii) during CPB, increased oxygen toxicity affected endothelial permeability [2,35]. Altogether, it is
reasonable to suggest that the higher GSH levels occurring during systemic reoxygenation in CHD
children may be indicative of a compensatory mechanism due to CPB and hyperoxia-mediated stress.
Lastly, we found that the PaO2/GSH ratio was superimposable to the one detected at the
preoperative time point. The explanation may reside in the decay of PaO2 levels at 24 h after surgery
and explained by the short half-life of GSH (about 10 min) [41].
Finally, the present study shows some limitations. The main ones reside in the small population
studied that did not allow to correct for the occurrence of cyanotic and non-cyanotic CHD and in the
lack of an expanded oxidative stress evaluation with other biomarkers such as glutathione disulfide,
non-protein bind iron and lipid hydroperoxides. Further studies in this regard are awaited.
In conclusion, the present data on elevated GSH levels, in CHD children undergoing open heart
surgery and CPB, suggest that caution is needed in controlling different CPB phases such as DHCA,
core body temperature, and systemic reoxygenation in a population that is per se more prone to CNS
stress or damage. The findings may lead to further investigation to detect the “optimal” temperature
and PaO2 target [40] by monitoring biomarkers as much as possible to avoid perioperative CNS stress
or damage.
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Abstract: Interferon-stimulated genes (ISGs) are a set of genes whose transcription is induced by
interferon (IFN). The measure of the expression of ISGs enables calculating an IFN score, which gives
an indirect estimate of the exposition of cells to IFN-mediated inflammation. The measure of the
IFN score is proposed for the screening of monogenic interferonopathies, like the Aicardi-Goutières
syndrome, or to stratify subjects with systemic lupus erythematosus to receive IFN-targeted treatments.
Apart from these scenarios, there is no agreement on the diagnostic value of the score in distinguishing
IFN-related disorders from diseases dominated by other types of cytokines. Since the IFN score is
currently measured in several research hospitals, merging experiences could help define the potential
of scoring IFN inflammation in clinical practice. However, the IFN score calculated at different
laboratories may be hardly comparable due to the distinct sets of IFN-stimulated genes assessed and
to different controls used for data normalization. We developed a reliable approach to minimize the
inter-laboratory variability, thereby providing shared strategies for the IFN signature analysis and
allowing different centers to compare data and merge their experiences.
Keywords: interferon signature score; inter-laboratory variability; data sharing; systemic lupus
erythematosus; interferonopathies; biostatistics
1. Introduction
Type I interferon (IFN) production is part of the innate immune response to viruses or intracellular
bacteria, which is triggered by the sensing of pathogen-associated nucleic acids [1]. Even though the
identification of IFNs dates back to the 50s–60s [2], the description of a group of mendelian disorders
with dysregulated IFN-mediated inflammation has only recently shed light on the fine regulation of
the production and action of these cytokines [3]. Of note, this new group of disorders, known as type I
interferonopathies, displays significant phenotypic overlaps with both systemic lupus erythematosus
(SLE) and congenital viral infections of the TORCH (Toxoplasmosis, Rubella, Cytomegalovirus, Herpes
simplex) and HIV (human immunodeficiency virus) groups [3,4].
Type I interferonopathies are marked by the hyper-expression of a set of genes (IFN-stimulated
genes, ISGs) in inflamed tissue and often in peripheral blood, leading to the definition of the so-called
“IFN signature” [5,6]. The IFN signature was firstly defined in subjects with SLE to assess the level of
IFN related inflammation and to help stratify patients to receive IFN targeted treatments [7–9].
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Since then, the measure of expression of the ISGs (IFN signature analysis) is increasingly used in
biomedical research centers, as well as for the functional classification of other conditions characterized
by a type I IFN dysregulation [10], to distinguish such conditions from classical inflammatory
disorders predominantly mediated by other cytokines, like Tumor Necrosis Factor α and Interleukin 1
(i.e., inflammatory bowel diseases, rheumatoid arthritis, and periodic fevers) [11].
Different ISG sets were identified to evaluate interferon-mediated autoinflammation and are
frequently restricted to 5-6 targeted genes [6,10,12,13], suitable, for example, for the discrimination
of Aicardi-Goutières syndrome (AGS) [6,10]. However, IFN signature analysis could be extended to
larger gene lists [7] or even restricted to just one single gene, particularly when directly assessed in
affected tissues, as in the case of dermatomyiositis [14–16].
Even though the IFN signature measure has become widely available at research hospitals, there
is no consensus for the selection of calibration controls. Thus, it is hard to compare data among distinct
centers and to estimate the potential of IFN signature testing for discriminating among inflammatory
conditions in the clinical practice. For example, thousands of subjects with antiphospholipid syndrome
have been described in multicenter studies [17], while the interferon score has been separately studied
in several small series without allowing the merging of results [18–22].
The main problem hindering the use of IFN signature analysis for in vitro diagnostics is the
expression of data relativized to independent healthy control(s) in each laboratory, leading to
unpredictable inter-laboratory variability. It is logical to assume that the use of pooled cDNA
from healthy donors can represent a convenient strategy for calibrating Real Time quantitative PCR
(qPCR) for the assessment of the IFN score. However, it can be difficult to predict the optimal number
of samples to be pooled, which requires minimizing variability between one pool and another prepared
at distinct laboratories, as already pointed out by others [23,24].
This study aims to investigate, through laboratory, bioinformatic, and statistical analyses, a reliable
approach to minimize the variability that can be observed in inter-laboratory assays.
The final goal is providing shared recommendations for IFN signature analysis and interpretation
of data in the clinical practice, thereby allowing data sharing among reference centers and improving
knowledge on IFN-related disorders.
2. Materials and Methods
The study is part of the IRCCS Burlo Garofolo project RC #24/2017, approved by the Institutional
Review Board and by the Friuli Venezia Giulia Independent Ethical Committee (2018-SPER-079-BURLO,
N. 0039851, approved on 12 December 2018). All investigations were performed after obtaining written
informed consent from volunteers and patients or their parents/guardians.
2.1. Subjects
On wet IFN signature analysis was assessed by quantitative PCR (qPCR) in ten young-aged
healthy subjects (Dataset A, ten out of eleven individuals, five males and five females).
To establish whether data from qPCR and RNAseq analysis were comparable, IFN signature on
wet (by qPCR) and in silico (by RNAseq) analysis was performed in twenty subjects with inflammatory
diseases, such as systemic lupus erythematosus (SLE), interferonopathies or inflammatory bowel
diseases (IBD), and patients’ relatives, recruited at our center (Dataset E). A brief description of patients’
clinical diagnosis is displayed in Table S1.
To increase healthy donors numerosity, in silico IFN signature investigation (by RNAseq)
has been performed in twenty healthy individuals, collected at our center Dataset A (four out of
eleven individuals), and selected from different whole blood RNA-sequencing (RNAseq) open-access
web-based datasets: we sorted another three datasets, while considering exclusively healthy control
samples, accessible at ArrayExpress (accession number E-MTAB-5735, Dataset B, five individuals) and
at the Gene Expression Omnibus (GEO) (accession number GSE112057, Dataset C, nine individuals;
GSE90081, Dataset D, two individuals). Specification about gender was not available for all the
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samples. However, sex has been easily inferred by expression analysis of the sex-specific genes RPS4Y1
and USP9Y.
The dataset composition is shown in Table 1.
Table 1. Dataset composition: subjects, size, methods and purposes.
Datasets Subjects n Total (F/M) Method (n) Purpose
A—Data of from our
center; Accession: #
Healthy donors 11 (5/6)
qPCR (10)
RNAseq (3)
To test the variability of expression
of the six ISGs in a healthy donor
small group available at out center
RNAseq (1)
To increase the healthy donor group
size, to improve the power of the
variability measurement
B—Accession:
E-MTAB-5735 Healthy donors 5 (2/3) RNAseq (5)
To increase the healthy donor group
size, to improve the power of the
variability measurement
C—Accession:
GSE112057 Healthy donors 12 (6/6) RNAseq (9)
To increase the healthy donor group
size, to improve the power of the
variability measurement
D—Accession:
GSE90081 Healthy donors 12 (12/0) RNAseq (2)
To increase the healthy donor group




recruited at our center
Patients 20 (9/11) qPCR (20)RNAseq (20)
To compare IFN signature results
between qPCR and RNAseq
analyses
# data not present in open-access web-based datasets.
2.2. Sample Collection, RNA Isolation and cDNA Preparation
Peripheral blood was collected in PAXgene Blood RNA Tubes (PreAnalytiX, Hombrechtikon,
Switzerland) and, after two-hours incubation at room temperature, tubes were frozen at −20 ◦C until
processing. Total RNA was extracted with PAXgene Blood RNA Kit (PreAnalytiX, Switzerland),
following the manufacturer’s instructions, and quantified with NanoDrop Spectrophotometer (Thermo
Fisher, Waltham, MA, USA). RNA integrity was checked using an Agilent Technologies 2100 Bioanalyzer.
Up to 1 μg of total RNA was retro-transcribed using SensiFAST cDNA Synthesis Kit (Bioline,
London, UK).
2.3. IFN Signature Analysis
The expression of six IFN-stimulated genes was assessed by qPCR using AB 7500 Real Time PCR
System (Applied Biosystems, Waltham, MA, USA), TaqMan Gene Expression Master Mix (Applied
Biosystems, USA) and UPL Probes (Roche, Basel, Switzerland) for IFI27, IFI44L, IFIT1, ISG15, RSAD2,
and SIGLEC1. Using AB 7500 Real Time PCR software, each target quantity was normalized with the
expression level of HPRT1 and G6PD, and the relative quantification (RQ) was conducted relating to a
“calibrator” sample (mix of ten healthy controls, Dataset A) using the 2−ΔΔCt method [25]. The median
fold change of the six genes was used to calculate the IFN score for each patient.
2.4. RNAseq Analysis
Transcriptome sequencing was performed using the TruSeq Stranded mRNA Sample Preparation
kit (Illumina, San Diego, CA, USA) and sequenced on a NovaSeq 6000 platform (Illumina, San Diego,
CA, USA), generating 2X100 bp paired-end reads (30 million reads per sample) in twenty subjects from
Dataset E (patients and patients’ relatives) and four out of eleven controls from Dataset A.
RNAseq raw data (either our data and open-access web-based data) workflow was conducted
as follows: quality control by FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/),
quality filtering by Trim Galore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/),
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read alignment to hg38 using annotation from GENECODE v.31 (https://www.gencodegenes.org/) with
STAR [26], reads counting into genes by featureCounts [27].
Data of patients with autoinflammatory diseases and three healthy individuals of our dataset
were normalized and analyzed for differentially expressed genes by DESeq2 [28]. From the result table,
we only considered the ISGs and evaluated their relative fold changes on each patient compared to the
set of controls.
To assess the ISGs expression variability within the group of twenty healthy subjects, shortlisted
from the datasets described above, we determined the expression values for each gene, normalized by
Fragments Per Kilobase per Million mapped reads (FPKM) method with edgeR (rpkm function) [29,30],
using the values from the “Length” column, in the featureCounts’ output, for the calculation.
Principal component analysis (PCA), useful for data visualization, was conducted with DESeq2,
to define the overall variability between samples.
2.5. Statistical Analyses
Considering that each of the six genes measured was expressed on a different scale, we decided to
calculate the sample size based on the coefficient of variation, instead than the mean and the standard
deviation. We further hypothesized that different runs did not increase the variation in comparing the
samples, assuming the only origin of variability to be represented by the subjects’ heterogeneity.
To determine the statistical power for data obtained by qPCR and RNAseq, we computed the
noncentrality parameter (λ) using GPower 3.1.9.2. software [31,32], with a generic two-tailed t-test,
given α = 0.05, β = 0.2, and degrees of freedom equal N-1. If the noncentrality parameter under these
conditions (reference value, “λref”) resulted in being lower than the one calculated on our samples, we
considered the sample size as appropriate.
GraphPad Prism 6 software was employed for χ2 contingency analysis; p-values <0.05 were
considered significant.
To identify the appropriate sample size for variability assessment, we computed λ for increasing
numerosity (up to forty) using GPower 3.1.9.2. (Heinrich-Heine University Düsseldorf, Germany), and
determined a “plateau value” by an exponential decay function (GraphPad Prism 6 software, La Jolla
California USA).
3. Results
3.1. Variability Assessment in IFN-Stimulated Genes Expression in Healthy Controls (Dataset A) Analyzed by
qPCR
The variability of expression of the six ISGs (IFI27, IFI44L, IFIT1, ISG15, RSAD2, SIGLEC1) was
assessed in ten healthy controls processed by on wet qPCR analysis. Five out of six genes showed
low variability coefficients and noncentrality parameters (λ) that fulfilled the analysis criteria (as
described in Materials and Methods, Section 2.5) (Table 2). Only IFI44L did not comply with the analysis
parameters, presenting higher variability and a lower λ than the reference value (λref) (Figure 1)
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Table 2. Variability assessment for interferon-stimulated genes (ISGs) expression values quantified in
ten out of eleven healthy subjects from Dataset A by qPCR.
IFI27 IFI44L IFIT1 ISG15 RSAD2 SIGLEC1
Mean 4.57 0.72 2.18 4.61 1.24 5.14
SD 1.04 0.91 1.05 0.60 1.20 0.42
Variability coefficient 0.23 1.26 0.48 0.13 0.96 0.08
λ (n = 10) 13.92 2.52 6.56 24.47 3.28 38.99
λref: 3.15
SD: standard deviation; λref: noncentrality parameter (λ) calculated based on α = 0.05, β = 0.2, and degrees of
freedom equal N-1. Sample size is considered as appropriate when λ computed on each gene is higher than λref.
The value below λref is highlighted in bold.
Figure 1. Graphical representation of the noncentrality parameter (λ) calculated for each ISG by on
wet qPCR analysis. The λref for ten subjects is displayed by the dashed line and reported in the figure.
Sample size is considered as appropriate when λ computed on each gene is higher than λref.
Thus, ten healthy controls could not be considered an appropriate sample size to represent an
ideal healthy population, in which the physiologically floating expression values of the ISGs present
acceptable variability. For this reason, we should increase the numerosity of healthy controls to obtain
a suitable pool in which the gene expression variability is minimized.
3.2. IFN-Stimulated Genes Expression Evaluated by qPCR or RNAseq Analysis Are Comparable
To improve the power of the variability measurement, we decided to take advantage of RNAseq
open-access web-based data, as an easy source to increase the number of healthy subjects to calculate
ISGs interindividual differences. This choice came from comparisons between the relative ISGs
fold change assessed in the same twenty subjects (Dataset E) by both qPCR and RNAseq analysis,
selecting the same set of three out of eleven healthy controls from Dataset A, to normalize data for
both techniques.
Some subjects showed different relative expression values for the same gene calculated by on wet
qPCR and in silico RNAseq, but the overall results of the IFN signatures (IFN scores) were extremely
consistent between the two techniques for each individual (χ2 contingency analysis p-value = 0.405, not
significant). The comparability of IFN scores is easily explained, considering that these values represent
the median of the six relative ISGs quantifications, and they broadly reflect the overexpression status in
the analyzed sample (Table 3). Thus, the two methods provided the same trend in gene expression in
subjects presenting low, intermediate, and high IFN signatures, as indicated by the three representative
graphs in Figure 2 (Subject n.9: low IFN signature; Subject n.14: intermediate IFN signature; Subject
n.11: high IFN signature).
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Table 3. Comparison of interferon (IFN) scores determined in twenty subjects by both qPCR and
RNAseq by χ2 contingency analysis (p-value = 0.405, not significant).
Subject n.
IFN Score


























Figure 2. Representative display of low (a), intermediate (b) and high (c) IFN signatures analyzed by
both qPCR and RNAseq for each subject. For the optimal graphical representation of all histograms,
the scales of values are set different. The IFN scores computed for each subject are reported in the
legend of the figures.
3.3. Preliminary Analysis for Sample Selection and Variability Assessment in IFN-Stimulated Genes Expression
Analyzed by RNAseq
Given the comparability of data between qPCR and RNAseq, we exploited the availability of
large open-access web repositories containing RNAseq data to calculate the proper sample size for the
assessment of the IFN score with an acceptable inter-laboratory variability.
To select the appropriate sample size, we firstly calculated the noncentrality parameter (λ) on a
numerosity up to forty individuals using GPower software. Then, we determine the plateau value
of the exponential decay function of the previously computed λ values. The provided plateau (3.01)
corresponds to λ for sample size n = 15 (Figure 3), leading us to consider fifteen subjects as an
appropriate sample size. For more experimental strength, we considered both n = 15 and n = 20 in
22
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the following analyses. We did not further increase the sample size over twenty subjects, whereas
exceeding this number might bring difficulties in term of donors’ collection.
Figure 3. Plateau value (reported as a red dot) threshold (reported as a dotted vertical line) of λ
computed for sample sizes up to forty subjects. Each sample size is represented by a black dot. In blue
the exponential decay function curve of the previously computed λ.
We performed a principal component analysis (PCA), a data visualization analysis, to evaluate
the total expression variation of the six ISGs and to define the most homogeneous set of twenty healthy
individuals. This investigation allows the detection of possible rare outliers with the highest variance
that might not be considered as suitable controls to study IFN signature.
RNAseq records have been chosen considering the presence of similar features such as blood
collection type, RNA extraction protocol and library selection, to reduce as much as possible the
technical procedure variability (Table 3).
As a first attempt, we investigated all the RNAseq samples of healthy donors from Dataset A
(data from our center, n = 4/11), Dataset B (E-MTAB-5735, n = 5) and Dataset C (GSE112057, n = 12),
twenty-one specimens in total. Figure 4a displays the PCA results showing the overall ISGs expression
variability between individuals. The analysis exhibited a higher variance in three out of twenty-one
subjects: we thus decided not to include these three samples in further studies, collecting eighteen
samples that were suitable for our purpose. To get the proper numerosity (n = 20), we examine
Dataset D (GSE90081, n = 12) and we ran the same analysis again, obtaining a satisfactory level
of variation, without outliers, between datasets and among individuals. From these preliminary
observations, we randomly chose two out of twelve samples from Dataset D, combining them with
data previously selected. Again, we observed an acceptable gene expression variability among our
final twenty-controls-sized group (Table 4), as shown in Figure 4b.
23
Diagnostics 2019, 9, 113
Figure 4. Overall ISGs expression variance between individuals. PCA of the first selection (a), with
evidence of the three outliers from Dataset C, and of the final twenty-controls-sized group (b), showing
twenty samples uniformly distributed (4 from Dataset A, 5 from Dataset B, 9 from Dataset C and 2
from Dataset D).
Table 4. Detailed report of final twenty-controls-sized healthy subject groups.





































































# data not present in open-access web-based datasets.
We calculated the λref for larger samples of healthy controls (fifteen and twenty subjects) using
GPower software, and the variability of the ISGs expression in fifteen and twenty healthy controls
processed by in silico RNAseq analysis. Table 5 shows that all the variability coefficients are considerably
low and all λ calculated fulfilled the analysis parameters (Figure 5) (expression values of single gene for
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each control are displayed in Table S2. Thus, we can hypothesize that pooling together samples from
fifteen or twenty healthy subjects could also be considered a proper sample size in qPCR analyses.
Table 5. Variability assessment for IFN-stimulated genes expression values evaluated in fifteen and
twenty healthy subjects by in silico RNAseq analysis.
IFI27 IFI44L IFIT1 ISG15 RSAD2 SIGLEC1
n = 15
Mean 0.35 1.14 5.06 30.17 2.21 1.17
SD 0.23 0.28 1.29 12.44 0.86 0.55
Variability coefficient 0.64 0.25 0.26 0.41 0.39 0.47
λ 6.09 15.64 15.16 9.39 9.93 8.21
Λref: 3.01
n = 20
Mean 0.33 1.26 5.17 30.09 2.47 1.22
SD 0.22 0.38 1.38 14.41 1.00 0.50
Variability coefficient 0.67 0.30 0.27 0.48 0.41 0.41
λ 6.68 14.70 16.77 9.34 10.98 10.90
λref: 2.95
SD: standard deviation; λref: noncentrality parameter calculated based on α = 0.05, β = 0.2, and degrees of freedom
equal N-1. Sample size is considered as appropriate when λ computed on each gene is higher than λref.
Figure 5. Graphical representation of λ calculated for each ISG by in silico RNAseq analysis. The λrefs
for fifteen and twenty subjects are displayed by the red dashed line and reported in the figure. Sample
size is considered appropriate when λ computed on each gene is higher than λref.
3.4. Pooling Twenty Subjects Could Be Considered an Optimal Strategy to Minimize Gene Expression
Variability among Healthy Controls for on Wet IFN Signature Analysis
We checked whether the values of mean, SD and variability coefficient obtained by on wet qPCR
on ten controls met the λ criteria considering n = 15 and n = 20 subjects as already calculated, assuming
that the variability coefficient does not change as the sample size increases (Table 6).
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Table 6. Estimated variability assessment for ISGs expression values in fifteen and twenty healthy
subjects for qPCR analysis assuming the same variability coefficient for increasing sample size.
IFI27 IFI44L IFIT1 ISG15 RSAD2 SIGLEC1
Mean 4.57 0.72 2.18 4.61 1.24 5.14
SD 1.04 0.91 1.05 0.60 1.20 0.42
Variability coefficient 0.23 1.26 0.48 0.13 0.96 0.08
λ (n = 15) 17.05 3.08 8.04 29.97 4.02 47.75
λref: 3.01
λ (n = 20) 19.69 3.56 9.28 34.61 4.64 55.14
λref: 2.95
Mean, standard deviation (SD) and variability coefficient values previously determined on ten subjects are reported
in the table. λref: noncentrality parameter (λ) calculated based on α = 0.05, β = 0.2, and degrees of freedom equal
N-1. Sample size is considered appropriate when λ computed on each gene is higher than λref.
The analysis provides quite good results for both sample sizes tested, even if IFI44L showed
a λ (3.08) very close to λref (3.01). For this reason, we can consider more adequate to increase the
numerosity to twenty subjects, a still easy-to-gather number of healthy donors. Thus, we could assert
that twenty healthy controls could be considered a suitable sample size for IFN signature analysis
performed by qPCR, as predicted by in silico RNAseq (Figure 6).
Figure 6. Graphical representation of λ calculated for each ISG by in silico RNAseq analysis and
hypothesized qPCR assessment considering fifteen (a) and twenty (b) subjects. The λrefs values are
displayed by the red dashed line and reported in the figure. Sample size is considered appropriate
when λ computed on each gene is higher than λref.
4. Discussion
The clinical employment of the IFN signature is strictly related to the screening of pathological
conditions characterized by type I IFN dysregulation [24]. However, several studies have been
carried out to associate the IFN-related inflammation with specific clinical or laboratory features of
rheumatologic conditions, like systemic lupus erythematosus, primary antiphospholipid syndrome,
Sjögren syndrome, rheumatoid arthritis, autoimmune myositis and systemic sclerosis [18,20,33–38].
Some Authors proposed that the assessment of IFN inflammation may help identify subgroups of
patients with a better response to specific treatments, as B cell targeted therapies [39–42]. Moreover, since
most anti-inflammatory or immunomodulatory agents have only a weak effect on IFN inflammation,
the calculation of the IFN score may also serve to guide targeted therapy approaches with novel drugs
like Janus Kinase inhibitors [10].
However, there is no consensus on a shared and validated method to classify different inflammatory
conditions by transcriptome analysis. Crow and collaborators used pooled cDNA from healthy donors
as calibrator for qPCR, and after assessing a large number of healthy controls and patients with
Aicardi-Goutières Syndrome calculated a fixed cut-off value of normality suitable for the screening of
interferonopathies [6]. However, this cut-off has been validated to facilitate the detection of monogenic
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interferonopathies and not to assess IFN inflammation in other conditions. Moreover, the reference to
locally pooled control cDNA may make it difficult to compare results obtained in distinct centers.
Even though multiple ISG panels have been described either in peripheral blood cells or affected
tissues, many laboratories set their assays by analyzing a minimal set of 5-6 targeted-genes, usually
including the set proposed by Crow et al. This set has been applied to thousands of analyses and
its potential for screening of monogenic interferonopathies is established. After the normalization
of results on at least two housekeeping genes, the main source of variability limiting interlaboratory
comparison of data consists in the use of different controls for data normalization. Indeed, this is a
remarkable problem, considering that the potential role of IFN signature analysis in clinical practice
can be defined only by sharing data among research centers, comparing or merging case series. Of
course, the best option for the future should rely on the development of industrially manufactured kits
validated for In Vitro Diagnostics (IVD) and usable worldwide with the same reference values, not only
in the most advanced research areas. Conversely, only the analysis and comparison of data available at
various centers can tell industries whether the development of such diagnostic kits is worthwhile or
not. Thus, we focused on a strategy that could be immediately applied in biomedical laboratories to
facilitate the sharing of experience and minimize the inter-laboratory variability.
We investigated if using a pool of biological samples from healthy controls could solve the
data normalization issue, which is the main source of inter-laboratory variability. We proposed
that this strategy could “equalize” the differences in gene expression that physiologically occur
among individuals.
For this purpose, we evaluated if any pool of healthy controls more than a given number n
of subjects could be suitable to level differences, through an approach based on laboratory (qPCR),
bioinformatic (RNAseq), and statistical data integration analyses.
Starting from the ISGs expression assessment in peripheral blood from ten healthy subjects by on
wet qPCR analysis, we found that this sample size is not suitable for equalizing the variable expression
levels of all the six ISGs in healthy volunteers. To find the appropriate number of samples to be
pooled together with low enough variability, we further investigated if public data from RNAseq can
be exploited to expand our analysis. We thus compared relative ISGs fold change values calculated
by qPCR and RNAseq analysis for the same subjects with the same calibrator, showing that the two
methods yield comparable results with very low variability between each other. Previous studies
compared gene expression measurements generated by in silico RNAseq and on wet qPCR assays,
showing consistent results between the two methods for most genes, with the only exception of some
genes generally characterized by small size and low expression levels. None of the ISGs is included in
the list of genes with inconsistent estimation of expression according to the Authors [43]. Our results
confirmed that RNAseq and qPCR generate consistent results in the assessment of ISGs expression
levels. Thus, based on the literature and on our preliminary results, we considered RNAseq as a good
asset to increase the number of healthy subjects on which to calculate interindividual differences in ISGs
expression, exploiting both RNAseq samples available at our center and open-access web-based data.
The results of our study support the choice of pooling twenty healthy controls for the normalization
of the assay, allowing to express results as relative to a “standard set of controls”. Of note, we validated
this sample size only for the selected set of six ISGs in peripheral blood cells. The expression of other
genes included in larger panels, may present higher variability among donors and between different
affected tissues. However, the same procedure that we have described can also be used to define the
optimal sample size for other transcription profiles, for interferonopathies or for other rheumatologic
disorders. The performance of the proposed twenty-controls-sized standard could be improved by
analyzing all the donors separately before pooling, and by performing cluster variance analysis, which
can enable excluding rare donors with outlier variance.
Supplementary Materials: The following are available online at http://www.mdpi.com/2075-4418/9/3/113/s1.
27
Diagnostics 2019, 9, 113
Author Contributions: Conceptualization: A.T. (Alberto Tommasini), A.P. (Alessia Pin), A.T. (Alessandra Tesser);
methodology: A.P. (Alessia Pin), A.T. (Alessandra Tesser), L.M.; software: A.P. (Alessia Pin), L.M.; validation:
A.P. (Alessia Pin), A.T. (Alessandra Tesser), E.P.; resources: A.T. (Alberto Tommasini); data curation: A.P. (Alessia
Pin), A.T. (Alessandra Tesser), L.M., E.P.; writing—original draft preparation: A.P. (Alessia Pin), A.T. (Alessandra
Tesser), L.M.; writing—review and editing: A.T. (Alberto Tommasini), E.P., A.T. (Andrea Taddio); supervision: A.T.
(Alberto Tommasini), A.T. (Andrea Taddio), E.P.; project administration: A.T. (Alberto Tommasini), A.T. (Andrea
Taddio), A.T. (Alessandra Tesser); funding acquisition: A.T. (Alberto Tommasini), A.T. (Andrea Taddio).
Funding: This research was funded by the Institute for Maternal and Child Health IRCCS “Burlo Garofolo” RC
#24/2017.
Acknowledgments: We thank Stefano Volpi from IRCCS Istituto Giannina Gaslini (Genova, Italy) for the long-term
support and scientific confrontation and Remo Sanges from International School for Advanced Studies (SISSA,
Trieste, Italy) for the bioinformatic analysis support.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Stetson, D.B.; Medzhitov, R. Type I interferons in host defense. Immunity 2006, 25, 373–381. [CrossRef]
[PubMed]
2. Isaacs, A.; Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 1957, 147,
258–267. [PubMed]
3. Crow, Y.J. Type I interferonopathies: A novel set of inborn errors of immunity. Ann. N. Y. Acad. Sci. 2011,
1238, 91–98. [CrossRef]
4. Crow, Y.J.; Black, D.N.; Ali, M.; Bond, J.; Jackson, A.P.; Lefson, M.; Michaud, J.; Roberts, E.; Stephenson, J.B.;
Woods, C.G.; et al. Cree encephalitis is allelic with Aicardi-Goutiéres syndrome: Implications for the
pathogenesis of disorders of interferon α metabolism. J. Med. Genet. 2003, 40, 183–187. [CrossRef] [PubMed]
5. Baechler, E.C.; Batliwalla, F.M.; Karypis, G.; Gaffney, P.M.; Ortmann, W.A.; Espe, K.J.; Shark, K.B.; Grande, W.J.;
Hughes, K.M.; Kapur, V.; et al. Interferon-inducible gene expression signature in peripheral blood cells of
patients with severe lupus. Proc. Natl. Acad. Sci. USA 2003, 100, 2610–2615. [CrossRef] [PubMed]
6. Rice, G.I.; Forte, G.M.; Szynkiewicz, M.; Chase, D.S.; Aeby, A.; Abdel-Hamid, M.S.; Ackroyd, S.; Allcock, R.;
Bailey, K.M.; Balottin, U.; et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome
associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: A
case-control study. Lancet Neurol. 2013, 12, 1159–1169. [CrossRef]
7. Yao, Y.; Higgs, B.W.; Morehouse, C.; de Los Reyes, M.; Trigona, W.; Brohawn, P.; White, W.; Zhang, J.;
White, B.; Coyle, A.J.; et al. Development of Potential Pharmacodynamic and Diagnostic Markers for
Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus. Hum. Genom. Proteom. 2009,
2009. [CrossRef] [PubMed]
8. Furie, R.; Khamashta, M.; Merrill, J.T.; Werth, V.P.; Kalunian, K.; Brohawn, P.; Illei, G.G.; Drappa, J.; Wang, L.;
Yoo, S.; et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe
Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017, 69, 376–386. [CrossRef]
9. Merrill, J.T.; Furie, R.; Werth, V.P.; Khamashta, M.; Drappa, J.; Wang, L.; Illei, G.; Tummala, R. Anifrolumab
effects on rash and arthritis: Impact of the type I interferon gene signature in the phase IIb MUSE study in
patients with systemic lupus erythematosus. Lupus Sci. Med. 2018, 5, e000284. [CrossRef]
10. Rice, G.I.; Melki, I.; Frémond, M.L.; Briggs, T.A.; Rodero, M.P.; Kitabayashi, N.; Oojageer, A.; Bader-Meunier, B.;
Belot, A.; Bodemer, C.; et al. Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease.
J. Clin. Immunol. 2017, 37, 123–132. [CrossRef]
11. Kim, H.; Sanchez, G.A.; Goldbach-Mansky, R. Insights from Mendelian Interferonopathies: Comparison of
CANDLE, SAVI with AGS, Monogenic Lupus. J. Mol. Med. 2016, 94, 1111–1127. [CrossRef] [PubMed]
12. Feng, X.; Wu, H.; Grossman, J.M.; Hanvivadhanakul, P.; FitzGerald, J.D.; Park, G.S.; Dong, X.; Chen, W.;
Kim, M.H.; Weng, H.H.; et al. Association of increased interferon-inducible gene expression with disease
activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006, 54,
2951–2962. [CrossRef] [PubMed]
28
Diagnostics 2019, 9, 113
13. Higgs, B.W.; Liu, Z.; White, B.; Zhu, W.; White, W.I.; Morehouse, C.; Brohawn, P.; Kiener, P.A.; Richman, L.;
Fiorentino, D.; et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and
scleroderma share activation of a common type I interferon pathway. Ann. Rheum. Dis. 2011, 70, 2029–2036.
[CrossRef] [PubMed]
14. Greenberg, S.A.; Pinkus, J.L.; Pinkus, G.S.; Burleson, T.; Sanoudou, D.; Tawil, R.; Barohn, R.J.; Saperstein, D.S.;
Briemberg, H.R.; Ericsson, M.; et al. Interferon-α/β-mediated innate immune mechanisms in dermatomyositis.
Ann. Neurol. 2005, 57, 664–678. [CrossRef] [PubMed]
15. Salajegheh, M.; Kong, S.W.; Pinkus, J.L.; Walsh, R.J.; Liao, A.; Nazareno, R.; Amato, A.A.; Krastins, B.;
Morehouse, C.; Higgs, B.W.; et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in
dermatomyositis muscle with perifascicular atrophy. Ann. Neurol. 2010, 67, 53–63. [CrossRef]
16. Uruha, A.; Nishikawa, A.; Tsuburaya, R.S.; Hamanaka, K.; Kuwana, M.; Watanabe, Y.; Suzuki, S.; Suzuki, N.;
Nishino, I. Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. Neurology 2017, 88,
493–500. [CrossRef] [PubMed]
17. Cervera, R.; Serrano, R.; Pons-Estel, G.J.; Ceberio-Hualde, L.; Shoenfeld, Y.; de Ramón, E.; Buonaiuto, V.;
Jacobsen, S.; Zeher, M.M.; Tarr, T.; et al. Morbidity and mortality in the antiphospholipid syndrome during a
10-year period: A multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 2015, 74, 1011–1018.
[CrossRef] [PubMed]
18. Palli, E.; Kravvariti, E.; Tektonidou, M.G. Type I Interferon Signature in Primary Antiphospholipid Syndrome:
Clinical and Laboratory Associations. Front. Immunol. 2019, 10, 487. [CrossRef]
19. Bernales, I.; Fullaondo, A.; Marín-Vidalled, M.J.; Ucar, E.; Martínez-Taboada, V.; López-Hoyos, M.;
Zubiaga, A.M. Innate immune response gene expression profiles characterize primary antiphospholipid
syndrome. Genes Immun. 2008, 9, 38–46. [CrossRef]
20. Grenn, R.C.; Yalavarthi, S.; Gandhi, A.A.; Kazzaz, N.M.; Núñez-Álvarez, C.; Hernández-Ramírez, D.;
Cabral, A.R.; McCune, W.J.; Bockenstedt, P.L.; Knight, J.S. Endothelial progenitor dysfunction associates with
a type I interferon signature in primary antiphospholipid syndrome. Ann. Rheum. Dis. 2017, 76, 450–457.
[CrossRef]
21. van den Hoogen, L.L.; Fritsch-Stork, R.D.; Versnel, M.A.; Derksen, R.H.; van Roon, J.A.; Radstake, T.R.
Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte
subsets, hydroxychloroquine and statin use. Ann. Rheum. Dis. 2016, 75, e81. [CrossRef] [PubMed]
22. Knight, J.S.; Meng, H.; Coit, P.; Yalavarthi, S.; Sule, G.; Gandhi, A.A.; Grenn, R.C.; Mazza, L.F.; Ali, R.A.;
Renauer, P.; et al. Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic
target. JCI Insight 2017, 2. [CrossRef] [PubMed]
23. Fryer, J.F.; Baylis, S.A.; Gottlieb, A.L.; Ferguson, M.; Vincini, G.A.; Bevan, V.M.; Carman, W.F.; Minor, P.D.
Development of working reference materials for clinical virology. J. Clin. Virol. 2008, 43, 367–371. [CrossRef]
[PubMed]
24. Kim, H.; de Jesus, A.A.; Brooks, S.R.; Liu, Y.; Huang, Y.; VanTries, R.; Montealegre Sanchez, G.A.; Rotman, Y.;
Gadina, M.; Goldbach-Mansky, R. Development of a Validated Interferon Score Using NanoString Technology.
J. Interferon Cytokine Res. 2018, 38, 171–185. [CrossRef] [PubMed]
25. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408. [CrossRef] [PubMed]
26. Dobin, A.; Davis, C.A.; Schlesinger, F.; Drenkow, J.; Zaleski, C.; Jha, S.; Batut, P.; Chaisson, M.; Gingeras, T.R.
STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 2013, 29, 15–21. [CrossRef] [PubMed]
27. Liao, Y.; Smyth, G.K.; Shi, W. featureCounts: An efficient general purpose program for assigning sequence
reads to genomic features. Bioinformatics 2014, 30, 923–930. [CrossRef]
28. Love, M.I.; Huber, W.; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data
with DESeq2. Genome Biol. 2014, 15, 550. [CrossRef]
29. Robinson, M.D.; McCarthy, D.J.; Smyth, G.K. edgeR: A Bioconductor package for differential expression
analysis of digital gene expression data. Bioinformatics 2010, 26, 139–140. [CrossRef]
30. McCarthy, D.J.; Chen, Y.; Smyth, G.K. Differential expression analysis of multifactor RNA-Seq experiments
with respect to biological variation. Nucleic Acids Res. 2012, 40, 4288–4297. [CrossRef]
31. Faul, F.; Erdfelder, E.; Lang, A.G.; Buchner, A. G*Power 3: A flexible statistical power analysis program for
the social, behavioral, and biomedical sciences. Behav. Res. Methods 2007, 39, 175–191. [CrossRef] [PubMed]
29
Diagnostics 2019, 9, 113
32. Faul, F.; Erdfelder, E.; Buchner, A.; Lang, A.G. Statistical power analyses using G*Power 3.1: Tests for
correlation and regression analyses. Behav. Res. Methods 2009, 41, 1149–1160. [CrossRef] [PubMed]
33. Bodewes, I.L.A.; Björk, A.; Versnel, M.A.; Wahren-Herlenius, M. Innate immunity and interferons in the
pathogenesis of Sjögren’s syndrome. Rheumatology 2019. [CrossRef] [PubMed]
34. Nezos, A.; Gravani, F.; Tassidou, A.; Kapsogeorgou, E.K.; Voulgarelis, M.; Koutsilieris, M.; Crow, M.K.;
Mavragani, C.P. Type I and II interferon signatures in Sjogren’s syndrome pathogenesis: Contributions
in distinct clinical phenotypes and Sjogren’s related lymphomagenesis. J. Autoimmun. 2015, 63, 47–58.
[CrossRef] [PubMed]
35. Cantaert, T.; van Baarsen, L.G.; Wijbrandts, C.A.; Thurlings, R.M.; van de Sande, M.G.; Bos, C.; van der Pouw
Kraan, T.C.; van der Pouw, T.K.; Verweij, C.L.; Tak, P.P.; et al. Type I interferons have no major influence on
humoral autoimmunity in rheumatoid arthritis. Rheumatology 2010, 49, 156–166. [CrossRef] [PubMed]
36. Castañeda-Delgado, J.E.; Bastián-Hernandez, Y.; Macias-Segura, N.; Santiago-Algarra, D.; Castillo-Ortiz, J.D.;
Alemán-Navarro, A.L.; Martínez-Tejada, P.; Enciso-Moreno, L.; Garcia-De Lira, Y.; Olguín-Calderón, D.; et al.
Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates
with Autoantibody Production. Front. Immunol. 2017, 8, 285. [CrossRef]
37. Ekholm, L.; Vosslamber, S.; Tjärnlund, A.; de Jong, T.D.; Betteridge, Z.; McHugh, N.; Plestilova, L.; Klein, M.;
Padyukov, L.; Voskuyl, A.E.; et al. Autoantibody Specificities and Type I Interferon Pathway Activation in
Idiopathic Inflammatory Myopathies. Scand. J. Immunol. 2016, 84, 100–109. [CrossRef] [PubMed]
38. Brkic, Z.; van Bon, L.; Cossu, M.; van Helden-Meeuwsen, C.G.; Vonk, M.C.; Knaapen, H.; van den Berg, W.;
Dalm, V.A.; Van Daele, P.L.; Severino, A.; et al. The interferon type I signature is present in systemic sclerosis
before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high
collagen synthesis. Ann. Rheum. Dis. 2016, 75, 1567–1573. [CrossRef] [PubMed]
39. Quartuccio, L.; Mavragani, C.P.; Nezos, A.; Gandolfo, S.; Tzioufas, A.G.; De Vita, S. Type I interferon signature
may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren’s
syndrome. Clin. Exp. Rheumatol. 2017, 35, 719–720.
40. de Jong, T.D.; Vosslamber, S.; Blits, M.; Wolbink, G.; Nurmohamed, M.T.; van der Laken, C.J.; Jansen, G.;
Voskuyl, A.E.; Verweij, C.L. Effect of prednisone on type I interferon signature in rheumatoid arthritis:
Consequences for response prediction to rituximab. Arthritis Res. Ther. 2015, 17, 78. [CrossRef]
41. Wright, H.L.; Thomas, H.B.; Moots, R.J.; Edwards, S.W. Interferon gene expression signature in rheumatoid
arthritis neutrophils correlates with a good response to TNFi therapy. Rheumatology 2015, 54, 188–193.
[CrossRef] [PubMed]
42. Raterman, H.G.; Vosslamber, S.; de Ridder, S.; Nurmohamed, M.T.; Lems, W.F.; Boers, M.; van de Wiel, M.;
Dijkmans, B.A.; Verweij, C.L.; Voskuyl, A.E. The interferon type I signature towards prediction of non-response
to rituximab in rheumatoid arthritis patients. Arthritis Res. Ther. 2012, 14, R95. [CrossRef] [PubMed]
43. Everaert, C.; Luypaert, M.; Maag, J.L.V.; Cheng, Q.X.; Dinger, M.E.; Hellemans, J.; Mestdagh, P. Benchmarking
of RNA-sequencing analysis workflows using whole-transcriptome RT-qPCR expression data. Sci. Rep. 2017,
7, 1559. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




The HD-OCT Study May Be Useful in Searching for
Markers of Preclinical Stage of Diabetic Retinopathy
in Patients with Type 1 Diabetes
Magdalena Kołodziej 1, Arleta Waszczykowska 2, Irmina Korzeniewska-Dyl 3,
Aleksandra Pyziak-Skupien 4, Konrad Walczak 3, Dariusz Moczulski 3, Piotr Jurowski 2,
Wojciech Młynarski 5, Agnieszka Szadkowska 6 and Agnieszka Zmysłowska 6,*
1 Department of Practical Obstetrics, Medical University of Lodz, 90-419 Lodz, Poland
2 Department of Ophthalmology and Vision Rehabilitation, Medical University of Lodz, 90-419 Lodz, Poland
3 Department of Internal Medicine and Nephrodiabetology, Medical University of Lodz, 90-419 Lodz, Poland
4 Department of Pediatrics, Silesian Medical University in Katowice, 40-055 Katowice, Poland
5 Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, 90-419 Lodz, Poland
6 Department of Pediatrics, Diabetology, Endocrinology and Nephrology, Medical University of Lodz,
90-419 Lodz, Poland
* Correspondence: agnieszka.zmyslowska@umed.lodz.pl; Tel.: +48-42-6177750; Fax: +48-42-6177798
Received: 30 July 2019; Accepted: 23 August 2019; Published: 26 August 2019
Abstract: The aim of the study was to analyze the thickness of individual retinal layers in patients
with type 1 diabetes (T1D) in comparison to the control group and in relation to markers of diabetes
metabolic control. The study group consisted of 111 patients with an average of 6-years of T1D
duration. The control group included 36 gender- and age-matched individuals. In all patients optical
coherence tomography (OCT) study was performed using HD-OCT Cirrus 5000 with evaluation of
optic nerve head (ONH) parameters, thickness of retinal nerve fiber layer (RNFL) with its quadrants,
macular full-thickness parameters, ganglion cells with inner plexus layer (GCIPL) and choroidal
thickness (CT). Lower disc area value was observed in the study group as compared to controls
(p = 0.0215). Negative correlations were found both between age at examination and rim area
(R = −0.28, p = 0.0007) and between superior RNFL thickness and duration of diabetes (R = −0.20,
p = 0.0336). Positive correlation between center thickness and SD for average glycemia (R = 0.30,
p= 0.0071) was noted. Temporal CT correlated positively with age at examination (R= 0.21, p= 0.0127).
The selected parameters the HD-OCT study may in the future serve as potential markers of preclinical
phase of DR in patients with T1D.
Keywords: diabetic retinopathy; type 1 diabetes; HD-OCT; ONH; RNFL; choroidal thickness
1. Introduction
Type 1 diabetes (T1D) is one of the most common metabolic diseases diagnosed in children and is
associated with the risk of development of numerous chronic complications. Diabetic eye disease—as
the most common of the chronic complications of T1D—may be connected with abnormalities in
various eye structures. However, the complication related to the greatest risk of loss of vision is diabetic
retinopathy (DR) and accompanying diabetic macular edema (DME) [1,2]. DR is considered to be
the earliest chronic complication of type 1 diabetes because it is present even after several years of
its course [3]. The development and progression of diabetic retinopathy is influenced mainly by the
degree of metabolic diabetes control, diabetes duration, presence of dyslipidemia, proteinuria, arterial
hypertension, pregnancy and genetic predisposition [4]. Many studies have shown that proper control
of glycemia, blood pressure and lipid levels may reduce the risk of DR development and significantly
slow its progression [5].
Diagnostics 2019, 9, 105; doi:10.3390/diagnostics9030105 www.mdpi.com/journal/diagnostics31
Diagnostics 2019, 9, 105
Currently, fluorescein angiography (FA) remains the gold standard in the diagnosis of clinical
phase of diabetic retinopathy, which enables detailed assessment of blood vessels of the fundus of
the eye as an invasive method [6]. FA is a test that involves taking a series of photographs of the
fundus after intravenous administration of a contrast agent (fluorescein). FA enables visualization of
the circulation in the retinal vessels and indirectly the uvea, as well as evaluation of the state of the
retinal pigment epithelium and retinal blood vessels which are not visible during fundus examination.
This technique has become fundamental when assessing the complications of diabetic retinopathy,
retinal vascular obstruction, or when diagnosing many macular diseases. However, FA is associated
with severe potential risks [7].
Thus, in an attempt to optimize diagnostic procedures, the most informative and least invasive
diagnostic method should be identified. Optical coherence tomography (OCT) is a safe, non-contact,
non-invasive and effective technique of imaging tissue and could be considered as a valid alternative
to FA. Intra-retinal leakage is not necessary to confirm the presence of DME, and FA is useful only as a
guide for focal or grid laser treatment of thickened areas. Therefore, numerous new diagnostic tools
such as high-definition OCT (HD-OCT) and spectral-domain (SD) OCT are being evaluated clinically.
These methods provide improved capabilities for the imaging of the intra-retinal morphology and/or
allow for the analysis of the structural and functional aspects of leakage activity. Moreover, they offer
realistic 3D imaging of retinal and subretinal levels in various diseases [8]. Cirrus HD-OCT (Carl Zeiss
Meditec, Inc., Dublin, OH, USA) is an SD-OCT that has an axial resolution of 5 μm and a scan velocity
of 27,000 axial scans per second. These features improve the ability to visualize smaller and thinner
structures that are difficult to visualize with time-domain OCT (Stratus OCT).
Therefore, alternative imaging methods such as OCT study are suggested in patients, especially
considering the new approach to pathologic mechanisms leading to DR development [9]. Until now,
diabetic retinopathy has been considered to be a mainly vascular complication, however, it is now
known that neurodegenerative processes take place in the retina before the clinical retinopathy, which
is its preclinical period [5]. Recent publications have shown that these early symptoms of neuronal
damage of the retinal layer are present before the appearance of changes visible at the fundus of the
eye and may contribute to the development of microvascular abnormalities [10,11]. These reports also
indicate a decrease in retinal thickness in diabetic patients, mainly in macular ganglion cells. This
suggests progress in neurodegeneration as an early, preclinical stage of diabetic retinopathy [12,13].
In addition, it is known that previous attempts to treat diabetic retinopathy are being made in its
clinical phase [14,15], whereas, from the patient’s point of view, it would be worthwhile to try to stop
the progress of retinal neurodegeneration at the earliest possible stage [16]. The lack of unambiguously
defined early markers of DR preclinical phase leads to their search based on new and non-invasive
imaging studies.
The aim of the study was to evaluate the thickness of retina in its individual layers in patients
with type 1 diabetes as compared to the control group and in relation to the parameters of metabolic
diabetes control.
2. Materials and Methods
The study was conducted in accordance with the Declaration of Helsinki, and the study protocol
was approved by the University Bioethics Committee at the Medical University in Lodz, Poland
(RNN/374/17/KE, 19/12/2017). Patients and/or their parents gave written informed consent for
participation in the study.
The work described has been carried out in accordance with The Declaration of Helsinki of 1975
and revised in 2013 for experiments involving humans.
The study group consisted of 111 patients (F-61/M-50) including 82 children and 29 adults aged
5.6 to 50.8 (min-max) years at the time of study, with an average 6-year course of clinically overt T1D.
In all patients, diabetes was diagnosed according to WHO criteria. The presence of autoantibodies
32
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characteristic for T1D and decreased C-peptide plasma levels were observed in all patients at T1D
onset. Detailed characteristics of the study group are shown in Table 1.
Table 1. Characteristics of the study group of patients with type 1 diabetes (T1D).
Parameter Median or Percentage IQR–Interquartile Range
Age at T1D onset (years) 8.63 4.5–10.8
Diabetes duration (years) 6.02 3.9–10.2
Age at examination (years) 14.47 10.7–20.6
Gender (F/M; %) 55/45 -
Average HbA1c level (%/mmol/mol) 7.10/54.1 6.7/49.77–8/63.9
Average blood glucose level (mg/dL) 155 135–180
Standard deviation for blood glucose level 72 59–79
BMI-Z-score at examination 0.55 −0.36–1.12
Insulin uptake (U/kg) 0.80 0.60–1.07
Total cholesterol (mg/dL) 181.53 153–311
LDL-cholesterol (mg/dL) 110 87–211
HDL-cholesterol (mg/dL) 62 52–98
Triglycerides (mg/dL) 75 55–110
Serum creatinine level (mg/dL) 0.66 0.6–0.7
The control group consisted of 36 healthy (F-23/M-13) gender- (p = 0.3466) and age-matched
(p = 0.1688) individuals with no glucose tolerance disturbances.
Patients under 5 years of age with diagnosed arterial hypertension, clinically manifest diabetic
retinopathy, diabetic kidney disease and previous ocular surgery, any eye disease, myopia and
hyperopia above 3 diopters, chronic use of topical medications were excluded from the study and
control groups.
The HD-OCT study was performed in the patients from the study and control groups in the
Department of Ophthalmology and Vision Rehabilitation of the Medical University of Lodz, Poland
using the Cirrus HD-OCT device (5000: Carl Zeiss Meditec. Inc., Dublin, OH, USA) after mydriasis
and evaluated independently by two experienced ophthalmologists.
Two scans, including one macular scan centered on the fovea (macular cube 512 × 128 protocol)
and one peripapillary retinal nerve fiber layer (RNFL) scan centered on the optic disc (optic disc cube
200 × 200 protocol) were acquired through dilated pupils. The mean retinal thickness values were
obtained on all images for foveal subfield and the inner and outer rings of a standard ETDRS (Early
Treatment of Diabetic Retinopathy Study) grid. Macular ganglion cell layer/inner plexiform layer
(GCIPL), RNFL (retinal nerve fiber layer) and optic nerve head (ONH) parameters were measured
automatically using the internal ganglion cell, RNFL and ONH analysis algorithms, respectively.
The following GCIPL thickness measurements were analyzed: Average, minimum and sectoral
(superonasal, superior, superotemporal, inferotemporal, inferior and inferonasal). RNFL total thickness
as well as superior, inferior, temporal and nasal RNFL thickness were evaluated. For the ONH analysis,
the following parameters were included: Disc area, rim area, cup volume and cup-to-disc (c/d) ratio.
Choroidal thickness (CT) was measured manually from the outer portion of the hyperreflective line
corresponding to the retinal pigment epithelium to the inner surface of the sclera, using the Cirrus
linear measurement tool (HD 21-line raster). To be included in this study, images had to be at least 6 of
10 in intensity and taken as close to the fovea as possible, by choosing to image the thinnest point of
the macula, with the understanding that slight differences in positioning could affect the measured
thickness. Choroidal thickness was measured at the fovea and 1-mm temporal and nasal to the fovea.
Averages from measurements in both eyes were calculated and used for further analysis.
The HD-OCT results were related to individual parameters and indicators of clinical course of
diabetes including: Age at the time of the study (years), gender, age at diabetes onset (years), duration
of diabetes (years), average HbA1c from the last year preceding the study (%), average blood glucose
(BG) level from 14 days before an examination (mg/dL), standard deviation (SD) for BG evaluating
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the fluctuations in BG results from 14 days before an examination, BMI-Z-score and mean insulin
uptake (U/kg).
HbA1c was determined by high-performance liquid chromatography (HPLC) using the Bio-Rad
VARIANTTM Hemoglobin A1c Program (Bio-Rad Laboratories Inc., Hercules, CA, USA) with its values
represented as percentages and in addition as mmol/mol according to IFCC (International Federation
of Clinical Chemistry).
Statistical Analysis
The assessment of the normality of distribution was carried out using the Kolmogorov-Smirnov
test and verified by the Shapiro-Wilk test. Comparisons of the HD-OCT variables between study and
control groups were performed using a non-parametric Mann-Whitney’s test. For the correlation
analysis, a Spearman correlation test was used. Categorical variables were presented as numbers
with appropriate percentages and continuous variables as medians with interquartile range (IQR).
Results with p-values < 0.05 were considered as statistically significant. Analyses were performed
using Statistica 13.1 PL software (Statsoft, Tulsa, OK, USA).
3. Results
The parameters of optic nerve head (ONH); thickness of retinal nerve fiber layer (RNFL) and its
quadrants; average retinal thickness, central retinal thickness, total retinal volume; macular ganglion
cell layer/inner plexiform layer (GCIPL) thickness; and choroidal thickness (CT) were compared
between the study and control groups. A significantly lower disc area value was observed in the study
group (Me 1.84 mm2; IQR 1.62–2.04) in comparison to the control group (Me 1.98 mm2; IQR 1.82–2.14,
p = 0.0215) (Table 2). There were no statistically significant differences in other HD–OCT parameters
between the studied groups (Table 2).
Table 2. Comparison of the parameters of ONH, thickness of RNFL and its quadrants, average retinal
thickness, central retinal thickness, total retinal volume, CT and GCIPL thickness, assessed using
high-definition optical coherence tomography HD-OCT of the study group of patients with T1D and
control group.
Parameter Study Group Median (IQR) Control Group Median (IQR) p Level
Disc area (mm2) 1.84 (1.62–2.04) 1.98 (1.82–2.14) 0.0214
Rim area (mm2) 1.43 (1.28–1.63) 1.53 (1.31–1.71) 0.2553
c/d area ratio 0.42 (0.33–0.55) 0.45 (0.32–0.56) 0.6356
Vertical CDR 0.41 (0.32–0.52) 0.43 (0.29–0.53) 0.8136
Cup volume (mm3) 0.07 (0.02–0.16) 0.08 (0.03–0.22) 0.4646
RNFL Total Thickness (μm) 93.00 (86.00–101.50) 91.25 (87.50–98.51) 0.4640
Superior RNFL thickness (μm) 116.50 (108.50–128.50) 117.50 (107.00–127.50) 0.6884
Inferior RNFL thickness (μm) 124.50 (109.50–134.50) 122.00 (113.25–128.75) 0.5841
Temporal RNFL thickness (μm) 63.50 (57.50–70.50) 63.75 (55.25–71.00) 0.8605
Nasal RNFL thickness (μm) 69.50 (60.50–76.50) 70.00 (60.5–74.00) 0.6686
Macular average thickness (μm) 283.50 (274.50–293.50) 284.25 (276.25–294.75) 0.4401
Center thickness (μm) 253.25 (241.00–264.00) 255.50 (240.75–266.00) 0.6661
Total macular volume (mm3) 10.20 (9.85–10.55) 10.22 (9.95–10.60) 0.3400
Choroidal thickness subfoveal (μm) 352.00 (319.50–393.00) 360.75 (331.50–399.75) 0.3528
Choroidal thickness nasal (μm) 354.00 (318.50–389.00) 359.00 (326.25–376.50) 0.8965
Choroidal thickness temporal (μm) 336.50 (301.50–384.50) 352.75 (314.50–383.00) 0.3070
Average GCLIPL thickness (μm) 83.50 (79.50–88.00) 82.25 (78.75–86.75) 0.6005
Minimum GCLIPL thickness (μm) 81.50 (76.50–86.00) 80.50 (76.75–83.75) 0.7340
GCLIPL superior (μm) 83.50 (79.00–87.50) 82.50 (77.75–87.00) 0.2140
GCLIPL superior-nasal (μm) 85.00 (81.50–89.50) 83.00 (79.50–87.00) 0.1240
GCLIPL inferior-nasal (μm) 84.00 (79.50–88.50) 81.75 (78.00–86.00) 0.1551
GCLIPL inferior (μm) 82.00 (78.00–86.00) 80.75 (77.50–86.00) 0.7551
GCLIPL inferior-temporal (μm) 83.50 (80.00–88.50) 82.75 (78.25–86.25) 0.3227
GCLIPL superior-temporal (μm) 82.50 (78.52–86.50) 81.50 (77.00–84.50) 0.2982
T1D—type 1 diabetes, IQR—interquartile range, ONH—optic nerve head, RNFL—retinal nerve fiber layer,
GCILP—ganglion cell layer/inner plexiform layer, CT—choroidal thickness; p < 0.05 are indicated in bold.
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Then, in the study group the correlations between HD-OCT and individual parameters and
markers of clinical course of diabetes were analyzed.
A negative correlation between rim area and age at the time of examination was observed
(R = −0.28, p = 0.0007) (Figure 1). Moreover, the c/d ratio correlated positively with age of patients at
the study time (R = 0.17, p = 0.0449). There was also a tendency to negative correlations between rim
area and age at T1D onset (R = −0.19, p = 0.0517) and disc area and HbA1c value (R = −0.17, p = 0.0843).
Figure 1. Correlation between rim area and age at examination in patients with type 1 diabetes
(R = −0.28, p = 0.0007).
In the study group, negative correlations between superior RNFL thickness and duration of
diabetes (R = −0.20, p = 0.0336) (Figure 2) and between inferior RNFL thickness and HbA1c (R = −0.20,
p = 0.0364) were also noted. There were positive correlations between macular center thickness and SD
for average blood glucose level (R = 0.30, p = 0.0071).
Figure 2. Correlation between thickness of superior retinal nerve fiber layer and duration of type 1
diabetes (R = −0.20, p = 0.0336).
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The age of patients at the study time showed a trend to negative correlations with both average
GCIPL thickness (R = −0.15, p = 0.0706) and GCIPL lower thickness (R = −0.15, p = 0.0759). A trend
with respect to a negative correlation between GCIPL low-temporal thickness and HbA1c (R = −0.18,
p = 0.0696) was also found.
It was also observed that temporal CT correlated positively both with age at the examination
time (R = 0.21, p = 0.0127) (Figure 3) and age at diabetes diagnosis (R = 0.22, p = 0.0255). A positive
correlation was also found between the subfoveal CT and the age at diabetes onset (R = 0.23, p = 0.0189),
while a tendency to a positive correlation between the subfoveal CT and the age at examination
(R = 0.16, p = 0.0596) was observed. Other parameters of clinical course of type 1 diabetes did not
correlate with the HD-OCT parameters (p > 0.1).
 
Figure 3. Correlation between temporal choroidal thickness and age at examination in patients with
type 1 diabetes (R = 0.21, p = 0.0127).
4. Discussion
In the present study, for the first time such a large number of patients with type 1 diabetes, both
children and young adults, were examined using the HD-OCT study.
A significant reduction of the disc area in the study group was observed in comparison to healthy
controls. Moreover, in patients with T1D the selected ONH parameters correlated with their age. In
previous studies, no differences in rim area, disc area or cup to disc ratio between pediatric patients
with T1D and control group [17] were found. Only significant differences in c/d ratio were noted in
patients with type 2 diabetes (T2D) without DR as compared to the control group [18]. In the studies,
more binocular RNFL thickness asymmetry in diabetic patients in relation to the controls without
significant differences in RNFL thickness [17,18] was also noted.
In our study, negative correlations in the study group between superior RNFL thickness and
duration of diabetes, and between inferior RNFL thickness and mean HbA1c value were observed.
Similar to our results, Tekin et al. noticed negative correlations between both global RNFL thickness and
macular thickness and HbA1c value and diabetes duration using the SD-OCT study in children with
T1D without clinical overt DR. They also found significantly thinner global RNFL thickness as well as
temporal and inferior outer macular thickness in relation to the controls [19]. Both overall and superior
RNFL thickness correlated with the age of T1D patients in the Dehghani et al. study, at the same time
being an indicator of peripheral neuropathy in the patients [20]. In other research, the significant
thinning of RNFL and its individual quadrants was confirmed in T2D patients without retinopathy
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in comparison to the controls [21]. Furthermore, there are also studies in which RNFL thinning
was found to correlate with the severity of retinopathy, but it was found also in T2D patients [22].
Interestingly, early structural damage of neuroretina was also related to glucose fluctuations assessed
in continuous glucose monitoring (CGM) in the group of T1D patients [23]. In our study, to evaluate
glucose variability, the SD for the average blood glucose (BG) level was measured within the two weeks
prior to the HD-OCT study. However, it correlated positively only with macular center thickness
confirming earlier reports of the effect of glucose fluctuations on the DR presence accompanied by
DME [24,25].
In the present study, no differences were found between the groups with respect to other macular
full-thickness parameters or GCIPL thickness. Only tendencies to correlation of average GCIPL and
lower GCIPL thickness with age and HbA1c were observed. In several studies, however, a reduced
GCIPL thickness was found in both pediatric T1D patients and adults with T2D without retinopathy,
suggesting that the presence of chronic hyperglycemia may have an early neurodegenerative effect on
retinal ganglion cells, even when vascular disorders are not yet present [26,27].
Previous studies on DR pathogenesis have shown that neuronal dysfunction and progressive
neurodegeneration are closely correlated with microvascular disorders. According to many authors, the
best method to prevent the appearance of diabetic eye disease is correct glycemic control, reducing the
risk of developing microvascular complications [28]. However, it seems that local hyperperfusion may
be present already at the preclinical stage of DR and may accompany the neurodegeneration progress.
In the paper by Golebiewska et al. it was noted that—besides the presence of early neuroretinal
lesions—the central choroidal thickness tends to be thicker in T1D children without DR in comparison
to healthy children and shows a correlation with gender of the subjects in favor of girls. However,
it does not correlate with the duration of diabetes or HbA1c [29]. In our study we did not observe
a relationship between CT and the gender, but with the age of the subjects. Moreover, positive
correlations between subfoveal and temporal parts of CT with the age of patients were found, both at
the time of examination and at the time of diabetes diagnosis.
The Niestrata-Ortiz et al. study carried out in the group of children with type 1 diabetes compared
to the age-matched control group also revealed that choroidal thickness is higher in patients with T1D
compared to the control group, and increases with the duration of diabetes, which makes it useful for
screening in children with type 1 diabetes [30].
Concluding, the results obtained in the group of children and young adults with type 1 diabetes
indicate a relationship between age of patients, duration of diabetes, chronic hyperglycemia, glycemia
fluctuations and the size of the ONH parameters, thickness of superior and inferior RNFL quadrant,
center macular thickness and subfoveal and temporal choroidal thickness.
Our findings can also confirm earlier observations of the researchers that the Cirrus HD-OCT
system achieves approximately double the axial resolution of the previous generation Stratus OCT
device and allows for better visualization of tissues. This processing HD-OCT software is unique
because images are generated by evaluating all of the pixel data to reduce noise and construct the
best possible image. This enables visualization and measurement of the full thickness of the choroid
and satisfactory repeatable GCIPL thickness measurements using the Cirrus HD-OCT Ganglion Cell
Analysis (GCA) algorithm [31,32].
The limitation of our work may be the lack of other—apart from SD for blood glucose
level—indicators of glycemia variability, which require CGM system connection to patients, as
well as ophthalmic parameters, including the assessment of visual acuity. The obtained results also
require further confirmation on a larger group of patients.
However, it seems that simultaneous measurement of choroidal thickness and several
neurodegeneration parameters using HD-OCT is useful and the selected parameters may be promising
markers of preclinical phase of diabetic retinopathy in patients with type 1 diabetes. This indicates the
usefulness of the HD-OCT study as a diagnostic tool and confirms the need for the HD-OCT study in
patients with several years of clinical course of type 1 diabetes.
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Abstract: Diabetes technology has continually evolved over the years to improve quality of life and
ease of care for affected patients. Frequent blood glucose (BG) checks and multiple daily insulin
injections have become standard of care in Type 1 diabetes (T1DM) management. Continuous glucose
monitors (CGM) allow patients to observe and discern trends in their glycemic control. These devices
improve quality of life for parents and caregivers with preset alerts for hypoglycemia. Insulin
pumps have continued to improve and innovate since their emergence into the market. Hybrid
closed-loop systems have harnessed the data gathered with CGM use to aid in basal insulin dosing
and hypoglycemia prevention. As technology continues to progress, patients will likely have to enter
less and less information into their pump system manually. In the future, we will likely see a system
that requires no manual patient input and allows users to eat throughout the day without counting
carbohydrates or entering in any blood sugars. As technology continues to advance, endocrinologists
and diabetes providers need to stay current to better guide their patients in optimal use of emerging
management tools.
Keywords: type 1 diabetes; continuous glucose monitor; insulin pump; continuous insulin infusion
system; hybrid closed-loop system; diabetes technology
1. Introduction
Type 1 diabetes (T1DM) is an autoimmune disease in which the β cells of the pancreas are
damaged and subsequently destroyed. Since these cells are critical in the production of insulin
hormone, this leads to a state of insulin deficiency. Landmark studies, such as the Diabetes Control
and Complications Trial (DCCT) and the ongoing Epidemiology of Diabetes Interventions and
Complications (EDIC) follow up study, have conclusively proven the long-term benefits of early
and intensive blood glucose control on the future development of diabetes-related complications,
such as heart, eye, kidney, and nerve disease, and improved life expectancy [1]. As a result, frequent
blood glucose (BG) checks and multiple daily insulin injections have become standard of care in T1DM
management. These advances have brought forth challenges of managing a chronic illness as well as
opportunities to apply technological advances from engineering to medicine.
Diabetes was referenced as early as 1500 B.C. in Egyptian manuscripts as a disease noted for
increased urination. The techniques for diagnosis of T1DM were described by the middle of the 16th
century when it was recognized by detection of sugar in the urine [2]. However, insulin was not
discovered until 1921, when Charles Best and Frederick Banting used canine pancreas extracts to
successfully treat diabetic dogs. In 1923, Eli Lilly introduced the first insulin product, a further purified
pancreas extract, to the market [3]. Since that time, many different insulins and innovative insulin
delivery devices have been developed from insulin pens to insulin pumps. Both diagnostic tools and
treatments have continued to evolve in the 20th and 21st centuries.
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The field of glucose monitoring and insulin administration technology has transformed in the
past two decades. Patients in the developed world use palm-size or smaller handheld glucometers
as a standard of care for managing their diabetes. Additionally, continuous glucose monitor (CGM)
devices, which allow patients to wear a sensor and obtain frequent automated BG readings, are quickly
gaining a central place in T1DM management. Furthermore, integrated insulin pump and CGM
systems are now increasingly available; this has improved the ease of insulin delivery in addition to
prevention of severe hypoglycemia, one of the most feared complications of treatment with insulin.
As the technology in diabetes care continues to evolve, providers must be up-to-date on available
systems and advocate for the care of their patients. In this review article, we discuss currently available
and shortly anticipated diabetes technology available for T1DM patients within the United States (US)
and Europe with the goal of providing a historical perspective and an update to clinicians caring for
patients with diabetes so they can facilitate discussions on therapeutic options with their patients.
2. Methods
A thorough review of the existing literature was conducted via PubMed and Google Scholar.
Keywords included were ‘diabetes’, ‘T1DM’, ‘continuous glucose monitor’, ‘CGM’, ‘insulin pump’,
‘continuous insulin infusion system’, ‘hybrid closed loop system’, ‘bihormonal’, ‘Abbott Freestyle
Libre’, ‘Dexcom’, ‘Medtronic’, ‘Tandem’, ‘OmniPod’, ‘iLet’. Relevant studies from 2007–2019 published
in the English language were reviewed and included.
3. Continuous Glucose Monitors
Continuous glucose monitors are devices that help patients with diabetes to monitor their glucose
levels over time. They allow for dynamic information that indicates direction of glucose change
allowing the user to observe the influence of diet, exercise, and insulin dosing on the patient’s glucose
level in real-time. Additionally, they can be used in conjunction with insulin pumps to better guide
insulin therapy. Studies have shown that CGM use can increase time spent in normoglycemia and
decrease the frequency and severity of hypoglycemia episodes [4,5]. In a randomized study of adults
with hypoglycemia unawareness, researchers found that patients in the CGM group had a 72%
reduction in hypoglycemia events [6]. Alarms may be set on some of these devices to alert the user
to urgent low glucose levels or elevated glucose levels. Many devices even allow sharing of data
to multiple smartphones providing parents with access to remotely monitor their child’s glucose
levels and allowing physicians to view their patient’s glucose trends and accordingly adjust insulin
therapy [7].
Medtronic Minimed CGM was the first CGM system approved by the FDA in 1999 after it had
been tested in Caucasian adults with T1DM [8]. This first available system was not meant to be used
in real-time and BG trends could only be evaluated after the window of therapy [9]. Additionally,
the FDA specifically stipulated that this device be used in conjunction with regular finger-stick BG
checks. Over the 20 years since the introduction of the first CGM system to market, many new systems
and updates have been introduced and have revolutionized management of T1DM. In early 2017,
the Centers for Medicare & Medicaid Services (CMS) determined that CGM systems that are FDA
approved for treatment decisions could be eligible for Medicare coverage [10]. Recently the American
Diabetes Association has endorsed use of CGMs in children and adolescents with T1DM to help
improve glucose control while minimizing risk of hypoglycemia [11].
A CGM consists of an electrode sensor placed subcutaneously, a transmitter, and a receiver.
The sensor detects glucose levels by electrochemical detection of glucose [9]. This sensor measures
the glucose levels in the interstitial fluid and is attached to a transmitter that sends the data to
a receiver. The glycemic data and trends are displayed on the receiver or on the pump screen of part of
an integrated system.
Various sensors that have been used include biosensors, which involve the use of natural oxygen
cofactor, artificial redox mediators, direct electron transfer between glucose oxidase and the electrode,
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and direct electro-oxidation of glucose [12]. The most commonly used method in CGM technology
today uses electrochemical sensors because of increased sensitivity and accuracy [13]. Typically,
this will use glucose oxidase (GOx) to detect glucose levels. This particular enzyme electrochemical
sensor reaction has gained widespread use because GOx remains stable at variable pH values and
temperatures. GOx, with the aid of a cofactor, facilitates transfer of electrons and production of
hydrogen peroxide. The electrochemical sensor detects the number of electron transfers and, therefore,
the number of glucose molecules present. Oxygen is important for this reaction to occur in the
subcutaneous tissue. In the setting of poor perfusion or hypoxia, sensors may not be able to accurately
detect glucose levels without appropriate levels of oxygen present [13,14]. Fluorescence-based sensors
have also been used and are discussed in further detail below.
Current recommendations for BG monitoring advise 6–10 BG readings daily to guide insulin
management of T1DM patients [15]. CGM systems allow for readings every five minutes approximately
throughout the day and night and, thus, provide information about accurate trends that previously
were not accessible. Additionally, with some of the new systems, routine BG checks for mealtime
insulin dosing may be replaced with CGM readings. At this point in time, there is a recommendation
to check a finger-stick BG manually to confirm hypoglycemia or if clinically warranted; however,
this may change in the future as sensor accuracy continues to improve.
Accuracy of systems is a critical aspect of CGM use and system calibrations have typically been
required to ensure accuracy of readings. With typical home glucometer use, there is approximately
a 20% margin of error for BG measurements [16]. Additionally, it is important to remember,
that finger-stick BG values measure glucose from capillary blood while CGM sensors measure glucose
from the interstitial fluid in the subcutaneous fat. These compartments do have slightly different
glucose values especially during periods of rapid change in glycemia. This discrepancy in measurement
values is known as ‘lag time’ in which the interstitial fluid glucose levels are lagging behind the blood
values by a median of 6.8 min and up to almost 10 min in some cases [17,18]. The accuracy of systems is
typically reported as a mean absolute relative difference (MARD) which is determined using data from
clinical trials and calculated by using the difference in the CGM measurement and concurrent reference
measurement of glucose used in the study [19]. Currently available CGM systems are discussed further
in the sections below with system comparisons outlined in Table 1.








FDA Approved Age 18 years and up 2 years and up 14 to 75 years 18 years and up
MARD 9.4% [20] 9% [21] 8.7% [22] 8.8% [23]
Duration of use 14 days 10 days 7 days 90 days
Calibration not required not required, but canif desired
2 required daily,
recommend 3–4 daily 2 required daily
Display options Scanner
Receiver, Smartphone,




May share to 5 devices
Smartphone; May
share to 5 devices
Warm up time 1 h 2 h 2 h 24 h
Alarms no yes yes yes
Approved insertion
sites/procedure arm
abdomen (2 years and
older); upper buttocks
(2–17 years)
abdomen implanted in office,upper arm
3.1. Standalone
3.1.1. Abbott Freestyle CGM Systems
Abbott’s first CGM was the Freestyle Navigator and was initially FDA approved in 2008.
This product was then subsequently pulled when Abbott’s newer system the Freestyle Libre Flash
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CGM, which did not require patient calibration with glucose entry, came out in 2014. Recently,
the system has been updated and may be worn for 14 days prior to requiring a new sensor. The sensors
are factory calibrated and require no calibration for the duration of the 14-day wear period [14]. There is
a 1 h warm up period for the device to start generating data. The data are transferred to the reader
when it is brought in proximity to the sensor. The reader then displays the current blood sugar with
an arrow indicating the direction of the glucose trend and the readings over the last 8 h. The sensor is
able to hold 8 h of data and data may be lost if the reader is not used in more than 8 h. The reader can
hold data for up to 90 days and may be uploaded using device software or accessed via an approved
smartphone device and the Freestyle LibreLink application. The Freestyle Libre has been approved for
insertion in the arm [24]. While in the US, it is approved by the FDA in patients greater than 18 years
old, it has been cleared for pediatric patients ages four years and up in Europe and Australia [25].
3.1.2. Dexcom CGM Systems
Dexcom is a company that focuses solely on CGM technology for diabetes patients. They first
came out with their Short-Term Sensor (STS) system in 2006. In 2015, they released the Dexcom
G4 Platinum CGM system. This system consists of a small sensor that measures glucose levels
subcutaneously, a transmitter that is attached to the top of the sensor, and a receiver which displays
the glucose readings and trends. With the introduction of their G4 system, Dexcom added share
technology so that BG readings and trends may be monitored remotely via smartphone. The system
originally worked exclusively with iOS systems, but is now compatible with some android devices.
The Dexcom G5 system allowed users to bypass the receiver altogether and directly send data from
the sensor/transmitter unit to their smartphone. The newest iteration, the Dexcom G6, can integrate
with Tandem and display CGM data on the Tandem X2 insulin pump.
In March 2018, Dexcom released the G6 CGM system that is FDA approved for patients as young
as two years old [26]. The G6 is factory calibrated with no need for calibration or finger-sticks to make
clinical decisions based on FDA approval. Additionally, the G6 system is approved for wear up to
10 days. Through the smartphone application or receiver, alarms can be set for glucose target ranges to
alert the user to episodes of hypoglycemia or hyperglycemia. Additionally, data may be shared with
more than one smartphone device allowing parents and caregivers to remotely monitor the patient’s
glucose measurements.
3.1.3. Senseonics Eversense CGM System
Senseonics Eversense is the only implantable CGM device currently on the market. The device
consists of an implantable sensor, removable transmitter, and a smartphone application. The transmitter
activates the sensor which flashes an LED light source exciting the fluorescent polymer coating
on the outside of the sensor. Glucose in the interstitial fluid will reversibly bind to the coating
and alter the amount of light emitted by the polymer coating. The amount of emitted light is
proportional to interstitial glucose concentration and is measured by photodetectors inside the
sensor. The smart transmitter is attached to the skin with an adhesive, sitting directly over the
sensor, and vibrates for alerts including hypoglycemia even when the smartphone is not in range.
The transmitter is rechargeable and does not need to be replaced every three months with the
implantable sensor. The implantation process can be done in the outpatient office setting by trained
health care professionals. There is a 24-h warm up period after the sensor is initially placed followed
by an initialization period that requires multiple calibrations within another 12-h period. Thereafter,
the system requires two calibrations daily and advises finger-stick checks for treatment decisions
regarding hypoglycemia or hyperglycemia. The transmitter does require charging daily that takes
approximately 15 min to complete. The transmitter is water resistant up to a depth of 3.3 feet for
30 min at a time; however, the user needs to avoid submersion for the first five days of wear [27].
In the PRECISE study, Eversense was tested in 71 adults with type 1 and type 2 diabetes in
multiple European countries. The mean absolute relative difference (MARD), a standard measure of
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CGM accuracy, was 11.1% with a similar error profile to current CGM technology [28]. Following
the initial study, the calibration methods were updated and a follow up study called PRECISE II was
performed. This study was a multicenter US, nonrandomized, blinded trial in 90 adults and reported
a MARD of 8.8% [23]. The in-development closed loop system iLet works in conjunction with the
Eversense CGM system [29].
3.2. CGM Integrated with Insulin Pumps
Medtronic CGM Systems
As mentioned before, the Medtronic Minimed CGM was released in 1999 and was the first
FDA-approved CGM device available. This system included a subcutaneous glucose sensor, a monitor,
a connecting cable, and a ComStation compatible with Windows 95. It was updated to include alarms
for hyperglycemia and hypoglycemia with a new device name, the Guardian Real-time CGM system.
The next Medtronic system approved in 2016 was the Medtronic Minimed iPro2 system and was
designed to be compatible with the Medtronic 530G insulin pump system.
The most recent Medtronic CGM system is the Guardian Sensor 3 system and works in conjunction
with the Medtronic 670G insulin pump utilizing hybrid closed loop technology or with the Medtronic
630G insulin pump providing low glucose suspend. The Guardian Sensor 3 requires calibration at least
twice daily, but recommends 3–4 calibrations per day for optimal accuracy. The new system does not
require the purchase of a separate receiver, but directly transmits data via Bluetooth to the Medtronic
insulin pump and/or an approved smartphone with the Medtronic application. The Medtronic
Guardian Sensor 3 CGM can also be used in conjunction with insulin injections and features prediction
of highs and lows with an alert 10–60 min prior to hyper- or hypoglycemia [30]. This sensor can alert
patients to glucose changes via their smartphone or smartwatch similar to SMS messaging.
3.3. Limitations
Continuous glucose monitor systems have improved the monitoring of BGs for T1DM patients
and allowed medical providers, caregivers, and patients access to BG trends that would otherwise
be missed. However, there are significant limitations that must be considered with CGM systems.
The cost of a CGM system can be prohibitive for patients who are uninsured or for whom insurance
does not cover CGM. There are not only initial costs for the transmitter and receiver set up, but also
monthly costs for sensor and transmitter replacement. Typically, sensors will last from 7–14 days
depending on the CGM model. Transmitters additionally may need to be replaced monthly to a couple
times per year. Since 2017, Medicaid has started to cover CGM costs with commercial insurance groups
beginning to cover CGM prior to that time.
Continuous glucose monitors also require an additional body site for insertion away from
an insulin pump site or injection site. In children and adults, CGM devices only have approval
in particular sites. For the pediatric population, typically this is in the abdomen or gluteus. Patients
however often need to interchange between multiple insertion sites most often in the abdomen,
gluteus, or bilateral arms. There seems to be no difference in accuracy between sites among pediatric
patients [31]. CGM systems over time have shown a variable degree of water resistance; therefore,
patients need to pay attention to specific system capabilities: Abbott Freestyle Libre is water resistant to
3 feet for up to 30 min, Dexcom G6 sensor/transmitter are water resistant, Medtronic Guardian Sensor
3 is water resistant to 8 feet for up to 30 min, and Senseonics Eversense is water resistant to 3.3 feet
for up to 30 min [25–27,30]. Due to the need for Bluetooth technology to transmit data to the receiver,
CGMs may lose contact during water-based activities, such as showers, baths, and swimming [26].
During times when data is not being received, alerts based on glucose values will not be functional.
While glucose measurements are comparable during times of homeostasis between CGM systems
and finger-stick glucose values, CGMs can lag behind when rapid glucose changes occur. Like all
populations, patients with T1DM are encouraged to engage in physical activity for their overall health.
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However, sudden changes in glucose might pose a challenge to current CGM capacity to accurately
depict glucose trends and forewarn patients of impending hypoglycemia during or after physical
activity. Zaharieva et al. reported a case study where they had a 40-year-old patient with T1DM who
wore a Medtronic 670G pump and CGM integrated system, a Dexcom G5, and an Abbott Freestyle
Libre during exercise. The patient performed one hour of moderate intensity running and monitored
glucose values through the CGM systems and finger-stick measurements. All three of the CGM
systems lagged behind finger-stick values when glucose values dropped during exercise with the
largest difference in glucose levels noted in the first 30 min of exercise [32]. Additional studies have
supported the finding that discrepancies between CGM and finger-stick values are greatest during
exercise and return to previous accuracy within a couple hours after aerobic exercise [33].
3.4. Future Directions
Continuous glucose monitors have improved immensely in the last 20 years of clinical care.
Future CGMs will need to improve upon the lag time of current devices to allow for better monitoring
and management during physical exercise and periods of rapid glucose changes. As these products
continue to develop, sensors and transmitters will likely become smaller and lower profile to skin for
ease of wearability. Additionally, new adhesive strategies need to be employed to keep these devices
in place as the lifetime of a sensor continues to improve. CGMs are already being used in hybrid
closed-loop systems with insulin pumps; simultaneously, more collaborations are ongoing to make
currently available CGM devices compatible with other independent insulin pumps with the goal of
developing closed loop and suspend before low systems in the near future.
4. Insulin Pumps
Currently, it is estimated that more than one million people worldwide use an insulin pump for
diabetes management including nearly 400,000 patients with T1DM in the US [34]. Insulin pumps
are small devices that deliver short acting insulin subcutaneously via a small cannula self-placed
by the patient every few days. They are designed to provide a near-continuous low dose of insulin
delivered frequently in small boluses to mimic the actions of the β cells of the pancreas and also allow
for bolus delivery of insulin at meal times or when needed for rapid correction of glucose. Insulin is
given through a small tube called a cannula that is inserted into the subcutaneous tissue with a small
needle and taped to the skin. Some insulin pump systems have tubing that runs from the device’s
insulin reservoir to the insertion site and some insulin pumps are tubing free. Tubing free systems
stick directly to the skin with a cannula inserted into the subcutaneous tissue below the pump.
The pump itself is a battery-powered programmable device that holds multiple settings. Providers
and patients are able to program multiple insulin delivery settings based on the time of day and in
multiple profiles. Within a profile, there will be basal rates for 24-h, and typically a programmed
carb ratio and insulin sensitivity factor with a target glucose. Additionally, settings may include
insulin action time to allow the pump to calculate current insulin activity when giving additional
boluses. Most pumps contain an insulin reservoir that typically is in a cylindrical shape. When the
user programs the pump to deliver insulin, the plunger is pushed by the pump’s internal mechanisms
to precisely deliver the amount of insulin desired. The Tandem insulin pumps, however, use a bag
reservoir for the insulin to allow for a smaller pump size.
The first insulin pump was designed by Dr. Arnold Kadish in the 1960s and was the size of a large
backpack. In the 1970s, Dean Kamen introduced the AS2C, also known as the ‘blue brick’, and later the
‘autosyringe.’ These initial systems were large and often difficult to use even requiring a screwdriver to
adjust insulin doses. By the mid-1980s, smaller and more precise systems were starting to emerge [35].
A large producer of insulin pumps, Animas announced in 2017 that it would be discontinuing insulin
pump production and support. The insulin pump market has continued to evolve and now has three
major companies producing insulin pumps in the US: Medtronic, Insulet, and Tandem. There are
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multiple other insulin pump brands out on the market and in development worldwide, including
Cellnovo, Kaleido, Roche Diagnostics Accu-Chek, and Sooil Dana Diabecare systems discussed below.
A major advantage of insulin pumps is that they allow patients to avoid multiple daily injections.
Some pumps have even featured remote bolus programming allowing for parents of pediatric patients
a convenient way to dose insulin for active kids. Additionally, insulin pumps allow for variable
basal rates throughout the day. Circadian rhythms affect insulin requirements over a 24-h period
and these differences can be more pronounced in pubertal patients [36]. Pumps certainly allow for
better accommodation of differences in circadian rhythm than is possible with a long acting insulin
administered once to twice daily. Insulin pumps allow for precise delivery of small insulin doses
with some pumps even allowing for dosing changes down to increments of 0.01 units and minimal
insulin delivery of 0.025 units per hour which may be helpful in very young patients who are often very
sensitive to insulin. Furthermore, some providers have argued that use of U10 (1/10th the concentration)
insulin instead of standard U100 insulin in insulin pumps could improve precision by allowing delivery
of very small doses [37]. However, others argue that insulin delivery is not truly continuous, but is
delivered frequently in small boluses to mimic endogenous basal production. Therefore, the option for
diluted insulin or very small basal dose increments may not change care in clinical practice.
When considering insulin pump therapy, accuracy of insulin delivery is also an important
consideration. Insulin pump manufacturers specify delivery accuracy to ±5% of insulin dose entered
by using an international standard method. Typically these evaluations look at an average of the
accuracy over 100 consecutive boluses within the system of interest. A 2013 study looked at insulin
delivery accuracy of three conventional insulin pumps and one patch insulin pump by testing bolus
accuracy in these systems. They noted a statistically significant difference in accuracy between the
traditional systems and patch insulin pump with better single-dose accuracy noted in the traditional
insulin pumps [38]. A standard measure of insulin pump accuracy, IEC 60601-2-24, helps to provide
consistent testing of systems, but some researchers argue that this measure may be incomplete and
alternative measures are being proposed [39].
Most importantly, pumps have been shown to improve glycemic control resulting in a lower
HbA1c. In a recent study of pediatric patients with T1DM, patients with insulin pump therapy were
shown to have lower rates of severe hypoglycemia, lower incidence of diabetic ketoacidosis, lower
HbA1c, and lower total daily insulin doses than matched patients on multiple daily insulin injection
therapy [40]. Insulin pumps allow patients increased flexibility in their routines and account of insulin
action time thereby reducing the risk of insulin stacking. Temporary basal rates can be used to decrease
hourly insulin during or after intense exercise. Patients are able to give multiple doses without
requiring additional injections and utilize variable bolus settings for high fat meals. In the following
sections, currently available insulin pumps are introduced and Table 2 provides a comparison of
systems available within the US.
Table 2. An overview of currently available insulin pump systems within the US.
Medtronic 670G OmniPod DASH Tandem X2
Ages approved 7 years and above All ages 6 years and above
Dosing increments Basal: 0.025 units/hour;Bolus: 0.025 units
Basal: 0.05 units/hour;
Bolus: 0.5 units
Basal: 0.001 units/hour at greater
than 0.1 units/hour; Bolus: 0.01







Tubing lengths—23”, 32”, and 43”
Can be disconnected from
infusion site
CGM integration Medtronic GuardianSensor 3 Dexcom G5/G6 Dexcom G5/G6
Hypoglycemia
prevention
Yes, low glucose suspend
with Sensor 3 No Yes, Basal-IQ with G6 only
Closed Loop Available Yes, Auto-mode No No
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4.1. Medtronic Insulin Pumps
Medtronic was founded initially in 1949 as a medical device repair shop. In 1983, they released
their first insulin pump to the market, the Minimed 502. Over the next several years, they launched
updates to insertion sites and infusion sets that allowed for temporary detachment from the pump
system. In 2003, they introduced the BolusWizard which wirelessly shared the glucose value from
the system-integrated glucometer and suggested an insulin dose. In 2006, they released the MiniMed
Paradigm Real-Time System that integrated CGM data for viewing on the insulin pump display.
In 2013, the FDA approved the MiniMed 530G with Enlite for patients greater than age 16 years.
This was the first system available in the US that provided ‘Threshold Suspend’ automation and would
stop insulin delivery for up to two hours if the glucose level reached a preset low limit with no user
response to the alert. The 630G was released in 2016 and was followed quickly by their most recent
insulin pump the Medtronic 670G System [41].
The Medtronic 670G system features two operational modes: manual mode in which the system
acts as a traditional pump, and auto mode in which the system acts as a hybrid closed loop device
using CGM input to alter basal insulin output. The Medtronic 670G system will be discussed in greater
detail below.
4.2. OmniPod Insulin Pumps
Insulet Corporation, the maker of OmniPod, was founded in 2000 and first received FDA clearance
for OmniPod in 2005. This system was the first developed ‘patch’ insulin pump with two components:
a disposable OmniPod infusion pump and the OmniPod Personal Diabetes Manager (PDM) [42].
The PDM is a handheld battery-powered device that controls insulin delivery from the disposable
infusion pump. The infusion pump can be worn for up to 3 days and is waterproof up to 25 feet for
60 min. It will deliver insulin based on the programmed basal rates set up in the PDM. The PDM
communicates wirelessly with the infusion pump and needs to be within five feet to give a bolus
insulin delivery or change previously set basal insulin delivery rates.
The most recent iteration, OmniPod DASH, is anticipated for wide availability in early 2019 [43].
This system uses Bluetooth technology for communication between the PDM and infusion pump
and allows users to view their PDM data on mobile phone applications. Additionally, with the
smartphone applications, users will be able to share data with up to 12 people. The application will
integrate Dexcom G6 CGM data with insulin delivery data on a single screen for streamlined analysis
of information. However, the user will still need the PDM to make basal rate delivery changes or to
give bolus insulin doses.
4.3. Tandem Insulin Pumps
In 2008, Tandem Diabetes Care, Inc. was founded from a previous company Phluid, Inc. [44].
The t:slim insulin pump received FDA clearance in 2011 and was the first ever touchscreen insulin
pump. In 2015, they received FDA approval for integration with the Dexcom G4 CGM system.
The t:slim, via Bluetooth technology, offered Dexcom G4 CGM data display on the insulin pump screen.
This allowed for data to be interpreted in real-time with only one device. The newest Tandem product,
the X2, was released in 2016.
The Tandem X2 insulin pump features integration with Dexcom G5 or G6 CGM systems. They use
Basal-IQ technology to reduce incidence of hypoglycemia in patients using both the X2 insulin pump
and a Dexcom G6 CGM. The PROLOG trial showed significantly reduced rates of hypoglycemia
without rebound hyperglycemia with use of the Tandem Basal-IQ system. The algorithm works by
predicting glucose levels 30 min into the future and suspends insulin delivery if the predicted glucose
value is <80 mg/dL or the actual glucose value is <70 mg/dL [45]. Updates of the Tandem insulin
pump will be through software updates that can be downloaded to the patient’s pump as new systems
are released.
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4.4. Insulin Pumps Systems Available Only Outside of the US
4.4.1. Cellnovo Insulin Pumps
The Cellnovo system is an insulin pump available to patients in Europe, but not currently available
in the US. The system is comprised of a small insulin pump that is controlled via Bluetooth technology
with a locked down Android device. The pump has short tubing and uses an adhesive to attach to
the skin. It is water resistant to a depth of 36 feet for up to 1 h. This system also includes an activity
tracker and food library, as well as applications for data management [46].
4.4.2. Kaleido Insulin Pumps
The Kaleido insulin pump is newly available in Europe at this point. Some of this pump’s
unique features include the option of placing the infusion site with variable lengths of tubing to
accommodate for different locations on the body and the insulin pump can be placed on the skin
with an adhesive or placed in a pocket. Also, the system comes with two rechargeable pumps that
can be used interchangeably and a handset that controls insulin delivery via Bluetooth technology.
The pumps are water resistant up to a depth of 3.3 feet for up to 1 h; however, the pump charging
station and handset must be kept dry. Kaleido also offers 10 color options for the insulin pump [47].
4.4.3. Roche Diagnostics Accu-Chek Insulin Pumps
The Accu-Chek Combo system first became available in the US in 2012 following approval by the
FDA. The system was comprised of an insulin pump and glucometer that was connected via Bluetooth
technology. The Accu-Chek insulin pumps are no longer supported in the US; however, they are still
prominent in Europe and continue to support glucometers within the US. Their most recent systems,
the Accu-Chek Spirit Combo and Accu-Chek Insight, are currently supported in many countries
around the world and offer some advantages. The systems, comprised of an insulin pump and smart
glucometer, allow the patient to change pump settings and use a bolus calculator without directly
changing settings on the pump by input through the Bluetooth connected glucometer. The Accu-Chek
Insight also allows patients to use pre-filled insulin cartridges instead of filling cartridges manually
when replacing insulin [48].
4.4.4. Sooil Dana Diabecare Insulin Pumps
The Sooil Company has two insulin pumps currently on the market, Dana Diabecare R and Dana
Diabecare RS insulin pumps. They are currently available in multiple countries in Europe and Asia.
The Dana Diabecare R model features a connected glucometer and lightweight design. The system also
allows for remote control of pump settings through an Android based smartphone application [49].
The Dana Diabecare RS system was released in 2018 and connects with smartphone applications for
both Android and iOS systems via Bluetooth technology [50].
4.5. Limitations
Insulin pumps have revolutionized insulin delivery by allowing for very precise insulin dosing
and small dose delivery, but there are limitations to therapy. Cost is an important issue in care of
patients with T1DM. In the DIAMOND study, researchers enrolled 75 adults with T1DM already using
CGM and randomized them to either insulin pump therapy or continued multiple daily injections
(MDI) therapy and followed these patients for 28 weeks [51]. They reported total per person costs for
the length of the trial as $8272 for patients in the CGM + insulin pump group and $5623 for patients in
the CGM + MDI group. Insulin pump therapy is often covered by insurance with improvement of out
of pocket costs, but has associated monthly costs for supplies required for pump therapy including
infusion sets, tubing, adhesives, batteries, insulin reservoirs or cartridges, and insulin.
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At this point, many insulin pumps are considered ‘open-loop’, meaning that the device acts based
on settings that have been programmed into the system and cannot alter its output based on the
effect of insulin on glucose. This requires careful monitoring of glucose values during therapy and
a well-trained patient or parent who can alter insulin pump settings to vary insulin delivery based on
clinical need.
With insulin pump therapy, there has always been a concern for increased risk of diabetic
ketoacidosis (DKA), a life-threatening complication of T1DM. Since insulin pumps utilize short-acting
insulin, with pump site failure or disconnection, patients would not have the safety of subcutaneously
injected long acting insulin to prevent DKA. In 2007, a consensus statement from the European Society
for Paediatric Endocrinology issued a warning that ‘individuals using continuous subcutaneous insulin
infusion (CSII) are potentially at increased risk of developing DKA, with DKA rates varying from
2.7–9 episodes per 100 patient-years’ [52]. More recently, Dogan et al. shared data from 205 adult
T1DM patients treated with insulin pump therapy from 2006 to 2015. They noted only 10 cases of
DKA in nine of their patients throughout the course of the study which indicates an incidence of
1.0 case/100 patient years which is reassuring [53]. Additionally, Hoshina et al. noted similar risk
of DKA between patients using insulin pump versus multiple daily injection methods. Interestingly,
they reported significantly lower rates of DKA in insulin pump patients who received care at a practice
with experience caring for more than 250 insulin pump patients [54].
4.6. Future Directions
Over the last 50 years, insulin pumps have continued to advance and improve now with more
precision and convenience than ever before. As these systems continue to evolve, more closed-loop
systems will emerge onto the market. Multiple closed-loop systems are currently in development with
unique algorithms designed to deliver insulin based on glucose levels measured with a connected
CGM system.
Bihormonal therapy with glucagon and insulin working together has long been discussed as ideal
to mimic the endogenous functioning pancreas. The iLet Bionic Pancreas which plans to utilize both
glucagon and insulin has been in development for several years [55]. In a randomized controlled trial,
bihormonal pump therapy was compared with insulin only pump therapy showing improvement in
mean blood glucose and reduction in incidence of hypoglycemia [56].
5. Hybrid Closed-Loop Insulin Delivery Systems
With the emergence of the first commercially available hybrid closed-loop system, the Medtronic
670G, diabetes care advanced a step closer to development of an artificial pancreas. These systems have
been shown to increase the percentage of time in glucose range for users. In a 2010 study, OmniPod
and Freestyle Navigator CGM were used to compare an open- versus closed-loop system showing
an improvement from 64% to 78% time within range for users [57]. Additionally, multiple studies have
shown reduction in incidence and severity of hypoglycemia in patients using closed-loop systems in
both pediatric and adult patients [58,59]. Multiple algorithms are under development for use in hybrid
closed-loop systems. Release of new hybrid closed-loop systems including the OmniPod Horizon,
the Tandem Control-IQ, and the Beta Bionics iLet, is anticipated in the next couple of years.
There are currently four main types of control algorithms being employed in the development of
closed loop systems. Model predictive control (MPC) algorithms are the most commonly used and
aim to predict glucose levels in the near future and adjust insulin delivery based on that prediction.
Another algorithm is the proportional integral derivative type which responds to real-time measured
glucose values. Fuzzy logic algorithms determine insulin doses based on CGM data in the way that
an expert clinician would make insulin adjustments. There are also bio-inspired algorithms that utilize
a mathematical model to determine insulin doses based on how β cells would act in response to
glucose in the body [60].
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5.1. Currently Available
Medtronic
The Medtronic 670G is the only hybrid closed-loop system currently available on the market and
is approved in the US and Europe in patients 7 years and up. This hybrid system uses the Guardian
3 sensor as well as SmartGuard technology during Auto mode to adjust insulin basal rates to help
keep glucose levels within target range. Basal insulin delivery is adjusted every five minutes based on
CGM readings to increase time within range. Additionally, the suspend before low feature, that can
also be used in manual mode, stops insulin up to 30 min prior to reaching a preset low glucose
value. The insulin delivery will automatically restart when glucose levels have recovered to avoid
rebound hyperglycemia.
The system requires patients to enter carbohydrate corrections at meal-times similar to a traditional
pump when in Auto Mode. For CGM operation and use in Auto Mode, patients must calibrate with
finger-stick glucose values every 12 h and when alerted by the pump to do so. However, at this
time, the system does not allow for sharing of real time CGM data with friends or family. In their
pivotal trial, they reported a decrease in average Hb A1c values from 7.4% to 6.9% and an increase
in time within desired glucose range (70 mg/dL to 180 mg/dL) from 66.7% to 72.2% of the time [61].
Stone et al. provide a further review of the Medtronic 670G Hybrid Closed-Loop System [62].
5.2. Anticipated in the Next 1–2 Years
5.2.1. Beta Bionics
Beta Bionics is currently working on the iLet system that would allow for infusion of both insulin
and glucagon in response to CGM data. The company is working with Senseonics Eversense CGM
which is a physician subcutaneously implanted device that would read glucose levels for up to
3 months [29]. Initial release of the system is anticipated in 2020 as an insulin-only device with addition
of glucagon anticipated in the next couple of years. In their 2017 study, they noted glycemic differences
in the bihormonal treatment group versus traditional pump therapy including average CGM glucose
of 140 mg/dL vs. 162 mg/dL and only 0.6% vs. 1.9% of time spent with glucose less than 60 mg/dL.
They did, however, note an increase in complaints of nausea based on their scale scoring system [56].
5.2.2. OmniPod
The OmniPod Horizon Automated Glucose Control System is under development. The system
uses Dexcom G6 CGM input and Insulet personal MPC algorithm. They presented the results of their
clinic trial at the 2018 American Diabetes Association meeting, showing increased time in range and
decreased hypoglycemia during both day and night in adults, adolescents, and children. Their initial
study showed mean time less than 70 mg/dL 0.7% in adults and 2% in pediatric patients and percentage
of time in the target range 69.5–73% in adult and pediatric age groups [63]. The system release is
anticipated in 2019.
5.2.3. Tandem
In 2016, Tandem announced the plan for development of a closed-loop insulin delivery system
called Control-IQ using Tandem X2 insulin pumps, Dexcom G6 CGM system, and TypeZero artificial
pancreas (AP) technology [64]. Their initial pilot study published in December 2018 included five adult
patients with well-controlled T1DM and showed mean time in range of 86% overall, mean glucose of
130 mg/dL, and median time less than 70 mg/dL of 2.8% [65]. They have recently completed another
clinical trial of the Control-IQ system and will likely submit results for FDA approval in the coming
months. The new system is anticipated later in 2019.
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5.3. Limitations
The current technology allows for closed-loop insulin delivery response to glucose values and
trends. However, at this point, users still need to check glucose values at least twice daily to calibrate
the CGM device used in conjunction with the closed-loop system. Additionally, currently available
systems require users to manually give bolus insulin for meal times by entering in carbohydrates and
the current glucose value from either CGM or finger-stick value.
For the currently available system the Medtronic 670G, options for glucose goals are limited
while in Auto Mode to 120 mg/dL or 150 mg/dL. For many pediatric patients who experience
hypoglycemia following exercise, an elevated glucose target of 150 mg/dL may be insufficient to
prevent hypoglycemia. Conversely, for older patients who can achieve very tight glycemic control,
a target of 120 mg/dL may be higher than desired. Patients have adapted to the system by giving ‘fake’
carbohydrate boluses to achieve tighter control; however, this practice could lead to increased risk of
hypoglycemia in the user [66].
5.4. Future Directions
Hybrid closed-loop systems are still new to the market with multiple new systems anticipated in
the coming years. Across the globe, several systems are currently in development or undergoing clinical
trials and may be several years away from introduction into the market. Previous reviews have detailed
systems in development extensively including the papers from Trevitt et al. and Bekiari et al. and
should be referenced for a more detailed overview of anticipated systems [60,67]. As this technology
continues to develop further, systems will ideally require less and less management from the patient
and the provider. As systems move forward, length of time they may be worn will likely increase.
Additionally, integrated CGM systems will require less calibration and significantly less finger-sticks.
As these systems continue to progress, meal-time insulin may no longer be required and therefore
the patient would not be required to enter carbohydrates consumed. Studies have started to look at
unannounced meals in the setting of hybrid closed-loop insulin delivery systems. In a study done
by Cameron et al., patients wore a closed-loop system in a hospital setting and a hotel setting and
challenged the system with unannounced meals and exercise. During the study, they were able
to report daytime mean glucose of 158 mg/dL showing promising results for a future system [68].
Forlenza et al. further investigated with both adults and adolescents in a hotel setting. In their study,
they tested an Android-based AP system with six adults and 4 adolescents in the setting of exercise
and unannounced meals. Although they showed overall mean CGM data of 157 mg/dL throughout
the study, they did note a significantly lower CGM value following announced versus unannounced
meals at 140 mg/dL versus 197 mg/dL. Meal announcement is still superior in glycemic control at this
time given current insulin pharmacokinetics, CGM accuracy and lag, and possible speed of insulin
delivery in current systems [69].
In recent studies, bihormonal pump therapy has shown improvement in mean blood glucose and
reduction in incidence of hypoglycemia in comparison with insulin only pump therapy [56]. In the
pursuit of bihormonal pump development, glucagon still is unstable in extended time periods in liquid
form. In the future, we will likely see the emergence of a bihormonal closed-loop system using both
insulin and glucagon, possibly as a standard of care.
6. Conclusions
Type 1 Diabetes is a chronic disease requiring glucose monitoring and intensive insulin therapy.
Diabetes technology has continually evolved over the years to improve quality of life and ease of care
for affected patients. Continuous glucose monitors allow patients to observe and discern trends in
their glycemic control. These devices also give peace of mind with preset alerts for hypoglycemia and
the ability for family or friends to follow a patient’s glucose trends. The major products available and
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in use today are the Abbott Freestyle Libre, the Dexcom G6, the Medtronic Guardian Sensor 3, and the
Senseonics Eversense.
Insulin pumps have continued to improve and innovate since their emergence into the market.
Pumps allow patients to infuse insulin for up to 3 days without giving individual insulin injections.
These devices allow for very low doses in pediatric patients and varied basal rates during different
times of day and during different activities. They also allow for more freedom in dietary schedule
and multiple carbohydrate-based doses in addition to mealtimes. Hybrid closed-loop systems have
harnessed the data gathered with CGM use to aid in basal insulin dosing and hypoglycemia prevention.
As technology continues to progress, patients will likely have to enter less and less information into
their pump systems manually.
In the future, we will likely see a system that requires no manual patient input and allows users to
eat throughout the day without counting carbohydrates or entering in any blood sugars. As technology
continues to advance, endocrinologists and diabetes providers need to stay current to better guide
their patients in optimal use of emerging management tools.
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Abstract: Sarcoidosis is a non-necrotizing granulomatous inflammatory syndrome with multisystemic
manifestations. We performed a systematic review of sarcoidosis in the pediatric population with
particular emphases on early onset sarcoidosis, high-risk sarcoidosis, and newly reported or unusual
sarcoid-related diseases. Blau Syndrome and early onset sarcoidosis/ BS-EOS are seen in children
younger than five years old presenting with extra-thoracic manifestations but usually without
lymphadenopathy and/or pulmonary involvement. The prevalence of high-risk sarcoidosis is very
low in children and is further limited by the difficulty of diagnosis in symptomatic children and
underdiagnosis in subclinical or asymptomatic patients. Reports of sarcoidal syndromes in users of
E-cigarette/marijuana/other flavorings and their induction in cancer immunotherapies are of interests
and may be challenging to differentiate from metastatic malignancy. The diagnostic considerations in
pediatric sarcoidosis are to support a compatible clinicoradiographic presentation and the pathologic
findings of non-necrotizing granulomas by ruling out granulomas of infective etiology. There is
no absolutely reliable diagnostic test for sarcoidosis at present. The use of endoscopic bronchial
ultrasound (EBUS) and transbronchial fine needle aspiration (TBNA) sampling of intrathoracic
lymph nodes and lung, and for superficially accessible lesions, with cytopathological assessment
and pathological confirmations provide fair diagnostic yield and excellent patient safety profile
in children.
Keywords: Paediatric sarcoidosis; high-risk sarcoidosis; early-onset sarcoidosis; diagnostics;
Blau syndrome
1. Introduction
Sarcoidosis is a multisystemic syndrome with a highly variable clinical course and diverse disease
manifestations [1]. The incidence of sarcoidosis in adults may be biphasic [2]. Historically, it was
thought to commonly affect young adults 30–50 years of age, but recent studies have reported that more
than half of incident diagnoses are made in patients over 55 years of age [2,3]. Erdal and others suggest
that the rates of sarcoidosis are increasing [4]. Approximately 25% of affected individuals with the
disease develop chronic and progressive disease, which contributes to increased disease burden [5,6].
The mortality rate also appears to be rising [7]. There is no single diagnostic test for sarcoidosis.
Instead, the diagnosis relies on specific pathologic and radiographic features in the appropriate clinical
settings. The disease is characterized by pathologic findings of non-necrotizing granulomas in one or
more involved organ systems after alternative diagnoses, in particular, infective etiologies, have been
entertained [8].
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Sarcoidosis is an ever-evolving process. The clinical phenotypes range from single-organ,
self-limited, asymptomatic disease to multi-organ involvement with high-risk manifestations [9]. Hilar
lymphadenopathy and pulmonary interstitial infiltrations are the most common manifestations [10].
The term “high-risk sarcoidosis” was introduced at the National Heart Lung and Blood Institute
Sarcoidosis Workshop 2017 [1] to denote several manifestations of sarcoidosis that are associated
with impaired quality of life and relatively high risk of death [9]. These include treatment-resistant
pulmonary sarcoidosis, cardiac sarcoidosis, neurosarcoidosis, and/or multi-organ involvement. The
high-risk manifestations and multi-organ involvements are often missed until late in the disease
course [9].
The diagnosis of sarcoidosis is relatively uncommon in children [8,11–13], and high-risk sarcoid
may present differently in children than in adults [8,14]. In this review, we search the English literature
and aim to review the clinical investigations and laboratory diagnostics of sarcoidosis in this population.
2. Materials and Methods
We performed a systematic narrative review on sarcoidosis with particular emphases on early
onset sarcoidosis, high-risk sarcoidosis, and newly reported or unusual sarcoid-related diseases
in the pediatric population. We searched PubMed, Scopus, Google Scholars, and Cochrane
Database of Systematic Reviews, using the following terms: sarcoidosis, pediatric, juvenile, children;
high-risk sarcoidosis; pulmonary sarcoidosis; treatment-resistant sarcoidosis; cardiac sarcoid; and
neurosarcoidosis. We also searched references from the appropriate reviews and case reports.
3. Results
The true incidence and prevalence of sarcoidosis in children is unknown as the disease is much
less common in children than in adults [13]. It is difficult to diagnose in symptomatic children and may
remain undiagnosed in subclinical or asymptomatic patients [8,11]. Several larger reviews reported
that the incidence of clinically recognized sarcoidosis in children was 0.22 to 0.29/100,000 children per
year, and gradually increases with age to a small peak in teenagers at 13–15 years of age [2,8,11,13,15].
Two distinct forms of childhood sarcoidosis appear to exist. Older children and young adults present
most frequently with a multisystemic disease in a combination of lymphadenopathy, pulmonary, ocular
and cutaneous involvement (erythema nodosum) [2,8,11,13], followed by joint (sarcoidal arthritis)
and hepatosplenic features [8,11,13]. The disease patterns and clinical outcomes are similar to those
in adults.
3.1. Blau Syndrome and Early Onset Sarcoidosis (BS-EOS)
In younger children, the majority of cases of EOS seen in children younger than five years old
uniquely presents with a clinical triad of uveitis, arthritis, and skin rash [2]. In 1985, Blau et al. reported
a rare autosomal dominant inflammatory disease characterized by a clinical triad of granulomatous
dermatitis, recurrent granulomatous uveitis, and systemic polyarthritis in 11 family members of four
generations [16,17]. A mutation of nucleotide binding oligomerization domain 2 (NOD2), also termed
caspase recruitment domain–containing protein 15 (CARD15), mapped on chromosome 16q12 was
identified [18] and found to be responsible for these granulomatous inflammations [16,18]. Early
onset sarcoidosis (EOS) is caused by a sporadic mutation of the NOD2 gene, with similar clinical
manifestations to Blau Syndrome [16]. Blau Syndrome/EOS patients rarely present with pulmonary
involvement, and ocular involvement tends to follow prior articular and cutaneous manifestations in
these patients [16,19].
CARD15/NOD2 encodes a multidomain cytosolic protein and is expressed primarily in the
cytosol of antigen-presenting cells [20]. Stimulation by bacterial or viral infection [21] may promote
the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and tumor
necrosis factor receptor-associated factor 3 (TRAF3) signaling pathways [21]. A possible role of
mycobacterial components has also been suggested as triggers of granulomatous autoinflammation in
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CARD15/NOD2 mutations in BS/EOS [22–24]. Crohn’s disease (CD) is a granulomatous inflammatory
bowel disease, involving any part of the gastrointestinal tract [25] but may mainly affect the distal
ileum and colon [22,26,27]. The CARD15/NOD2 gene has been identified as one of the genes linked
to susceptibility to CD [22,28]. It has been hypothesized that NOD2 susceptibility loci in intestinal
Paneth cells led to defective NF-κB activation, altered intestinal bacterial clearance and granulomatous
inflammation [22,29,30]. Juvenile sarcoidosis presenting as Crohn’s disease of the GIT has been
reported [31].
3.2. High-Risk Sarcoidosis
Approximately 25% of affected individuals with sarcoidosis develop chronic or progressive
disease [6]. Manifestations of sarcoidosis associated with poor prognosis and a relatively high risk
of death include treatment-resistant pulmonary-, cardiac-, neuro-, and multiorgan sarcoidosis [9].
Pulmonary disease is the most common cause of chronic disease and death in adults [9]. As in adults,
older children usually present with hilar lymphadenopathy and up to 50% present with interstitial
lung disease and multiorgan involvement, while progression to chronic diseases occurs in 12% of these
children [2,8,13]. Korsten et al. defined pulmonary sarcoidosis refractory to treatment as progressive
disease and significant impairment of life despite glucocorticoid therapy for at least three months and
the need for additional anti-sarcoid drugs [32]. These patients develop progressive pulmonary fibrosis
and associated complications, including pulmonary hypertension and infections and are seen in more
than 10% of patients at specialized centers [32,33]. In infants and children younger than five years, the
typical pulmonary diseases are usually not seen [8]. In a retrospective study of 41 pediatric patients,
which were followed for 18 months on disease presentation, management, and clinical outcome, those
patients with pulmonary sarcoidosis diagnosed before 10 years old were more likely to recover and
presented with fewer relapses compared with the patients diagnosed after 10 years old [34].
Recent progress in cell-mediated immunity and granuloma formation has advanced our
understanding of the development of sarcoidosis [8,35]. Macrophages bearing increased expression
of major histocompatibility (MHC) class II molecules, different subsets of T-lymphocytes and other
immune effector cells such as mast cells and natural killer cells may be at play [8,35]. In sarcoidosis
involving the lung, before the formation of granulomas, early lesions consist of alveolitis with a high
proportion of activated CD4+ T-cells [36]. T-cells play a role in amplification of the local cellular
immune response and are responsible for secretion of cytokines, including tumor necrosis factor
(TNF), which favors granulomatous response at the sites of disease activity. The diagnostic approach
to pulmonary sarcoidosis has been revolutionized in the past decade by the use of endobronchial
ultrasound (EBUS) real-time guided transbronchial sampling of intrathoracic lymph nodes and lung
biopsies [6]. Cytopathological assessments by fine needle aspiration provide fair diagnostic yield
and excellent patient safety profile in children [37,38]. Combining EBUS and transbronchial needle
aspiration (TBNA) lung biopsy and cytopathologic study may increase the diagnostic sensitivity to
close to 100% [39,40]. On bronchoalveolar lavage (BAL) fluid with lymphocytosis (15%) and increased
ratio of CD4 to CD8 (>3.5:1), the specificity for the diagnosis of sarcoidosis approaches 95% [36,41].
Cardiac sarcoidosis (CS) is a rare but potentially fatal condition [42]. Clinically recognizable cardiac
involvement occurs in 5% of adult patients with sarcoidosis [43], and granulomatous inflammation
of the heart was recognized in up to 25% in an autopsy series [13,44]. Rare cases of pediatric cardiac
sarcoidosis had been reported [8]. Patients with CS may present with a wide variety of signs and
symptoms, ranging from asymptomatic ECG abnormalities to sudden death [42]. Congestive heart
failure and conduction abnormalities are the two most common clinical manifestations in CS [42], with
one case presenting with pericardial effusion [2,8]. Many patients with pulmonary/systemic sarcoidosis
have asymptomatic cardiac involvement [43]. A high index of suspicion and early diagnosis are
crucial when immunosuppression therapy may result in reduced mortality rate [8]. Various imaging
modalities including echocardiography and/or CMR imaging may be utilized [43].
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Neurosarcoidosis occurs in fewer than 5% of adult with systemic sarcoid with isolated
neurosarcoidosis being more rare [45], and to our knowledge, 53 cases of pediatric neurosarcoidosis
have been reported in the English literature [14,46]. In these children, the most common manifestations
include headache, seizures, cranial neuropathy, optic neuritis, and hypothalamic and/or pituitary
dysfunction [14,46]. Compared to the adult counterparts, prepubertal children with neurosarcoidosis
are more likely to present with seizures and a space-occupying lesion but less likely with cranial
nerve palsies. These children do however tend to evolve to an adult pattern of presentation during
puberty [14]. Single cases of aqueductal stenosis [13] and obstructive hydrocephalus [47] have also
been reported. The most reliable method for diagnosing neurosarcoidosis is via biopsy of lesion in
the central nervous system revealing non-caseating granuloma [46]. Microscopically, granulomatous
inflammation is typically found in the meninges, ventricles (including choroid plexus) and adjacent
brain or spinal cord parenchyma. Inflammatory infiltrate may involve optic nerve and chiasm, cranial
nerves such as facial, auditory, and vestibulocochlear nerve. In cases where biopsy is not possible,
neuroimaging becomes an important diagnostic modality. The most common neuroimaging finding
is said to be leptomeningeal enhancement on T1-weighted MRI with contrast administration [48].
Enhancement may also be seen in the basilar region, leading to abnormalities in the hypothalamus, optic
chiasm, and pituitary region [46]. As neurosarcoidosis is a diagnosis of exclusion, differential diagnoses
that need to be considered and ruled out include tuberculosis, fungus, Wegener’s granulomatosis and
hypertrophic meningitis, as these may also present with leptomeningeal enhancement and granulomas.
To the best of our knowledge, cases of pediatric spinal neurosarcoidosis have not been reported in the
English literature.
3.3. Acute Sarcoidosis
In contrast to the chronic progressive disease with organ dysfunction in high-risk sarcoidosis,
two acute sarcoidosis syndromes are of relatively benign clinical outcome. Lofgren syndrome is
characterized by fever, bilateral hilar lymphadenopathy, erythema nodosum, and arthralgia, typically
in young women, primarily Caucasian. Prognosis is excellent with complete resolution of the disease
in 90% of the patients within two years [8,49,50]. Heerfordt syndrome or uveoparotid fever, presenting
with a combination of fever, parotidomegaly, anterior uveitis, and cranial nerve palsy is usually seen in
adults but has been reported in children [8,49]. The disease is normally self-limiting with cure achieved
between 1–3 years [8,51]. The acute sarcoidosis syndromes may be confidently diagnosed on clinical
grounds without surgical biopsy confirmation in adults [8,49,52]. However, the clinical manifestations
in children may be variable necessitating biopsy histopathology confirmation [8,15,49,53].
Pathology images of the spectrum of pediatric sarcoidosis involving different organs (Figures 1–7).
 
Figure 1. Mediastinal nodal sarcoidosis. H&E Magnification 20×.
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(a) (b) (c) 
Figure 2. Pulmonary sarcoidosis. (a) Pulmonary sarcoidosis. (b) Pulmonary nodular sarcoidosis.
(c) Pulmonary fibrotic sarcoidosis. H&E. Magnifications 20×, 50×.
 
Figure 3. Cardiac sarcoidosis. H&E Magnification 50×.
 
Figure 4. Neurosarcoidosis. H&E. Magnification 100×.
 
Figure 5. Lung sarcoidosis young E-cig vaper. H&E. Magnification 200×.
 
Figure 6. Acute sarcoidosis salivary gland. Cytopathology Pap stain 200×.
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(c) 
Figure 7. Immune cell phenotypes: T-cells: CD3, CD4, CD8; macrophage CD68. (a) Early onset
sarcoidosis (EOS) skin sarcoidosis; (b–c) EOS skin sarcoidosis.
Recent case reports of sarcoidosis developing after antigen exposure to inhalation or in
immune-therapy are of interests. The popularity of electronic cigarettes (E-cig) has recently been
increasing among adolescents and young adults [54–56]. E-cig usage or “vaping” contains E-liquid
carrier components, flavorings, and marijuana product with cannabidiol (CBD) formulations [57–60].
In anecdotal stories, the use of medical marijuana, in particular vaping with CBD oil may be linked
to improvement of refractory pulmonary sarcoidosis [61]. In E-cig and marijuana users, sarcoidal
granulomas are found in multiple organs in case reports, raising the clinical suspicion of metastatic
malignancy [62,63]. The development of sarcoidal granulomas may be related to vaped marijuana
product tetrahydrocannabinol (THC), E-cig flavorings, or contaminants. An association of vaped
THC has been reportedly seen in close to 500 cases of severe pulmonary disease with six confirmed
deaths [56]. As tumor necrosis factor-alpha (TNF-α) plays an important role in both formation and
maintenance of sarcoidal granulomas, anti-TNF-α may provide a therapeutic option to patients with
sarcoidosis [64]. However, many anti-TNF-associated cases of sarcoidosis have also been reported [65],
negating its therapeutic usage. Pulmonary sarcoidal granulomas are found in patients undergoing
interferon-alpha therapy [66]. The use of immune checkpoint inhibitors by enhancing anti-tumor
immunity has revolutionized cancer therapy recently, and their use for cancer immunotherapy in
pediatric patients may have potential benefits [67,68]. However, pulmonary sarcoidosis and the
exacerbation of sarcoidosis leading to central nervous system involvement after immune checkpoint
inhibitor therapy have been reported [25,69].
3.4. Diagnostic Challenges and Considerations in Pediatric Sarcoidosis
There is no absolutely reliable diagnostic test for sarcoidosis [52]. A number of clinical tests and
biomarkers assay have evolved over time in the diagnosis and include: tubulin skin test of anergy
(Kvim test), serum angiotensin-converting enzyme (SACE), serum amyloid A (SAA), and cytokine
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levels [33,52,70]. The lack of sensitivity and specificity of these tests or biomarkers poorly suited
as screening tests, disease activity or prognostic markers for sarcoidosis [33,52,70]. As in adults,
the diagnosis is difficult to confirm in symptomatic children, and there is a significant number of
asymptomatic patients who remain undiagnosed [13].
In the spectrum of pediatric sarcoidosis, depending on the initial clinical presentation and
subsequent investigations including various diagnostic imaging modalities, sarcoidosis is a diagnosis
of exclusion, with ruling out granulomatous infections, in particular by Mycobacterial and fungal
organisms [8,52]. A high index of suspicion is critical in the diagnosis, especially in early onset of
the disease or Blau syndrome in a child younger than five years of age who presents with a clinical
triad of uveitis, arthritis, and skin rash, and without the adult manifestations of lymphadenopathy
and/or pulmonary involvement. The early presentation of arthritis in early onset sarcoidosis may
be misdiagnosed as juvenile rheumatoid arthritis (JRA) [71]. Pediatric sarcoidosis involving the
gastrointestinal tract may raise a differential diagnosis mostly with Crohn’s disease [31]. Both
sarcoidosis and CD are chronic granulomatous inflammatory disorders. The presence of granulomas
in the gastrointestinal tract might be misleading and the diagnosis of sarcoidosis should be established
when extraintestinal features become evident [31]. For BS/EOS and acute sarcoidosis syndromes,
pathological and/or cytopathological confirmation and exclusion of other etiologies by biopsies
of accessible lesions such as skin (including erythema nodosum, which is a non-granulomatous
panniculitis) [49], salivary glands, and peripheral lymph nodes are highly desirable.
Cases of high-risk sarcoidosis in children with the involvement of treatment-resistant pulmonary
disease, cardiac sarcoidosis, neurosarcoidosis, and multi-organ disease and the recent reports of
E-cigarettes and immunotherapy-related sarcoidosis are uncommon. The lung is the most frequent site
for biopsy confirmation, followed by skin, peripheral lymph nodes, and liver [49,72]. The diagnostic
considerations are to support a compatible clinicoradiographic presentation and the demonstration
of non-caseating granulomas. The use of EBUS-TBNA sampling of intrathoracic lymph nodes and
lung [6], with cytopathological assessments and pathological confirmations provide fair diagnostic
yield and excellent patient safety profile in children [6,52] (Figure 8).
Figure 8. Paediatric Sarcoidosis: Diagnostic Considerations. Legends: BHL Bilateral hilar
lymphadenopathy, ILD Interstitial lung disease, GIT gastrointestinal tract, EBUS-TBNA endoscopic
bronchial ultrasound-transbronchial needle aspiration, NG non-necrotizing granulomas, JRA Juvenile
rheumatoid arthritis, NOD2 Nucleotide binding oligomerization domain 2.
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4. Discussions
Since the initial clinical description by Jonathan Hutchinson [73] in 1877, followed by the
histologic findings of Caesar Boeck [74] in 1899, recent progress in immunology and molecular
biology has advanced our understanding of the pathogenetic mechanisms for the development of
sarcoidosis [8,35,75]. The proposed model of sarcoidal granuloma development in children involves the
interplay of environmental triggers by a variety of antigens and immunologic/genetic/epigenetic factors,
and requires three or more events to take place [8] (Figure 9)—environmental exposures to antigen
(e.g., infectious agents, E-cigarettes flavorings, marijuana), acquired cellular immunity directed against
the antigen, and the appearance of immune effector cells that promote a non-specific inflammatory
response [8]. The subsequent Th1 (CD4+ T cell) polarized immune response with increased cytokine
activities (TNF, IFNγ, interleukin) [75], and high-level IFNγ-secreting Th17 effector cells [35] are at
play in the recruitment and proliferation of immune cells. Genetic factors (e.g., CARD15/ NOD2
mutation) may play a role by interacting with mycobacterial/bacterial/viral components, promoting the
activation of NF-κB and tumor necrosis factor receptor-associated factor 3 (TRAF3) signaling pathways
and triggering granulomatous autoinflammation in BS/EOS patients [22–24]. Immune checkpoint
inhibitor (PD-1/PD-L1) for the immunotherapy of a variety of cancers may activate T-cells and promote
granuloma formation [25,69]. Progression of granulomatous inflammation and putative antigen
persistence promotes fibrosis and the development of high-risk organ-system manifestations [35,75].
Figure 9. Proposed Pathogenetic Mechanisms in Pediatric Sarcoidosis.
Lofgren syndrome patients develop acute sarcoidosis, and show reduced frequency of
lung-resident regulatory T cells (T-reg). The T-reg, however, super-synthesizes interleukin IL10,
as supported by the detection of increased BAL fluid IL10 concentration [76], thus, creating an
immunosuppressive micro-environment [35]. B lymphocytes may also be involved in sarcoidal
granuloma formation, as Lofgren syndrome patients exhibit higher levels of Proprionibacterium
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acnes-specific IgA antibodies [77]. In chronic diseases, sarcoid T-reg fails to efficiently suppress
proliferation and cytokine production by T helper cells [78], and with accumulation of Th1/Th17 cells,
further support stabilization of granulomas and chronic disease progression [35]. In contrast, highly
plastic and qualified effector T-cells aiming at clearance of the antigens from the granulomas leads to
recovery [35,76].
We summarize the clinicopathologic spectrum of pediatric sarcoidosis and the diagnostic
considerations in Table 1. Erdal and others suggest that the rates of adult sarcoidosis are increasing [4].
With the risks of increasing environmental exposure to increasing number of antigens, we would
expect the prevalence of pediatric sarcoidosis also correspondingly increases. At present, there are
no absolute diagnostic tests or biomarkers for screening, disease activity or prognostic markers for
sarcoidosis. Fortunately, the diagnosis of sarcoidosis in children is improving with ever improving
diagnostic techniques and imaging modalities. The development of minimally invasive procedures
including EBUS-TBNA, for cytopathology or pathological confirmation of non-necrotizing granulomas
and the resultant improving prognosis outcome appear promising. Recent advances in the use of
genome-based approaches in identifying novel biomarkers to support the diagnosis and predict disease
activity yield some promising results [70]. However, further researches are needed in sarcoidosis
involving the young population.
Table 1. Pediatric sarcoidosis—clinicopathologic spectrum.









































-Not reported in children
-Not reported in children












Triad: erythema nodosum BHL
(CXR), arthritis,













BAL bronchoalveolar lavage, EBUS endoscopic transbronchial ultrasound biopsy, TBNA transbronchial needle
aspiration, IFNα interferon-alpha therapy, CPI checkpoint inhibitor therapy, Electronic-cigarette E-cig, BHL (CXR)
bilateral hilar lymphadenopathy on chest X-ray.
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Abstract: Aim: To investigate whether the presence of left ventricular myocardial dysfunction
(LVMD) assessed by Tei index (LVTX) impacts the outcomes of healthy infants with Respiratory
Syncytial Virus Bronchiolitis (RSVB). To explore whether N-terminal pro-B-type natriuretic peptide
(NT-proBNP) increases the accuracy of traditional clinical markers in predicting the outcomes.
Methods: A single-centre, prospective, cohort study including healthy infants aged 1–12 months
old admitted for RSVB between 1 October 2016 and 1 April 2017. All patients underwent clinical,
laboratory and echocardiographic evaluation within 24 h of admission. Paediatric intensive care unit
(PICU) admission was defined as severe disease. Results: We enrolled 50 cases of RSVB (median age
of 2 (1–6.5) months; 40% female) and 50 age-matched controls. We observed higher values of LVTX in
infants with RSVB than in controls (0.42 vs. 0.36; p = 0.008). Up to nine (18%) children presented
with LVMD (LVTX > 0.5), with a higher incidence of PICU admission (89% vs. 5%; p < 0.001). The
diagnostic performance of NT-proBNP in predicting LVMD was high (area under the receiver operator
characteristic curve (AUC) 0.95, CI 95% 0.90–1). The diagnostic yield of the predictive model for PICU
admission that included NT-proBNP was excellent (AUC 0.945, CI 95% 0.880–1), and significantly
higher than the model without NT-proBNP (p = 0.026). Conclusions: LVMD could be present in
healthy infants with RSVB who develop severe disease. NT-proBNP seems to improve traditional
clinical markers for outcomes.
Keywords: respiratory syncytial virus; NT-proBNP; echocardiography; pulmonary hypertension;
myocardial dysfunction; tissue doppler imaging; Tei index; biomarkers; infants
1. Introduction
Respiratory Syncytial Virus Bronchiolitis (RSVB) is the leading cause of lower respiratory infection
and hospital admission among children up to 2 years of age worldwide [1]. Approximately 2–6% cases
of RSVB will develop a severe form of the disease, requiring admission to the paediatric intensive care
unit (PICU) and mechanical ventilation (MV) [1,2]. RSVB constitutes approximately 13% of all PICU
admissions [2]. Current guidelines recognize the identification of specific risk factors (congenital heart
disease (CHD), chronic lung disease (CLD), prematurity, etc.) and clinical evaluation as the best tools
to assess severity, predict evolution and tailor management [3].
Cardiovascular involvement seems to be a relevant prognostic factor in RSVB. Cardiovascular
complications are present in up to 9% of cases of RSVB and constitute the second most common
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extrapulmonary manifestation after infectious complications [4]. These events usually present in an
abrupt and unexpected manner in children with severe RSVB, and infants with CHD are particularly
susceptible to these complications and adverse outcomes [5]. Interestingly, nearly half of the children
admitted to PICU with RSVB are healthy prior to the clinical event [2]. In these patients, the presence
of acute lung injury secondary to RSVB can also lead to important cardiovascular effects, especially
elevated pulmonary vascular resistance and overload on the right ventricle (RV) [6–8]. Moreover,
previous studies assessing the plasma levels of cardiac troponin in RSVB suggest an underrecognized
yet clinically significant incidence of myocardial damage in this population [9–11]. Furthermore, RV
global dysfunction in ventilated healthy infants has been reported [12]. Recently, we found that mild
to moderate forms of pulmonary hypertension (PH) could impact the outcome of healthy infants with
RSVB [13].
Adverse RV–LV interactions and left ventricle (LV) myocardial dysfunction (LVMD) are emerging
as important determinants of PH outcomes. PH can induce complex changes in LV geometry
and causes an abnormal relaxation and non-uniform contraction pattern in the LV wall, leading to
LVMD [14–16]. However, most studies in healthy infants with RSVB found no abnormalities when
assessing LVMD through conventional echocardiographic parameters [12,13,17–19]. Remarkably, there
are no studies to date assessing LVMD in RSVB by more sensitive methods such as tissue Doppler
imaging (TDI) echocardiography.
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a hormone synthesized and released
into the circulation by ventricular myocytes in response to pressure/volume overload and an increase
in myocardial wall stress [20]. Elevated serum NT-proBNP levels have been defined as a powerful
biomarker in the diagnosis of PH, and both LVMD and RV myocardial dysfunction (RVMD) secondary
to pulmonary diseases [21–25]. Of note, we recently showed how NT-proBNP could be considered an
adequate biomarker for PH in previously healthy infants with RSVB [13].
In this study, we aimed to investigate the presence of adverse RV–LV interactions and LVMD
(assessed by TDI-echocardiography) in previously healthy infants with RSVB. We hypothesized that
acute PH with RV pressure overload may indeed have a direct impact on LV performance. We also
hypothesized that those infants with LVMD are prone to developing a more severe form of disease.
Finally, we sought to test NT-proBNP as a biomarker for LVMD and explore whether NT-proBNP
increases the accuracy of traditional clinical markers in predicting the severity of the disease.
2. Materials and Methods
2.1. Design, Settings and Study Population
This was a single-centre, prospective, cohort study including infants aged 1–12 months old admitted
to the paediatric department in our institution (a tertiary university-affiliated hospital in Spain) due to
RSVB (determined by a confirmed Respiratory Syncytial Virus (RSV) antigen test) between 1 October
2016 and 1 April 2017. All patients underwent clinical, laboratory and echocardiographic evaluation
within 24 h of admission. We excluded patients with co-existing CHD or CLD, prematurity, those that
received MV or intravenous fluid before assessment, and those with poor-quality echocardiographic
images or incomplete medical records. Severe cases were screened for coinfection and, if present, were
also excluded. The control group consisted of age-matched healthy infants who underwent evaluation
for heart murmur at our paediatric cardiology outpatient clinic during the study period. These controls
followed the same echocardiographic protocol as study patients. Our Institutional Review Board
approved the study. Informed consent was obtained for all patients.
2.2. Clinical and Laboratory Assessment and Outcomes
The bronchiolitis score of Sant Joan de Déu (BROSJOD) [26] was used to assess severity at
admission clinically. A BROSJOD score greater than 10 points is indicative of a severe clinical state.
Venous pH and pCO2 were determined and respiratory acidosis (RA) was diagnosed when pH
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< 7.35 and pCO2 > 45 mmHg. Plasma NT-proBNP levels at admission were determined using a
commercially available electrochemiluminescent immunoassay kit (ElecSys 2010, Roche Diagnostics).
The primary outcome was PICU admission during hospitalization. PICU admission criteria for RSVB
at our institution include the presence of: apnea, extreme bradycardia, the need for respiratory support
greater than high-flow nasal cannula oxygen therapy or inotropic support.
2.3. Echocardiographic Assessment
Standard techniques to obtain M-mode, two-dimensional and Doppler (color, pulsed, continuous
and TDI) echocardiograms were performed by the same experienced paediatric cardiologist (RGM) as
recommended in the guidelines for the paediatric echocardiogram [27]. Images were obtained using a
Phillips IE33 ultrasound scanner with an 8 or 12-MHz sectorial transducer. Each examination was
recorded, and all the studies were reviewed off-line by 2 observers (RGM and PRA), who were blinded
to the patient’s clinical profile. All echocardiographic measurements represent the average of 3 beats.
Control and case echocardiographic data were deidentified before data analysis. Figures 1 and 2 show
the main echocardiographic measures used in this study.
 
Figure 1. Echocardiographic parameters used for the estimation of LV performance. The left panel
shows a four-chamber apical view. The right panel shows the waves used to assess LV performance. The
Mitral PW-Doppler wave is obtained at the level of the LV inflow (white point). The Mitral TDI-Doppler
wave is obtained at the level of the lateral mitral annulus (black point). MV (mitral valve; dotted
arrow). RV (right ventricle). LV (left ventricle). RA (right atria). LA (left atria). PW (pulsed wave). DTI
(Doppler tissue imaging). Sm (Doppler imaging (TDI)-derived peak systolic annular velocity). Em
(TDI-derived early diastolic mitral annulus velocity). Am (TDI-derived late diastolic mitral annulus
velocity). PW-E (PW-derived mitral peak early diastolic velocity). PW-A (PW-derived mitral peak late
diastolic velocity). IVCT (TDI-derived isovolumic contraction time). IVRT (TDI-derived isovolumic
relaxation time). ET (TDI-derived ejection time).
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Figure 2. Echocardiographic parameters used for the estimation of RV and pulmonary hemodynamics.
The figure shows a parasternal short axis view at the level of the papillary muscles. The left panel shows
a schematic representation and the right panel shows real echocardiographic imaging. The LV systolic
eccentricity index (LVEI) is obtained with de D2/D1 (dotted lines) ratio measured in systole as showed
in the illustration. A LVEI > 1.2 is suggestive of raised RV pressures or pulmonary hypertension in
infants32. RVDD (right ventricular diastolic diameter; dotted arrows). LVDD (left ventricular diastolic
diameter; dotted arrows). IVS (Interventricular septum). RV (right ventricle). LV (left ventricle). D2
(LV systolic anteroposterior diameter). D1 (LV systolic laterolateral diameter).
2.3.1. Right-Sided Echocardiographic Assessment
The RV end-diastolic diameter (RVEDD) and the RV/LV ratio (RVLVr) were used as indicators
of RV dilation. RV systolic function was assessed by the tricuspid annular plane systolic excursion
(TAPSE) [28], and by the tissue Doppler imaging (TDI) derived peak systolic annular velocity at the
tricuspid level of the RV free wall (St). RV Tei index (RVTX) was used as a measurement of global
(systolic and diastolic) RV function. It was calculated using the TDI-derived isovolumic contraction
(IVC), isovolumic relaxation (IVR) and ejection time (ET) intervals (measured at the lateral part of the
tricuspid annulus) as previously described [29]. RV systolic pressure was calculated by the systolic
gradient of the tricuspid regurgitation jet (TRJG) and using the simplified Bernoulli equation [30].
Due to the absence of an adequate tricuspid regurgitation jet in most patients, the RV outflow tract
acceleration time/ejection time ratio (ATET) [31], the LV systolic eccentricity index (LVEI) [32], and
the presence of septal flattening at the end of systole on the qualitative assessment were also used
as indicators of RV systolic pressures [30]. The LVEI was also used as a measurement of leftward
displacement of the interventricular septum (IVS).
2.3.2. Left-Sided Echocardiographic Assessment
The LV end-diastolic diameter (LVEDD) was used as an indicator of LV dilation. The LV shortening
fraction (LVSF) and the tissue Doppler imaging (TDI)-derived peak systolic annular velocity at the
mitral level of the LV free wall (Sm) were used to assess LV systolic function. To assess the diastolic LV
function, we obtained the mitral peak early (E) and late (A) diastolic velocity using the pulsed wave
Doppler of the mitral valve inflow. Also, the TDI-derived early diastolic mitral annulus velocity (Em)
was measured at the lateral part of the mitral annulus. The E/Em ratio and E/A ratio were calculated as
indicators of LV filling pressures. LV Tei index (LVTX) was used as a measurement of global (systolic
and diastolic) LV function. It was calculated using the TDI-derived isovolumic contraction (IVC),
isovolumic relaxation (IVR) and ejection time (ET) intervals (measured at the lateral part of the mitral
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annulus) as previously described [29]. Cui and Robertson reported in 2006 that the mean normal value
of the LVTX for infants aged 1–12 months is 0.35 (0.09), and that a LVTX less than 0.5 is the upper limit
of normal (2Zscore) [33]. Therefore, a LVTX > 0.5 was defined as LVMD in this study.
2.4. Reproductibility
To explore intra-observer and inter-observer agreement, 30 echocardiographic studies were
randomly selected and analysed offline. To estimate the intra-observer agreement, the first observer
(RGM) remeasured the LVTX, RVTX and LVEI with a 30-day interval blinded to previous measurements
and patient information. To assess the inter-observer agreement, the means of both observers for each
measurement were compared.
2.5. Statistical Analysis
Continuous data are presented as the median (range) or mean (standard deviation) after testing
for normality with the Shapiro–Wilk test; categorical data are presented as frequencies and percentage.
Mean comparison was performed using the Student’s t test or Wilcoxon Mann–Whitney test as
appropriate. Proportions were compared using the Chi-square test or exact methods as necessary.
Pearson and Spearman coefficients were used to assess correlations between continuous data. A
receiver operator curve (ROC) analysis was used to determine the diagnostic accuracy of NT-proBNP
for LVMD. The best cut-off value of NT-proBNP to detect LVMD was empirically estimated based on the
Liu method, and values of sensitivity (Se), specificity (Sp), negative predictive value (NPV) and positive
predictive value (PPV) were calculated for the obtained cut point. We selected 2 predefined predictive
models for PICU admission. The selection of the included variables was based on the theoretical
background and the exploratory analysis. Model 1 (proposed model) included age, BROSJOD score
and NT-proBNP levels and model 2 (traditional model) included age and BROSJOD score. Prediction
models were evaluated through multivariate logistic regression analysis. The discriminating ability
of each model was assessed by the area under the receiver operator characteristic (AUC) curve. The
AUCs from the obtained models were then compared by using the DeLong method [34] to determine
whether any model resulted in increased predictive accuracy. The reliability of echocardiographic
measurements was evaluated with the intra-class correlation (ICC) coefficients and Bland–Altman (BA)
analysis [35]. Based on the 95% confident interval of the ICC coefficients, values less than 0.5, between
0.5 and 0.75, between 0.75 and 0.9, and greater than 0.90 were considered indicative of poor, moderate,
good, and excellent reliability, respectively. All the statistical analyses were performed using the Stata
13.0. (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP.). A
p value < 0.05 was considered statistically significant.
3. Results
3.1. Baseline Characteristics and Outcomes of Patients with RSVB
We enrolled a total of 50 cases of RSVB with a median age of 2 (1–6.5) months (40% female). The
control group consisted of 50 healthy infants with no differences regarding age, sex or body surface area
(BSA) distribution (Table 1). RSVB patients were admitted 2.76 (1.23) days after the initial symptoms,
with a median BROSJOD score of 6 (1–14), a median SpO2 of 93% (87–98%), and a median heart rate of
118 bpm (89–179 bpm). Up to nine (18%) cases presented RA and a BROSJOD score > 10. A total of
10 (20%) cases needed PICU admission within 1.20 (0.38) days from hospitalization (length of PICU
stay 5 (2–9) days) and were classified as having severe RSVB. A total of 3 of these 10 cases required
MV and seven of them required continuous positive airway pressure (CPAP). No cases of arrhythmia
different from sinus tachycardia were observed. No patient required inotropic support and none of the
included patients died.
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Table 1. Baseline clinical and laboratory characteristics of the Respiratory Syncytial Virus Bronchiolitis
(RSVB) population and comparison with controls.
Variable RSVB Group (n = 50) Control Group (n = 50) p Value
Age (months) 2 (1–6.5) 2 (1–9) 0.591
Female sex 20 (40) 23 (46) 0.545
BSA (m2) 0.28 (0.18–0.43) 0.27 (0.18–0.42) 0.617
Time of symptoms (days) 2.76 (1.23) - -
BROSJOD score 6 (1–14) - -
SpO2 (%) 93 (87–98) 99 (95–100) <0.001
Heart rate (bpm) 118 (89–179) 109 (87–133) 0.002
pH 7.36 (7.22–7.45) - -
pCO2 42 (31–71) - -
Nt-proBNP (pg/mL) 511 (62–5532) - -
Respiratory Acidosis 9 (18) - -
BROSJOD > 10 9 (18) - -
PICU admission 10 (20) - -
BSA (body surface area); PICU (paediatric intensive care unit); BROSJOD score (bronchiolitis score of Sant Joan de
Déu); Nt-proBNP (N-terminal pro-B-type natriuretic peptide); PICU (Paediatric intensive care unit).
3.2. Echocardiographic Alterations in Patients with RSVB
The RSVB group had a higher proportion of pericardial effusion (34% vs. 6%; p < 0.001). All cases
of pericardial effusion were mild and did not require any treatment. We observed higher values of
LVTX (0.42 vs. 0.36; p = 0.008) in infants with RSVB than in controls (Figure 3). The RSVB group also
presented more cases of septal flattening (28% vs. 6%; p = 0.003), and higher TRJG (27 vs. 22 mmHg;
p = 0.013), RVTX (0.39 vs. 0.36; p = 0.005) and LVEI (1.08 vs. 1; p < 0.001) than the control group. There
were no differences between RSVB and control groups regarding echocardiographic parameters of
ventricular dimensions, systolic or diastolic function (Table 2).
 
Figure 3. Box-plot diagram showing that the cases of RSVB presented higher values of LVTX at
admission than healthy controls (p = 0.008). LVTX (Left ventricular Tei index).
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Table 2. Baseline echocardiographic characteristics of the RSVB population and comparison
with controls.
Variable RSVB Group (n = 50) Control Group (n = 50) p Value
Pericardial effusion 17 (34) 3 (6) <0.001
Left ventricle
LVDD (mm) 21 (17–29) 21 (14–28) 0.470
LVSF (%) 38.5 (5.6) 39 (5) 0.851
Sm (cm/s) 8.7 (1.6) 9 (1.2) 0.573
Mitral E (cm/s) 98 (79–125) 96 (76–123) 0.798
Mitral A (cm/s) 75 (49–97) 71 (51–93) 0.259
Mitral E/A 1.25 (0.93–1.98) 1.43 (1–2) 0.200
Mitral Em (cm/s) 9.4 (6–5–14) 10 (6.6–15) 0.110
Mitral Am (cm/s) 9 (5–15) 9 (6–13) 0.182
Mitral E/Em (cm/s) 10.2 (5.8–20) 9.8 (5.2–17) 0.283
LVTX 0.42 (0.25–0.65) 0.36 (0.26–0.47) 0.008
Right ventricle
RVDD (mm) 10 (7–19) 10 (7–14) 0.264
RV/LV ratio 0.49 (0.28–0.80) 0.46 (0.28–0.76) 0.473
TAPSE (mm) 12.3 (1.6) 12 (1.8) 0.624
St (cm/s) 8.5 (2) 9.1 (1.7) 0.901
RVTX 0.39 (0.25–0.65) 0.37 (0.26–0.48) 0.005
Adequate TRJ 25 (50) 30 (60) 0.633
TRJG (mmHg) 27 (18–47) 22 (16–34) 0.013
ATET 0.38 (0.06) 0.39 (0.03) 0.288
LVEI 1.08 (0.98–1.45) 1 (0.95–1.12) <0.001
Septal Flattening 14 (28) 3 (6) 0.003
LVDD (left ventricle diastolic diameter); LVSF (left ventricular shortening fraction); LVTX (left ventricular Tei index);
RVDD (right ventricular diastolic diameter); RV (right ventricle); LV (Left ventricle); TAPSE (tricuspid annular
plane systolic excursion); RVTX (Right ventricular Tei index), TRJ (tricuspid regurgitation jet); TRJG (tricuspid
regurgitation jet gradient); ATET (right ventricular acceleration time/right ventricular ejection time ratio); LVEI
(systolic left ventricular eccentricity index).
3.3. Adverse LV–RV Interactions in Patients with RSVB
In the RSVB group, increased LVTX was related to echocardiographic parameters indicating
higher RV dimensions (Rho RVDD = 0.56, Rho RVLVr = 0.60), higher RV pressures (Rho TRJG = 0.54,
Rho ATET = −0.50, Rho LVEI = 0.77), and decreased RV global function (Rho RVTX= 0.74). We did not
find associations of echocardiographic measurements of RV systolic function (TAPSE and St) with
LVTX (Table 3 and Figure 4).
Table 3. Correlation coefficients between LVTX and RV echocardiographic parameters and plasmatic
NT-proBNP levels in RSVB cases.
Variable Rho p Value
RVDD 0.56 0.003








RVDD (right ventricular diastolic diameter); RV (right ventricle); LV (Left ventricle); TAPSE (tricuspid annular
plane systolic excursion); RVTX (Right ventricular Tei index); TRJ (tricuspid regurgitation jet); TRJG (tricuspid
regurgitation jet gradient); ATET (right ventricular acceleration time/right ventricular ejection time ratio); LVEI
(systolic left ventricular eccentricity index).
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Figure 4. A representation of the correlation found between LVTX and parameters of RV function
(RVTX, right panel) and RV pressures (LVEI, left panel). LVTX (Left ventricular Tei index). RVTX (right
ventricular Tei index). LVEI (systolic left ventricular eccentricity index).
3.4. LVMD in Patients with RSVB
We found LVMD, defined by a LVTX > 0.5, in nine (18%) patients with RSVB (Table 4). LVMD
was associated with PICU admission (89% vs. 5%; p < 0.001). These patients presented with a higher
BROSJOD score (11 vs. 6; p < 0.001), lower SpO2 (90% vs. 94%; p < 0.001), more cases of RA (55% vs.
9%; p = 0.001), and higher NT-proBNP levels (2221 pg/mL vs. 377 pg ml; p < 0.001) than those with
a normal LV myocardial function. The LVTX was also strongly correlated with NT-proBNP levels
(Rho = 0.73) (Figure 5).
Table 4. Clinical and laboratory characteristics in patients with RSVB and LVMD, and comparison with
those patients with normal LV function.
Variable LVMD (n = 9; 18%) Normal LV Function (n = 41; 82%) p Value
Age (months) 2 (1–4.5) 2 (1–6.5) 0.538
Female sex 2 (22) 18 (44) 0.230
BSA (m2) 0.29 (0.18–0.33) 0.28 (0.18–0.43) 0.742
Time of symptoms (days) 2 (1.5) 3 (1–7) 0.488
BROSJOD score 11 (9–14) 6 (1–13) <0.001
SpO2 (%) 90 (87–93) 94 (88–98) <0.001
Heart rate (bpm) 135 (100–164) 116 (89–179) 0.141
pH 7.3 (7.25–7.42) 7.36 (7.22–7.45) 0.115
pCO2 (mmHg) 54 (31–61) 41 (31–71) 0.009
Nt-proBNP (pg/mL) 2221 (891–5532) 377 (62–1779) <0.001
PICU admission 8 (89) 2 (5) <0.001
LVMD (left ventricular myocardial dysfunction); BSA (Body surface area); PICU (paediatric intensive care unit).
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Figure 5. The left panel is a box-plot diagram representing the comparison of NT-proBNP levels
between patients with and without LVMD. The right panel represents the correlation found between
LVTX and NT-proBNP levels. LVTX (Left ventricular Tei index); LVMD (Left ventricular myocardial
dysfunction).
3.5. NT-ProBNP as Biomarker for LVMD
The diagnostic performance of NT-proBNP to predict LVMD in infants with RSVB resulted in an
area under the ROC curve of 0.91 (CI95% 0.79–0.98) (Figure 6). The best estimated cut-off value to
predict LVMD on echocardiography was 1500 pg/mL, correctly classifying 92% of cases, with a Se of
0.80 (CI95% 0.49–0.94), Sp of 0.95 (CI95% 0.83–0.98), a PPV of 0.80 (CI95% 0.49–0.94), and an NPV of
0.95 (CI95% 0.87–0.99) (Youden index 0.75).
Figure 6. Representation of the receiver operating characteristic curve of NT-proBNP to detect LVMD
in infants with RSVB. LVMD (Left ventricular myocardial dysfunction).
3.6. Clinical and Laboratory Predictors of PICU Admission in RSVB
We developed two different and predefined prediction models for PICU admission in RSVB. The
variables used were clinical parameters that are traditionally used to assess severity in RSVB (age and
clinical score), and NT-proBNP as biomarker for LVMD. Model 1 (the proposed model) included age < 3
months, BROSJOD score > 10, and NT-proBNP > 1500 pg/mL. Model 2 (the traditional model) included
age < 3 months and BROSJOD score > 10. The diagnostic yield of model 1 for PICU admission was
excellent (AUC 0.945, CI95% 0.880–1), and significantly higher than the yield for model 2 (p = 0.026). In
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model 1, the presence of NT-proBNP levels > 1500 pg/mL was the only independent predictive factor
for PICU admission in RSVB, with an OR 27.03 (CI95% (1.50–487), p = 0.025) (Table 5 and Figure 7).
Table 5. Univariate and Multivariate logistic regression analysis performed to find a predictive model




p Value Multivariate Analysis
OR (CI 95%)
p Value pseudoR2
Model 1 <0.001 0.51
Age < 3 months 0.88 (0.19–4.04) 0.875 0.71 (0.66–7.58) 0.777
BROSJOD score > 10 44.33 (6.22–315.50) <0.001 3.06 (0.12–76.44) 0.494
NT-proBNP > 1500 pg/mL 76 (9.27–622) <0.001 27.03 (1.50–487) 0.025
Model 2 <0.001 0.38
Age < 3 months 0.88 (0.19–4.04) 0.875 0.52 (0.06–4.21) 0.541
BROSJOD score > 10 44.33 (6.22–315.50) <0.001 49.27 (6.38–380) <0.001
OR (Odds ratio); CI (Confidence interval).
 
Figure 7. Graphical representation of the comparison between the areas under the receiver operator
characteristic curves of the predictive models selected.
3.7. Reproductibility
The intra-observer and inter-observer agreement for LVTX, RVTX and LVEI were good or excellent,
with all ICC coefficients > 0.75 (Table 6).
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Table 6. Intra-observer and inter-observer agreement scores for the main echocardiographic
measurements performed in this study, the left ventricular and right ventricular Tei indexes (LVTX and
RVTX), and the systolic left ventricular eccentricity index (LVEI).
Variable
Intra-observer (RG.M) Inter-observer (RG.M and PR.A)
ICC (95% CI) BA (LOA) ICC (95% CI) BA (LOA)
LVTX 0.95 (0.93–0.99) 0.00 (−0.03–0.03) 0.84 (0.74–0.93) −0.01 (−0.07–0.05)
RVTX 0.97 (0.95–0.99) −0.002 (−0.02–0.02) 0.86 (0.77–0.95) −0.015 (−0.07–0.04)
LVEI 0.89 (0.82–0.96) −0.007 (−0.04–0.03) 0.84 (0.73–0.94) −0.01 (−0.05–0.03)
ICC (interclass coefficient); CI (confidence interval); BA (Bland–Altman average); LOA (limits of agreement).
4. Discussion
The main finding of our study is that LVMD was observed at the early stages of the disease in up
to 18% of previously healthy infants with RSVB when assessed by DTI-derived LVTX. The LVMD was
associated with a more severe respiratory state, PICU admission, and echocardiographic signs of RV
pressure overload and RVMD, indicating the presence of adverse RV–LV interactions in cases of severe
RSVB. Also, we observed that NT-proBNP accurately identified LVMD. Moreover, we found an added
benefit to the addition of NT-proBNP to the clinical evaluation in predicting the development of severe
disease in this population.
CHD is an important cause of morbidity and mortality in RSVB [5]. This may be related to multiple
physiological factors including baseline compromised cardiorespiratory function and the potential
development of PH. However, little is known about LVMD and its association with RV function,
pulmonary hemodynamics, and outcomes in previously healthy infants with RSVB. In accordance
with the literature, the present study reveals that conventional parameters of myocardial function are
not altered in RSVB [17–19]. Only one previous study has assessed myocardial performance using the
TEI index in RSVB [12]. Our results are consistent with those reported by Thorburn et al. who found
RVMD in ventilated patients with severe RSVB. However, they did not demonstrate any association
between PH and RVMD. This may be due to the use of TRJG alone as an echocardiographic marker of
RV pressure, and the presence of PH may had been underestimated. In a recent work from our group,
we used a combination of different echocardiographic parameters to assess RV pressures and PH was
reported in up to 22% of RSVB cases at early stages of the disease. In agreement with Thorburn et al.,
we did not find an association between PH and RV or LVMD [13]. We assessed ventricular function
only by conventional parameters (TAPSE and LVSF).
To the best of our knowledge, this is the first study to evaluate LVMD using TDI-derived LVTX,
and to assess RV–LV interactions in infants with RSVB. LVTX, which includes both systolic and
diastolic time intervals to assess the global cardiac dysfunction, is an easily performable, recordable
and reproducible parameter with normal reference values that can be applied to the entire spectrum
of the paediatric population, regardless of age, heart rate, and BSA [36]. Using LVTX, we found
LVMD in nearly 20% of cases. The RV shares muscle fibres, the inter-ventricular septum (IVS), and the
pericardial sac with the LV. Consequently, changes in RV affect the LV, a concept termed ventricular
interdependence [16,37,38]. In this study, we observed a moderate to strong correlation between LVTX
and leftward displacement of the IVS (LVEI), raised RV pressures (TRGJ, ATET) and reduced RV global
function (RVTX), confirming the presence of adverse RV–LV interactions in cases with severe RSVB.
These results do not imply casualty, but in the absence of primary (myocarditis, cardiomyopathies,
CHD) or secondary (sepsis, severe acidosis...) causes of LVMD, we suggest RV pressure overload and
RV dysfunction due to pulmonary disease as the underlying condition for LVMD in our RSVB cohort.
Recent paediatric studies have reported that PH can induce complex changes in LV geometry and causes
an abnormal relaxation and non-uniform contraction pattern in the LV wall, leading to LVMD [14–16],
supporting our hypothesis. These observations could add new insights into the pathophysiology of
RSVB, highlighting a key role of the cardiovascular system, especially LV myocardial performance in
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this setting. Validating our findings in similar populations in different settings may also provide a basis
to implement new therapeutic approaches for this disease, which currently has no effective treatment.
Possible new therapeutic approaches may include the initiation of early respiratory support in cases
with increased NT-proBNP, pulmonary vasodilators to reduce RV pressure overload and avoiding
epinephrine in cases with LVMD.
In RSVB, the major goals are the prevention and early identification of infants at risk for severe
disease in order to provide the best management options and decrease morbidity. Current guidelines
recommend only clinical observation for this purpose in infants without known comorbidities [3].
However, most clinical scores for RSVB are not well validated and fail to predict outcomes [39,40].
Recently, the BROSJOD score, a validated clinical score for RSVB, has shown a strong capacity to predict
the evolution in the course of RSVB, but it is not yet generalizable due to the single-centre character of
the study [26]. In this context, the identification of novel biomarkers with adequate predictive value
for disease severity in RSVB is an area of increasing research interest. Neutrophins, cytokines and
leukotrienes are promising but not widely available for clinical practice [41]. Previous studies have
also tested cardiac troponin as a prognostic marker with inconsistent results [9,10,12,13]. The LVMD
found in our population was only identifiable by TDI-echocardiography, suggesting that it was mild
in most of our patients. Nevertheless, this does not mean that LVMD is inconsequential in RSVB.
Remarkably, most patients with LVMD presented with severe disease at admission and most of them
required PICU admission. Of note, we included non-ventilated infants at early stages of the disease
(mean time of 2.76 (1.23) days after the initial symptoms), when the patients had not yet been admitted
to the PICU, increasing the prognostic value of our results. Therefore, assessing and understanding
myocardial function in RSVB seems to be relevant.
Another interesting finding of our study was that NT-proBNP could be a useful biomarker for
LVMD and subsequent outcomes in RSVB. Previous studies have also documented the correlation
between LVTX and NT-proBNP plasma levels [42–44]. We explored the diagnostic accuracy of
NT-proBNP to detect LVTX > 0.50, which was high (AUC 0.91), with an optimal cut-off value of 1500
pg/mL (Se 0.80, Sp 0.95, PPV 0.80, NPV 0.95). We also tested the benefit in adding NT-proBNP to the
currently used clinical data to assess outcomes in RSVB. Although the predictive models including age
and BROSJOD score presented a high predictive accuracy for PICU admission in our population, we
observed that the addition of NT-proBNP to this model increased the predictive value significantly, and
that NT-proBNP was the only independent factor within the analysed values that predicted a severe
course of the disease. Most cases of RSVB are mild forms manageable on an outpatient basis without
the need for laboratory exams. Nevertheless, many children sufficiently ill to require hospitalization
will routinely have laboratory studies drawn. Adding NT-proBNP measurement to these studies could
be useful in order to identify high-risk patients who benefit from echocardiographic screening to PH,
RVMD or LVMD. Based on our results, it might be reasonable to perform an echocardiogram in those
patients with NT-proBNP levels > 1500 pg/mL.
This work included some limitations. Our study was performed at a single centre and with a
relatively small size. We excluded irritable or unstable patients, where the technical difficulties due to
respiratory comorbidity and the patient’s inability to tolerate the evaluation could impact the results.
The PICU admission criteria and, subsequently, the definition of severe diseases in the study are based
on the protocol of our hospital, which can vary between institutions. Therefore, a larger multicentre
cohort study including irritable or unstable cases and with uniform PICU admission criteria may be
needed for the verification and generalization of our results. Finally, the assessment of myocardial
function and PH on echocardiography was not confirmed by an independent gold-standard method,
such as cardiac magnetic resonance imaging or right heart catheterization, and therefore some patients
could have been misclassified.
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5. Conclusions
Adverse RV–LV interactions and LVMD could be present in healthy infants with RSVB during the
early stages of the disease, negatively impacting the outcome. NT-proBNP seems to be an adequate
biomarker for LVMD. Adding NT-proBNP to traditional clinical markers to assess outcomes in RSVB
could improve the early detection of those cases that will develop a severe illness. Future research is
need in order to confirm these results and to design new therapeutic approaches based on them.
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Abstract: Tonsillectomy is a commonly performed surgery in the daily practice of an
otorhinolaryngologist. For patients as well as health professionals, the best known complication is
post-operative bleeding. Among the less noted, but potentially life-threatening, complications are the
development of subcutaneous emphysema and the presence of bacteremia due to group A hemolytic
streptococci. In this report, we describe a severely complicated clinical course after an uncomplicated
adenotonsillectomy in a young boy. Increased awareness of relatively unknown complications after
adenotonsillectomy amongst surgeons, pediatricians and anesthesiologists is desirable to facilitate
rapid diagnosis and adequate treatment in order to prevent life-threatening situations.
Keywords: tonsillectomy; subcutaneous emphysema; mediastinal emphysema; mediastinitis;
complication; bacteremia
1. Introduction
Adenotonsillectomy is one of the most frequently performed surgical procedures in the daily
practice of an otorhinolaryngologist, especially in children. Nevertheless, the operation is associated
with several severe pre- and post-operative complications. According to literature, primary or
secondary bleeding, pain and temporary taste disorders are the most common complications [1–5].
In the Netherlands, according to the national guideline, potential postoperative bleeding and
taste disorders are obliged to be mentioned by the otorhinolaryngologist during the pre-operative
intake [2,3,6,7]. Other less frequent complications include damage to teeth, otalgia, lingual edema,
injury to the glossopharyngeal nerve and injury to the carotid artery [4]. Infectious complications
are not frequently reported but can be serious in case of bacteremia [8]. Furthermore, a known but
rare and potentially life-threatening complication is the development of (cervico)facial subcutaneous
and/or mediastinal emphysema [9–13].
In this case report, we describe the case of a young boy with cervicofacial subcutaneous and
mediastinal emphysema after adenotonsillectomy followed by a serious systemic infection caused
by group A beta-hemolytic streptococci. We will summarize the current literature on cervicofacial
subcutaneous and/or mediastinal emphysema and infectious complications after adenotonsillectomy.
2. Case Report
A 22-month-old boy with Down syndrome was admitted to our department for elective
adenotonsillectomy because of sleep apnea due to adenoidal and tonsillar hypertrophy.
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Despite conservative treatment for the previous five months with nasal rinsing and intranasal
steroid spray, his symptoms had deteriorated and he was indicated for surgery with post-operative
observation overnight. Except for the presence of habitual belching, his medical history revealed no
other abnormalities.
After a nontraumatic and uneventful orotracheal intubation, guillotine adenotonsillectomy was
performed under general anesthesia. Hemostasis was achieved by dry gauze compress on both sides,
no bipolar cautery was necessary. Both tonsils were easily removed without remarkable adhesions
and there was no excessive bleeding during or after the procedure. Our patient was monitored in the
recovery room and discharged to the ward after 40 min.
The next morning during visitation rounds, the patient’s dismissal home was postponed due to
inadequate fluid intake. The physical examination and vital signs showed no aberrant findings. In the
afternoon the patient was reassessed because of a swelling on the right side of his face. His vital signs
were normal and there was no fever or difficulty breathing. Further physical examination showed
facial swelling on the right side and crepitus was felt during palpation. There were no signs of cellulitis.
Oral examination of the tonsil bed revealed normal wound healing without obvious mucosal tears.
Ultrasound confirmed the presence of subcutaneous emphysema.
The progression of the emphysema quickly resulted in signs of an obstructed airway with a
saturation of 81% SpO2 and the use of accessory muscles of respiration. The patient was quickly
transferred to the pediatric intensive care unit where he was intubated. Shortly after successful
intubation, the patient went in cardiac arrest and 2 min of cardiopulmonary resuscitation was
performed. Bedside evaluation arrest ruled out pneumothorax, cardiac tamponade, hypoxia or airway
obstruction and hypovolemia. Cardiac ultasonography showed a diminished ventricular function.
Blood tests showed white blood cell count of 0.78 × 103e/uL and a C-reactive protein of 142 mg/L.
Blood cultures were positive with group A beta-hemolytic streptococci. A computed tomography scan
(Appendix Figure A1) revealed mediastinal infectious infiltration besides subcutaneous emphysema.
In retrospect, the cause of the cardiopulmonary arrest turned out to be due to sepsis/mediastinitis.
Our patient was treated with broad spectrum antibiotics, inotropes and intravenous
immunoglobulin. The further course was uneventful. The subcutaneous emphysema resolved over the
following days and the patient could be extubated 6 days after admission to the PICU. Finally, 15 days
after surgery he was discharged home. Fortunately, follow-up consultations showed no neurological
residual symptoms.
3. Discussion
Subcutaneous emphysema has been described in the literature as a complication following
tonsillectomy. The seriousness of emphysema varies and includes bilateral cases, pneumomediastinum,
pneumothorax and even pneumoperitoneum.
Massive emphysema can compress the trachea, especially in young children, since their tracheal
rings are soft. Due to the connection between the parapharyngeal and retropharyngeal space,
emphysema can subsequently spread to the mediastinum, causing a pneumomediastinum and
even pneumothorax, with major respiratory consequences [14,15]. The typical clinical finding by
physical examination is crepitus on palpation. Other diagnoses such as hematoma, allergic reaction or
necrotizing fasciitis have to be excluded.
The latter is especially important to distinguish, since rapid treatment with intravenous antibiotics
and surgical debridement can be curative. Local tenderness and erythema with variant vital signs are
warning signs of infection [16].
It has been suggested that patients with severe adhesions of the tonsil to the superior constrictor
muscle, for example after recurrent tonsillitis or peritonsillar abscess, are more prone to develop
postoperative subcutaneous emphysema. Due to the adhesions, the dissection of the tonsils from
the tonsillar bed can be difficult, increasing the risk of injury to the tonsillar fossa [12]. Accordingly,
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assuming that removing pediatric tonsils is easier, we found only three cases of pediatric patients with
subcutaneous emphysema since 2000, with ages of 6, 7 and 11 years [15,17,18].
Although the exact pathophysiological mechanism is still unknown, “ascending” and
“descending” routes are described [9,17,19].
In the ascending mechanism, a rupture occurs anywhere along the tracheobronchial tree from
a pre-existing abnormality such as an alveolar bleb or laryngocele or from an acquired defect from
traumatic intubation. Following excessive positive pressure ventilation or because of increased
intrathoracic pressure, the pre-existing defect can rupture causing the entry of air into the peritracheal
or perialveolar tissue. In the case of an alveolar rupture, air can pass through the perivascular sheaths
into the mediastinum. Through the subfascial tissue, air can ‘ascend’ to the subcutaneous tissues of the
neck and facial area [17].
In the descending pathway, subcutaneous air infiltration into the pharyngeal space is caused
by deep dissection into the tonsil fossa, causing a breach of the superior constrictor muscle and the
underlying fascia. Increased intrathoracic pressure (coughing, vomiting, physical exertion, straining
and/or manual positive pressure mask ventilation) allows air to migrate through the defect.
Since the subcutaneous emphysema was initially limited to our patient’s face and there was a
nontraumatic intubation, we consider the ‘descending’ pathway to be more likely.
The habitual belching also supports the presence of the descending mechanism.
In order to prevent the occurrence of subcutaneous emphysema, it is important to perform careful
surgery. In our patient, we performed a tonsillectomy using the Guillotine technique, according
to the Dutch guideline. The aim, as in all techniques, is to remove the tonsils completely with
minimal hemorrhage and minimal postoperative complications [20]. However, to date there is
no international consensus on which technique is best to perform a tonsillectomy. In the case
reports describing the development of subcutaneous emphysema, different techniques were used (i.e.,
electro-dissection with bipolar scissors, tonsil dissector, Ultracision Harmonic scalpel and cold steel
elevators). Conclusions about the used technique and its role in the development of subcutaneous
emphysema cannot be made. A tonsillotomy (intracapsular, partial or subtotal tonsillectomy), in
which the tonsil parenchyma is removed without damage to the tonsillar fossa and the superior
constrictor muscle, might minimalize the risk of postoperative subcutaneous emphysema [20,21].
Furthermore, if possible, patients can be instructed to avoid activities that increase intrathoracic
pressure. Unfortunately, our patient could not repress the belching.
The treatment of subcutaneous emphysema is mostly conservative but includes broad-spectrum
antibiotics to prevent infection from the oral cavity. In case of an evident mucosal rupture, reparation
of the damage is recommended. Medication to suppress increasing intrathoracic pressure, such as
anti-emetics, codeine or stool softeners can be prescribed [9]. In most cases the subcutaneous
emphysema resolves spontaneously and no further treatment is necessary. Of the 43 cases described
in a review by Saravakos, three patients needed re-intubation, one patient required temporary
tracheostomy to secure their airway and three patients underwent thoracotomy for air drainage
out of the mediastinum [9,10,18,22–25].
Our patient was intubated because of progressive, airway-obstructing emphysema, but despite
effective airway management he deteriorated due to a systemic infectious disease.
Bacteremia after tonsillectomy has also been described and is relatively innocent in most cases.
According to the literature, transient bacteremia occurs in 22% to 70% of all post-tonsillectomy patients
and generally ceases within 20 to 40 min in healthy patients [26]. The most commonly responsible
micro-organism is the Haemophilus influenza. Although group A beta-hemolytic streptococci are
frequently found in local tonsillar oropharyngeal cultures, they are rare in blood cultures and we found
only two previous cases describing the presence of a severe systemic group A streptococcal infection
in otherwise healthy patients after tonsillectomy. In the first case, a four-year-old girl developed a
severe streptococcal septic shock syndrome the night after surgery. In the second case, a four-year-old
boy revealed invasive streptococcal infection symptoms 5 days after surgery. He died 4 days after
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re-admission due to a ruptured mycotic aneurysm of the ascending aorta and hemorrhagic pericarditis
caused by group A streptococcal sepsis [8].
Invasive infections with group-A-streptococci can be devastating due to endotoxin release
resulting in a septic shock syndrome. The overall mortality of such streptococcal septic shock syndrome
is around 50% [27].
Although rare, serious infectious complications after tonsillectomy can occur and should be kept
in mind. Prompt recognition and treatment are necessary. Authors should discuss the results and how
they can be interpreted in the context of previous studies and of the working hypotheses. The findings
and their implications should be discussed in the broadest context possible. Future research directions
may also be highlighted.
4. Conclusions
We described a severely complicated clinical course after an uncomplicated adenotonsillectomy.
Since the development of subcutaneous emphysema as well as the presence of a group A hemolytic
streptococci bacteremia after tonsillectomy are both rare but life-threatening complications, we
should all be aware of their (co-)existence. Intensive co-operation by surgeons, pediatricians and
anesthesiologists is necessary for fast and adequate diagnosis and treatment to prevent further damage.
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Appendix A
 
Figure A1. Computed tomography scan of our patient taken two days after the adenotonsillectomy.
The image shows infiltrative soft-tissue and subfascial emphysema in the facial region particularly on
the right side.
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Abstract: The primary indication of fine-needle aspiration cytology of the head and neck region is a
thyroid nodule or a mass located in the cervical area or the head. Although a thyroid nodule may
raise the suspicion of malignancy, less than one in 20 cases results in a carcinoma. In addition, the list
of differential diagnoses is quite different according to the age of the patient. A number of benign
lesions, such as branchial cysts, sialadenosis, and sialoadenitis are often seen in childhood and youth.
The malignant lesions that are on the top of the list of a pediatric mass of the head and neck (H&N)
region include rhabdomyosarcoma, neuroblastoma, and papillary carcinoma of the thyroid gland.
This critical review of the diagnostic features of a pediatric mass of the H&N region is accompanied
by panels of several cytology features that may be of help to the cytopathologist and clinician.
Keywords: cytopathology; head and neck; children
1. Introduction
In the era of transcriptomics and advancements identified at increasing pace in this 2nd decade
of the 3rd millennium, an apparently simple approach with a needle, a slide, and some staining
tools may be awkward. It seems that the fine needle aspiration biopsy was performed first in 1857,
although several techniques and new protocols have transformed this seemingly simple procedure
into a practice that is impressively diffuse worldwide. Aside from scarring in some patients, there are
complications due to unnecessary surgery which is well known to many pediatricians. In adults, fine
needle aspiration cytology (FNAC) has been used with great success as the primary screening test
for thyroid nodules [1–3]. In non-thyroid nodules, FNAC has also increased rates of sensitivity and
specificity in numerous studies [4]. However, such a structured approach has remained unused in the
evaluation of pediatric nodules and instead, urgent analysis using scalpel and surgery is performed.
This critical review of the literature highlights the information we can receive using FNAC in pediatrics
and shows some illustrative cytologic features that may be extremely useful for both training or
experienced cytologists and pediatricians. The present study was designed to critically review the role
of FNAC and its utility in pediatric head and neck (H&N) lesions. It is not a comprehensive atlas and
has no aim to fill all gaps of the H&N lesions in pediatrics, which are covered in excellent texts and
books. Nevertheless, our paper emphasizes the procedure and specifies the spectrum of the H&N
lesions in the pediatric age group, highlighting some studies gathered from the literature comparing
cytology and histology of the H&N lesions.
2. Methodology
A neck mass that is resistant to antibiotics for more than four weeks should be considered
the primary indication to proceed with non-thyroid FNAC. Other signs should also include cases
of asymmetric benign lymphadenopathy as well as cervical lymph nodal enlargement showing
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unusual location, fast expansion, evidence of weight loss or loss of appetite, and night sweats.
The identification of skin changes and/or a fixed/immobile mass may favor a malignant lesion
and is also an indication to proceed with FNAC. An FNAC with a critical result may often be managed
in our institution within a few hours planning for surgery to be performed in the same day or the
day after. Nonthyroidal FNAC should be conducted while keeping in mind that the patient may be
a potential surgical candidate. Other indications for an FNAC may involve an atypical presentation
with systemic symptoms; the urgency made clear by the medical team or family and the willingness
to diagnose the lesion before the typical 2–7 days of surgical processing. In consideration of the high
percentage of papillary thyroid carcinomas in childhood and youth, FNAC should be offered as the
first procedure for all pediatric thyroid nodules following an ultrasound scan showing a lesion with a
diameter of 1 cm or more. In the case of pediatric thyroid nodules with lesions measuring less than 1 cm
in diameter, an FNAC with a critical result processing (same day or day after or within 24 h) should be
offered in the event that concerning ultrasonographic results are present. Ultrasound anomalies will
include hypoechogenicity, irregularity of the margins, or increased vascularity of the lesion. FNAC is
usually performed in the Otolaryngology/ear-nose-throat (ENT) clinical department or inpatient ward
by specialized and well-trained personnel, including a cytopathologist, an interventional radiologist, or
a (pediatric) surgeon. Topical (4% lidocaine cream) anesthesia is used with some general low sedation,
and all biopsies should be performed using image guidance. In our opinion, the practice to use
palpation should be discouraged or left to very palpable nodules to reduce the annual false negativity
rate [5–7]. The procedure involves the use of a 25- to 27-gauge needle, and a range of 3 to 5 passes are
performed for each targeted site, representing a single FNA procedure. If a patient has multiple targeted
nodules or masses, various aspirates are usually performed at the discretion of the medical personnel.
The aspiration of the material is then used for smear preparation, which includes air-dried slides
stained with Diff-Quik and alcohol-fixed slides stained with the Papanicolaou stain. It is paramount
to perform additional testing at the same time to avoid unnecessary delay in the diagnosis. In fact,
residual material is typically used for ThinPrep processing (Hologic Inc., Marlborough, MA, USA),
microbiology, and molecular biology studies. To confirm whether the material is adequate in a lymph
node, a small drop of the aspirate is placed onto the preparation slides for immediate assessment (also
technically labelled ‘rapid on-site evaluation’), while the remainder is rinsed in a cell preservative.
Typically, 10 million cells are considered adequate for cytopathology assessment, which requires 2–3
passes indeed.
The cell block preparation is routinely performed in our institution and not only in case of
ambiguous interpretation of the aspirates. It is also important to advise the lab technician to stain some
tissue sections of the cell block with hematoxylin-eosin and keep some unstained tissue sections for
histochemical (special) stains, immunohistochemical stains, and further ancillary testing as required.
The cytology aspirates are interpreted initially by a cytotechnologist and subsequently by a pediatric
pathologist with an intra-institutional cytopathology consultation adjured by a cytopathologist. FNAC
cases receive diagnoses with an adequacy interpretation (unsatisfactory, satisfactory), a primary
interpretation (nondiagnostic, negative for malignant cells, atypical cells present, suspicious for
cancerous cells, or positive for malignant cells), and a free text explanatory diagnosis. The category
‘less than optimal’ is not often used in our institutions to avoid non-categorical decisions.
It is also advisable to perform a yearly outcome rating using spreadsheet-based correlation to
surgical histopathology and clinical follow-up. In the case of clinical monitoring, laboratory values and
clinical presentation are part of a 6-month–1-year follow-up, while surgical histopathology, which is
based on either an incisional surgical biopsy or an excisional surgical biopsy, is considered the reference
standard in the diagnosis of tumors of the H&N region. In the setting of a quality assurance program,
true positives are cytopathologic results that warrant surgical treatment and are confirmed as such
using surgical histopathologic biopsy. True negatives are cytopathologic results that did not designate
a need for surgery and are established as such using the surgical histopathologic biopsy. Clinical
true negatives are negative conditions on cytology that resolve or did not progress without surgical
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intervention. In case of false positives cytology, cytopathology results are positive, but there would
have been no need for surgical treatment, while false negatives are unremarkable cytopathologic
results without a need for surgery, although a surgical intervention would have been the right option.
To avoid bias in any cytology-pathology correlation quality assurance program, it is prudent that
pathologists interpreting surgical histopathology slides are distinct from cytopathologists interpreting
the FNAC. Some infective or non-malignant conditions, such as atypical mycobacterial infection,
cervicofacial abscess, or lymphatic malformations, may require surgical diagnosis or treatment but
may also appropriately be managed by medical therapy. If the appropriate medical treatment is
initiated and results efficacious and efficient, the result is labeled as an actual clinical positive. The 2015
Standards for Reporting of Diagnostic Accuracy (STARD) guideline for reporting diagnostic accuracy
studies should be used [8].
In the setting of procedure complications, care should be taken when considering the side effects
of FNAC, e.g., infection and damage to nearby structures. By reviewing the literature, we found a
limited core of evidence for such side effects if a safe procedure is applied. In particular, an honest
and straightforward report provided by Chen et al. [9], who reported a 19-year-old girl with a painful
goiter, which became more painful after fine needle aspiration (FNA). The patient’s second FNAC
revealed only many neutrophils and an antibiotic treatment improved the pain, but the goiter persisted.
The third FNA revealed cytology of papillary carcinoma cells and the total thyroidectomy showed
ischemic necrosis with neutrophilic aggregation around the needle track other than a papillary thyroid
carcinoma. This report reveals the possibility of missing malignant cells in a background of an
infection following an improper FNA. Secondary infection and ischemic necrosis may indeed occur
after FNA, and aseptic procedures are necessary to prevent bacteria from seeding into the thyroid
gland. Disinfection of the FNAC site and experienced personnel are mandatory for laboratories
that harbor periodic accreditation by the College of the American Pathologists (CAP) operating in
healthcare institutions in United States of America and Canada. Thus, side effects may occur following
an FNA procedure. Nevertheless, we consider that FNAC in children and adolescents is accurate, safe,
and well-accepted in a wide range of lesions of the head and neck regions. A CAP accreditation or a
similar accreditation outside of North America should be requested by all pediatricians and parents of
the affected child.
3. Diagnostics
In most of the cases, FNAC of the H&N region is performed to investigate clinically
suspicious lymphadenopathy, and the primary differential diagnoses include congenital anomaly,
reactive/infectious lymphadenopathy, lymphoma, and metastatic disease, but also thyroid gland
disease and salivary gland disease.
3.1. Congenital Lesion
The age is also particularly important to keep in mind, and 75% of branchial cysts occur in
20–40 year-old patients [10–14]. Benign squamous-lined cysts are usually characterized by abundant
inflammatory cells (neutrophils), with few unremarkable squamous epithelial cells with bland nuclear
features, and cholesterol crystals, while a large number of squamous cells with or without occasional
nuclear hyperchromasia, nuclear membrane irregularity, and high nucleus to cytoplasm ratio portend
for a malignant diagnosis.
3.2. Reactive/Infectious Lymphadenopathy and Malignant Lymphoma
In about 2/3 of cases, de novo lymphadenopathies of the H&N region are benign, and even
a history of malignancy present in a child with a de novo lymphadenopathy will have a rate of
benignancy probably approaching half of the cases [15,16]. Moreover, additional surgical procedures
have been avoided in up to 61% of cases in one review [17]. The cytopathological diagnosis of reactive
is mostly accurate in children and youth with less in 1 out of 20 (~5%) subsequent (false-negative)
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malignant diagnoses [2,18]. Cytologic features of reactive lymphadenopathy include polymorphic
lymphoid cells showing a clear-cut sequence of maturation, prominent reactive cells arising from
germinal centers, the presence of tingible body macrophages, the lack of a monomorphic lymphoid
population and the simultaneous presence of a variegated (non-homogeneous) cell population
smear, and the lack of a subpopulation (even minimal) of large, irregular lymphoid cells potentially
indicative of Hodgkin’s lymphoma, anaplastic T-cell lymphoma, large B-cell lymphoma). Necrotizing
granulomata are often characteristic of underlying tuberculous infection (particularly systemic),
although they may also be found in fungal infection and other acid-fast bacilli (AFB) (e.g., mycobacteria
causing scrofula). In a child, the finding of granulomata may suggest non-tuberculous AFB, especially
in a child, and cat-scratch disease should be considered in this age group. Granulomas without
evidence of necrosis are suggestive of sarcoidosis, toxoplasmosis, or foreign-body giant cell reaction.
In all cases, a thorough microbiological investigation is paramount (e.g., Bartonella henselae for
cat-scratch disease). The correlation between clinical and laboratory findings using electronic medical
charts or liaising with the clinician is essential. In fact, serological tests may be useful in a subset
of cases for differentiating systemic lupus erythematosus lymphadenitis from Kikuchi–Fujimoto’s
disease, which is histiocytic necrotizing lymphadenitis. Finally, it is important not to forget that a florid
granulomatous pattern can mislead the cytopathologist disguising both Hodgkin’s lymphoma and
Non-Hodgkin’s lymphoma.
3.3. Rhabdomyosarcoma and Neuroblastoma
In a pediatric setting, the most fearful malignant diagnoses in the H&N region, apart from
malignant lymphoma, are rhabdomyosarcoma and neuroblastoma. Rhabdomyosarcoma is considered
to harbor three main subtypes, including embryonal, which is the most frequent type, the alveolar,
and the pleomorphic, which most commonly seen in adults. Rhabdomyosarcoma occurs very
often in the head and neck region and the extremities, with the trunk reserved for the third
location. Cytomorphology features of the embryonal rhabdomyosarcoma include a variability of
patterns including round to spindle-shaped cells, some pleomorphism (different from the marked
pleomorphism of the pleomorphic type of the rhabdomyosarcoma of the adult), a variable number of
rhabdomyoblasts may be the distinctive clue for the cytopathologist, and, occasionally, inclusion-like
cytoplasmic condensation, which is also known as myogenic differentiation [18]. Rhabdomyoblastic
differentiation is characterized by elongated, strap- or tadpole-shaped cytoplasm, and nuclear
eccentricity. The nuclear diagnostic clues also rely on dense hyperchromatic chromatin and nuclear
membrane irregularity (Figure 1a,b). The alveolar rhabdomyosarcoma is distinctively identified by
larger, uniformly round to variably polygonal cells with an increased number of mitotic figures in
the background with scattered rhabdomyoblasts and giant cells with wreath-like nuclei. Metastatic
neuroblastoma to the neck is quite rare in adulthood, but it is a principal differential diagnosis in
infants and children, especially in infants. Although most neuroblastomas arise in the adrenal gland
or the paravertebral sympathetic chain bilaterally, this pediatric tumor can occur anywhere along
the sympathetic chain. Cytomorphology of neuroblastoma may be entirely different according to the
degree of ganglionic differentiation of the neuroblastoma. These features include a fibrillary matrix,
dyshesive small undifferentiated cells, sparse Homer–Wright rosettes, a nuclear pattern labeled as
“salt and pepper” for the variability of the granularity of the nuclear chromatin, and, occasionally,
ganglion-like cells (Figure 1c,d). In rare occasions, necrotic debris and dysmorphic calcifications are
seen [18]. It is paramount to distinguish reactive/reparative changes from the diagnoses mentioned
above [19] (Figure 1e,f). A spectrum of appearance needs to be kept in mind in case of benign fibrous
proliferation. The retention of a low nucleus to cytoplasm ratio is crucial in case of prior radiation
where cells may be large, showing irregularity of the nuclei, multinucleation, all features that may
be quite worrisome. In fact, the resolution may decrease the inflammatory background, making the
diagnosis particularly distressful for an inexperienced pathologist. Moreover, the myofibroblasts that
occur in benign fibrous proliferations may become slender with less conspicuous nucleoli during the
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healing process. In all cases, the identification of pleomorphism, nuclear hyperchromasia, high nucleus
to cytoplasm ratio, and atypical mitoses suggest malignancy that needs to be surgically acted upon as
soon as possible.
 
Figure 1. (a,b) Rhabdomyosarcoma cytology in cell block (Papanicolaou, ×200) and smears fixed
and immunostained with the antibody anti-desmin (Avidin-Biotin-Complex immunostaining, ×630).
(c,d) Neuroblastoma cytology in smears and cell block showing hyperchromatic cells with high nucleus
to cytoplasm ratio (Diff-Quik, ×100 and ×100, c and d, respectively). (e,f) Reactive changes of soft tissue
showing a mixture of cells with variable morphology (cell block and smears stained with Papanicolaou
and Diff-Quik, ×100 and ×100, e and f, respectively).
3.4. Thyroid Gland Disease
The introduction of synoptic reports has been crucial in improving healthcare worldwide,
allowing a common platform for adequately assessing patients with neoplastic disease. Thyroid
cases receive an adequacy interpretation, a first interpretation using “The Bethesda System for
Reporting Thyroid Cytopathology” (TBSRTC), and a free text explanatory diagnosis with a comment
according to the pathologist or cytopathologist [2]. It is also encouraged that the cytopathologist
or the pathologist liaise with the clinical team in case an FNAC may indicate suspicious malignant
cells or some distinct cancerous cells. TBSRTC categories include insufficient for diagnosis, benign,
atypical cells of undetermined significance, suspicious for a follicular neoplasm, suspicious for
a Hürthle cell neoplasm, suspicious for malignancy (papillary carcinoma, medullary carcinoma,
lymphoma, metastatic tumor, other), and malignant. Despite iodine supplementation, multinodular
goiter (MNG) occurs in North America. MNG is a common disorder of the thyroid gland with
multiple nodules [18]. The macrofollicular pattern of a follicular neoplasm is indistinguishable
from MNG Cytologically, a benign follicular nodule shows mainly macrofollicles, low/moderate
cellularity, cohesive follicular cells with uniformity and even spacing, coarse chromatin, as well as
colloid, which may be copious. The differential diagnosis of benign follicular nodules includes
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suspicious follicular nodule, suspicious Hürthle cell nodule, and papillary carcinoma. In some
benign nodules, focal cytologic atypia may be present and becomes a diagnostic challenge. Of note,
Hürthle cell metaplasia is often seen in MNG and the cells may show at places marked nuclear
atypia. Hashimoto or chronic lymphocytic thyroiditis is characterized by a mixed population of
lymphocytes, tingible-body macrophages, dendritic-lymphocytic clusters, Hürthle cells and scant
colloid. Hyperplastic Hürthle cells nodules may occur in Hashimoto thyroiditis mimicking a Hürthle
cell tumor [18]. The differential diagnosis of Hashimoto thyroiditis includes a reactive lymph node,
MNG with predominant Hürthle cell change, primary malignant lymphoma of the thyroid gland,
Hürthle cell neoplasm, and papillary thyroid carcinoma. A subacute thyroiditis and Riedel disease are
not a common event in pediatric age or youth. The category of suspicious for a follicular neoplasm
has some cytologic features including marked cellularity, scant colloid, predominant microfollicles or
epithelial trabeculae, and enlarged, crowded follicular cells (differently from the uniformity and even
spacing of the benign lesions) [18]. In a pediatric setting, a suspicious for a follicular neoplasm poses
a differential diagnosis of a benign follicular nodule, papillary thyroid carcinoma, and parathyroid
adenoma or carcinoma. Other malignant masses have other distinguishing features in childhood
and youth. A suspicious for Hürthle cell neoplasm diagnosis has cytologic features showing an
almost complete cell population of Hürthle cells, usually dyshesive cells with prominent nucleolus,
and pseudopsammoma bodies. Cytological features of papillary thyroid carcinoma include sheets,
microfollicles, and papillae, although the nuclear changes need to be searched carefully. The nuclear
changes include grooves, pseudoinclusions, “powdery” chromatin, and thickened and irregular
nuclear membrane. There is also nuclear crowding or molding. Cells show a variable amount of
cytoplasm and psammoma bodies may be present. The differential diagnosis of papillary carcinoma
includes a benign follicular nodule, a follicular neoplasm, Hashimoto thyroiditis, radiotherapy effect,
and a hyalinizing trabecular tumor. Although the anaplastic carcinoma does not play any role in
childhood or youth, an important entity to keep in mind is the medullary carcinoma. Cytologically,
this endocrine parafollicular cells derived tumor shows numerous isolated cells, loose aggregates of
cells with epithelioid, plasmacytoid, or spindle-shaped morphology, nuclear changes (rounding or
elongation, granularity of the chromatin, inconspicuous nucleolus, pseudoinclusions, and multiple
nuclei), cytoplasmic changes (red granules) on Diff-Quik stained preparations, and amyloid. Although
rare, two primary malignant lymphomas of the thyroid gland need to be kept in mind and include the
diffuse large B cell lymphoma and the extra-nodal marginal zone B-cell lymphoma.
3.5. Salivary Gland Disease
Salivary gland lesions are rare in children, although an increase of salivary gland disease in
adolescence and youth has been reported recently [20–22]. Previous research has shown that salivary
gland tumors are rare in the young population, but the incidence of all primary salivary gland
carcinomas increased with increasing patient age, particularly in patients younger than 30 years.
Lesions of the major cephalic salivary glands, with the exception of mumps and cytomegaly,
are unusual in children and adolescents, but these lesions may give rise to some different tentative
diagnoses [23–25]. Since malignant salivary gland tumors are relatively more frequently recognized in
younger patients, a safe approach is advisable, and intradepartmental consultation is crucial. Cytologic
diagnoses of malignant tumors are confirmed histologically in 93% of cases, while benign tumor
diagnoses are confirmed on histology in 95% of cases. Inflammatory lesions are confirmed on histology
in 73%, while benign salivary gland tissue is ascertained as such histologically in 18% of cases [26].
Non-rare malignant salivary gland tumors in childhood and youth are a mucoepidermoid carcinoma,
adenoid cystic carcinoma, acinic cell carcinoma, malignant lymphomas, and metastatic tumors
from a tumor of the H&N region or paraganglia (e.g., neuroblastoma). Benign neoplasms include
pleomorphic adenoma and Warthin’s tumor (Figure 2a,b). In childhood, 80–90% of all malignant
salivary gland tumors are constituted by mucoepidermoid carcinomas, adenoid-cystic carcinomas,
and acinic cell carcinomas.
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Figure 2. (a,b) Pleomorphic adenoma and Warthin tumor (Papanicolaou stain, ×100 and ×100, a and
b, respectively). (c,d) Acinic cell carcinoma (Papanicolaou stain, ×40 and ×100, c and d, respectively).
(e,f) Mucoepidermoid carcinoma (Papanicolaou stain, ×400 and Papanicolaou stain, ×400, e and f,
respectively). The mucin in the background and the nuclear detail are supportive of a diagnosis of
mucoepidermoid carcinoma. (g,h) Adenoid cystic carcinoma (Diff-Quik, ×100 and ×100, g and h,
respectively). For the details of the single salivary gland tumors, please refer to the text.
In adults, the corresponding figure is only 45% [23]. Despite the low incidence of 15–25% of
malignant neoplasms for adults identified in 1969 [27], in a study carried out on 2632 patients following
teams and investigations reported a significantly higher relative proportion in young patients [23].
Acinic cell carcinoma is characterized by a hypercellular aspirate with a clean background with tumor
cells seen in disorganized clusters with loss of round groupings and lack of an associated ductal
epithelium and on higher magnification cells show some uniformity resembling normal serous acinar
cells with the cytoplasm being foamy or bubbly and harboring fine dark granules (Figure 2c,d) [28,29].
The examination of the background highlights many naked nuclei. Apart from clear cell tumors,
mainly low-grade mucoepidermoid carcinoma and epithelial-myoepithelial carcinoma), oncocytic
tumors, sialadenosis, and normal salivary gland tissue need to be kept in the differential diagnosis list.
Smears of mucoepidermoid carcinoma are usually low in cellularity with a particularly striking dirty
background of mucin and debris. In the smears, the presence of scattered cell clusters of intermediate
cells with overlapping epithelial groups, some mucin-coated cells (goblet-cells-like), and few squamous
epithelial cells are particularly evident features for the diagnosis of mucoepidermoid carcinoma
(Figure 2e,f). However, both components may be quite bland or missing in one or all slides. According
to the grade of differentiation, nuclear features may vary from bland to hyperchromasia with a high
nucleus to cytoplasm ratio, although this tumor is usually low-grade in childhood and adolescence.
Some potential pitfalls in diagnosing the mucoepidermoid carcinoma are some cystic nature of these
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tumors, which may harvest only hypocellular (even acellular in some cases) mucoid material [30].
Moreover, extracellular mucin is typically copious, mimicking the fibrillary stroma seen in pleomorphic
adenomas, although the mucin of pleomorphic adenomas stains less intensely and has no fibrillary
pattern. Finally, squamous metaplasia is not only characteristic of mucoepidermoid carcinoma but
may be found in other tumors, such as pleomorphic adenoma and Warthin’s tumor (Figure 2a,b).
The adenoid cystic carcinoma features are large globules of extracellular matrix with or without
surrounding basaloid cells. In FNAs with a predominance of basaloid tumor cells, both benign and
malignant salivary gland tumors of epithelial–myoepithelial differentiation should be considered
in the differential diagnosis (Figure 2g,h) [28,29]. If TBSRTC has received a warming acceptance in
many countries, the Milan System for Reporting Salivary Gland Cytology (MSRSGC) seems that
will have similar success in the coming years [31–35]. The MSRSGC is an evidence-based tiered
classification system that comprises six diagnostic categories associated with an average risk of
malignancy (ROM) and clinical management strategies (Table 1). It is expected that the MSRSGC
will improve communication between the cytopathologist and the treating pediatrician, facilitating
cytologic-histologic correlation, and lead to overall improved patient care.
Table 1. Milan System for Reporting Salivary Gland Cytology (adapted from [36]).
Category significance
Category I => Nondiagnostic, harboring a ROM of 25%
Category II => Nonneoplastic, harboring a ROM of 10%
Category III => Atypia of undetermined significance, harboring an estimated ROM of 20%
Category IV => Neoplasm
Subcategory IVA => Benign, harboring a ROM of <5%
Subcategory IVB => Salivary gland neoplasm of uncertain malignant potential, harboring a ROM of 35%
Category V => Suspicious for malignancy, harboring a ROM of 60%
Category VI => Malignant, harboring a ROM of 90%
Notes: ROM, risk of malignancy.
4. Study Comparison
FNAC is now being considered as a valuable diagnostic aid in many children’s hospitals across
continents, not only in North America. In most studies, FNAC reveals good aspects, showing the
early availability of results, its simplicity, minimal trauma or injury, and the low rate of complications.
Ancillary techniques, including flow cytometry, cytogenetics, immunohistochemistry on the cell
block, and electron microscopy can be easily applied for the characterization of tumors [20,21,37,38].
Furthermore, FNA does not usually need heavy sedation, and general anesthesia is not necessary.
FNAC of the H&N region is a well-accepted technique that has high specificity in most studies [21].
In Table 2, a comparison of four studies is provided.
Table 2. Study Comparison (adapted from [21]).
Study Rapkiewicz [37] Jain [20] Handa [38] Mittra [21]
Topics H&N lesions H&N lesions Cervical LNs H&N lesions
Cases 85 748 692 (584 LNs) 100
Age group 0–18 years 0–12 years 0–14 years 0–15 years
Adequacy N.A. 94% 93.4% 93%
Common site LN (69.4%) LN (81%) LN (84.3%) LN (87%)
Benign 83% 98.5% 98.5% 88.2%
Malignant 17% 1.5% 1.5% 11.8%
Notes: H&N, Head and Neck; LN, lymph nodes; N.A., not available.
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5. Limitations
Most of the studies have several limitations that are inherent in their retrospective nature.
First, the lack of standardization of the enrolled patients is reflective of both the diversity of pediatric
nodules and the variable diagnostic and treatment approaches of different clinical and surgical
teams [17]. In fact, there is often a significant variation in the use, duration, and timing of antibiotic
treatment, and the accessibility of the clinical and surgical services was also variable and change
over time was present in most of the retrospective studies. The lack of universal follow-up is also an
essential drawback of numerous FNAC studies. The importance of the monitoring may be enshrined
for all patients with negative FNAC results that need to be instructed to follow up if the mass persists,
increases in size, or any concerns remain.
6. Conclusions
The potential avoidance of surgery with associated scarring, early and late septic and non-septic
surgical complications, general anesthetic risk, recovery time, and significant expense bills have all
been heralded as benefits of FNAC, especially given the high prevalence of non-neoplastic pediatric
tumor and masses of the H&N region. FNAC shows an impressive diagnostic accuracy in numerous
studies. FNAC is supported by an active lab safety profile and carries a very limited number of
drawbacks considering that in the case of a dubious cytology result, a surgery can be planned in
a very short time identifying FNAC as a useful triage procedure. In conclusion, FNAC is a safe,
well-tolerated, and accurate tool for diagnosing pediatric masses of thyroid and non-thyroid origin in
childhood and youth. FNAC plays a vital role in giving comfort to obviate the need for unnecessary
immediate surgery in benign nodules (congenital/reactive/inflammatory) and plan a primary surgical
intervention in malignant lesions. In consideration of significant health care changes worldwide, we
would like to strongly emphasize that when such a triage of pediatric masses of the H&N region is
handled, there is a potential decrease in both surgical morbidity and health care costs.
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Abstract: Somatosensory evoked potentials (SSEPs) are a valuable tool to assess functional integrity
of the somatosensory pathways and for the prediction of sensorimotor outcome in perinatal injuries,
such as perinatal hypoxia-ischemia (HI). In the present research, we studied the translational potential
of SSEPs together with sensory function in the male adult rat with perinatal HI compared to the male
healthy adult rat. Both somatosensory response and evoked potential were measured at 10-11 months
after global perinatal HI. Clear evoked potentials were obtained, but there were no group differences
in the amplitude or latency of the evoked potentials of the preceding sensory response. The bilateral
tactile stimulation test was also normal in both groups. This lack of effect may be ascribed to the late
age-of-testing and functional recovery of the rats.
Keywords: somatosensory evoked potential; preterm brain; rat model; cerebral palsy; hypoxia-ischemia
1. Introduction
Somatosensory evoked potentials (SSEPs) are a valuable tool to assess functional integrity of the
somatosensory pathways of the peripheral and central nervous systems [1]. SSEPs are widely used
for the prediction of motor outcomes in perinatal injuries, where the long-term effects of the injury
are difficult to ascertain early in life [2]. Hypoxic-ischemic encephalopathy (HIE) is a common injury
in neonates, with a global occurrence of 8.5 infants per 1000 live births in 2010 [3]. Infants with HIE,
especially preterm infants, are considered to be at risk for developmental disorders [4]. They present
a heterogeneous clinical picture, varying by individual, and ranging from major disorders like
cerebral palsy (CP) to less severe impairments like developmental coordination disorder (DCD). DCD is
commonly associated with other developmental comorbidities, including attention deficit/hyperactivity
disorder (ADHD) and learning disabilities, and could be related to an impaired sensory process.
Several studies have shown that SSEPs, in combination with other electrophysiological tools
and neuroimaging, are useful in the diagnosis of encephalopathy after HIE and could improve
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the prediction of infants that will have poor neurodevelopment outcomes two years after perinatal
HIE [2,5–7]. However, the predictive value of SSEPs decreases with longer follow-up periods. Neonatal
SSEP latencies do not correlate with neurodevelopmental outcomes at school-going age in infants
with mild HIE. The long-term prognostic value of neonatal SSEPs in this patient group is unclear [1].
It is also unknown whether the neonatal SSEP abnormalities persist in adults with HIE. On the other
hand, SSEPs are suited to evaluate patients suffering from more severe forms of disability such as
cerebral palsy (CP), in whom neurological deficits might reflect disruption of motor as well as sensory
connections [8,9], suggesting a neural network disorder. Furthermore, both motor and behavioral
skills involve the process of receiving a sensory input. In this context, motor-behavioral deficits
could be treated by sensory-based therapies. Indeed, this may be acceptable as one component of a
comprehensive treatment plan in the management of children with developmental, behavioral, and
motor disorders of different etiology [10].
SSEP is a relatively simple, objective, and reproducible diagnostic procedure that assesses the effect
of the somatosensory input in the peripheral and central neuronal networks. In the present experiments,
we used a perinatal rat model of hypoxic-ischemia (HI) injury by submersion [11]. Previous studies
using this model of global perinatal preterm HI demonstrated that severe HI (submersion lasting
for 19–20 min) decreased locomotor activity in the adult rat, while milder HI insults might increase
locomotion [12,13]. In this respect, our experimental group is a cohort of male adult rats that recovered
from moderate global perinatal HI and showed cognitive (memory) as well as motor abnormalities
(hyperactivity) within the spectrum of ADHD at the age of 6–8 months [14]. To test whether this cohort
had a problem in coordination (DCD), we evaluated the sensory functioning using a bilateral tactile
stimulation test and we recorded cortical SSEPs after unilateral tibial nerve stimulation at 11 months of
age [14].
The present study reports the outcomes of the SSEPs and behavioral tasks of sensory functioning
of male adult rats subjected to moderate perinatal HI. We hypothesized that long-term sensory deficits
were relevant to the combined sensory and motor deficits previously demonstrated in this cohort of
male rats after perinatal HI.
2. Materials and Methods
2.1. Rodents and Ethics Approval
The experiments were performed in Sprague-Dawley rats from Charles River (Leiden,
The Netherlands). The rats were housed at the Central Animal Experimentation Facilities of the
Maastricht University, The Netherlands. Experimental female rats were synchronized with luteinizing
hormone-releasing hormone (Cat. L4513, Sigma-Aldrich, The Netherlands), and time-mated between
15:00 and 07:00 the following morning. All experiments were conducted under ethical approval from
the Dutch Central Committee for Animal Testing according to the guidelines of the EU directive
2010/63/EU (approval code: AVD107002016540, approved on 16 July 2016).
2.2. Perinatal Hypoxia-Ischemia (HI) Procedure
In the afternoon of embryonic day 21 (expected delivery on E21–E22), a pregnant female rat
was euthanized by rapid decapitation and the uterine horns, still containing the pups, rapidly
removed and submerged in saline solution at 37 ◦C for 16–18 min according to previously-described
methodology [12,13]. After submersion, the pups were delivered, manually stimulated to breathe,
and placed in a closed pediatric incubator to recover for an hour (HI group). The control Cesarean-section
rats (C-section) were delivered from the same litters without submersion and placed in the closed
pediatric incubator to recover with their HI littermates. After recovery, the mixed litter of HI and
C-section pups was placed with a foster mother that had given birth the day before to minimize the
impact of maternal care differences on outcomes. The mortality rate for the HI procedure was 39%.
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2.3. Housing
After weaning, the rats were fed a standard laboratory diet and housed in pairs in individually
ventilated cages, up to 8 months of age, when they were housed 4 per cage in larger filter top cages.
The rats were housed on a reverse day night cycle (lights off at 7:00/lights on at 19:00).
2.4. Adhesive Removal (‘Sticker Test’)
The adhesive removal test was performed at 10 months of age. Somatosensory response was
assessed with a bilateral tactile stimulation test adapted from a method previously reported [15,16].
For the sticker test, rats were placed in an empty cage with videotaping from the sides. One investigator
restrained the rat, whilst another investigator placed two brightly colored circular adhesive labels
(1.27 cm diameter, Avery office products, Houten, The Netherlands) on the dorsum of both forepaws
of the rat. Adult rats normally touch and remove the stickers with their teeth. The time from placing
the rat in the arena to the initial purposeful sticker contact (‘noticed’) and to removal from both paws
(‘removed’) was recorded and the latency time from initial contact to removal was calculated. The time
limit for adhesive removal was 180 s. Group sizes for this test were C-section (n = 12) and HI (n = 11).
2.5. Sedation
For the SSEPs, the rats were placed under anesthesia with an induction of midazolam (0.5 mg/kg),
followed by a mixture of ketamine (0.75 mg/kg), medetomidine (0.06 mg/kg) and atropine (0.04 mg/kg)
in saline (KMA). Sedation was maintained during the procedure with an intraperitoneal infusion of
the KMA mixture.
2.6. Somatosensory Evoked Potentials (SSEPs)
The SSEP was conducted according to methodology previously described by Zhang, et al. [17] at
the age of 11 months. A Nicolet Viking IV P™ (Nicolet Biomedical, Madison, WI, USA) was utilized to
record and analyze the waveform of SSEPs. Twelve-millimeter long monopolar needle electrodes with
attached lead wire were used for active, reference, and ground electrodes. A sedated rat was placed on
a board and the needle electrodes were carefully inserted into the scalp and placed on the surface of
the skull, parallel with the long axis of the rat body. The active electrode was located on the midline of
the skull and crossed the point of bregma for right hemisphere recording.
The reference electrode was placed on the skull surface over the olfactory bulb and the ground
electrode was placed in the shoulder. Left tibial nerve stimulation was performed with 0.2 ms pulses at
1.7 Hz (filter set to 2–3000 Hz) with an intensity of 1–3 mA, depending on the twitch response, for
an average of 500 stimuli. We studied the cortical SSEPs P1 and N2 amplitudes and latencies, which
were registered by a child neurologist (JSHV) and reviewed together with a clinical neurophysiologist
(VHvKM) and a clinical neurophysiology technician (PB).
We recorded 6 male rats per group, for the following groups: C-section (body weights: 601 ± 36 g)
and HI (body weights: 574 ± 33 g).
2.7. Statistics
Stata 10 (Statacorp, TX, USA) was used to assess group differences by means of the non-parametric
Kruskal-Wallis H-test followed by post-hoc Dunn’s test of equality. Regarding SSEPs, the averaged
value between two runs was used. P values <0.05 were considered as statistically significant. Figures
regarding average ± standard error means were constructed with GraphPad Prism 6 (GraphPad
Software Inc., La Jolla, CA, USA). Outliers were not considered in the analysis.
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3. Results
3.1. Adhesive Removal Test (‘Sticker Test’)
The results of the sticker test are shown in Figure 1. There were no significant differences between
groups regarding the time the rats took to notice the sticker on their paws (p = 0.943), the time to
remove it (p = 0.546), or the time from notice to removal (p = 0.244).
Figure 1. The adhesive removal test showing the latency to notice (N) and remove the stickers from the
front paws (R), as well as the time elapsed between notice and removal (R-N). CTR: control C-section
group, HI: hypoxia-ischemia group.
3.2. Evoked Potentials
Reproducible SSEPs were obtained in all rats. After exclusion of one outlier, our group sizes were:
C-section (n = 5) and HI (n = 6). There were no significant differences for the amplitude of the P1 peak
(p = 0.078), the N2 peak (p = 0.891), or the absolute difference in the amplitude of the P1-N2 peaks
(p = 0.469). There were also no significant group effects on the latencies of these peaks P1 (p = 0.667),
N2 (p = 0.558) (Figures 2 and 3). Exclusion of the outlier did not statistically change the results.
Figure 2. Representative example of tibial somatosensory evoked potentials (SSEPs) recording in adult
rats. N1, P1 and N2 cortical latency and amplitude.
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Figure 3. The latencies and amplitudes of the SSEP test. Each data point represents a single male
animal; horizontal lines represent regional medians with the standard error medians. P1 latencies,
N2 latencies, P1 amplitude, N2 amplitude, Absolute differences in amplitude. CTR: control C-section
group, HI: hypoxia-ischemia group.
4. Discussion
In human newborns, particularly those born preterm, HI is an important cause of long-term
neurological disabilities, such as learning and memory deficits and sensorimotor and motor functioning
deficits like CP [18,19]. The present study investigated the long-term effects of moderate HI on
somatosensory functioning in male survivors using an established rat model of preterm HI.
Recording of SSEPs is a quantitative method for evaluation of both the central and peripheral
nervous system. Peripheral sensory information reaches the parietal-occipital cortex by thalamocortical
pathways e.g., corona radiata and internal capsule. The parietal cortex connects to neocortical areas
including premotor, prefrontal areas as well as to the cerebellum through pontine nuclei. Merging
this information with the basal ganglia, pre-Rolandic motor areas control motor activity through
the descending corticospinal tracts [20]. SSEPs are suited to evaluate children and adult patients
suffering from CP [9]. Through the findings of neuroimaging studies, a correlation has been reported
in CP patients between disrupted descending corticospinal pathways and disrupted thalamocortical
pathways connecting to the sensory cortex [20]. The role of SSEPs in children and adults with milder
deficits after HI is unclear. Identifiable sensory processing and motor interaction during early childhood,
e.g., reaching and touching objects using hands and mouth, provides a critical foundation for normal
growth, development, and learning. This sensorimotor integration explains why sensory impairments
affect motor recovery, and why sensory based strategies might promote motor and behavioral recovery.
The seminal work reported by de Louw, et al. (2002) on the short-term effect of severe perinatal
HI on spinal cord apoptosis using this perinatal model of submersion showed an increased lumbar
grey and white-matter apoptosis [21]. These changes may contribute to the permanent motor deficits,
which are the main neurological manifestations of brain injury in the premature infant. We investigated
whether preterm HI had a long-term effect on expected sensorimotor deficits.
In the adhesive removal test, we did not observe a statistically significant effect of HI. We used
the time for removal from both paws, since we caused a global insult which was expected to affect
both hemispheres equally. In adult rats with unilateral lesions, a bias to touching the non-affected
forepaw first has been reported [15]. A previous study of neonatal unilateral hypoxic-ischemic injury
also did not find significant group differences with the adhesive removal among five-week-old rats
with a modest brain injury [16].
Tibial SSEPs evaluate the somatosensory pathway including dorsal columns of the rat’s spinal
cord and the contralateral parietal cortex. Our study found that the perinatal HI insult did not influence
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the SSEPs. A previous study with SSEPs after neonatal stroke in the rat, found profound unilateral
changes in SSEPs one week after the insult, but recovery of the deficits 3 weeks postnatally. This may
indicate large-scale plasticity of the somatosensory networks even after a unilateral neonatal injury [22].
It is thus possible that sufficient recovery occurred at 11 months after the global asphyxic insult and
ameliorated changes observed in evoked potentials.
SSEPs were performed unilaterally (left tibialis nerve stimulation) assuming symmetrical and
global central nervous system impact inherent to the global perinatal hypoxic-ischemic insult.
This statement has been corroborated by the symmetrical adhesive removal test, which complements
the SSEP data. In summary, we did not find any permanent significant sensory behavioral or
electrophysiological changes in rat adulthood explaining the hyperactivity disorder and recognition
memory deficit shown by this rat cohort. However, these results raise the question whether the
somatosensory functioning of our rats has sufficiently recovered over time, or whether the SSEPs was
not sensitive enough to detect deficits in adult rats.
There are several methodological and study limitations that could explain why we failed to detect
preclinical SSEPs:
(a) Due to our cross-sectional design, we might have missed SSEP changes in early postnatal age
and adolescence.
(b) Midazolam, ketamine and medetomidine were used as systemic anesthetics during SSEPs
recordings. Accordingly, this anesthetic combination may have influenced SSEPs results; however,
both experimental groups received the same anesthetic regime [23]. In humans, SSEPs are known
to be less sensitive to the injectable anesthetics that we used, than to inhalation anesthetics [24].
(c) The lumbar spinal cord apoptosis observed in severe HI models (19–20 min of submersion) may
not necessarily be the postnatal hallmark of the moderate HI model (16–18 min of submersion)
used in this experiment [21].
(d) Evidence supports more neurological impairments and higher mortality for male preterm infants.
In line with the human data, behavioral studies have consistently shown that the male sex is
associated with an increased risk of long-term motor deficits in the rat preterm HIE [11]. Therefore,
only male rats were included in this study.
(e) Our global HI insult was conducted around the time of birth, when the rodent brain development
is comparable to that of human infants born at a very low gestational age [11]. Studying SSEPs in
larger animal models with brain development comparable to humans, such as sheep, may be
more predictive of the human clinical situation [25]. However, larger animals are less suitable for
chronic, long term studies.
Despite the aforementioned limitations, the present study found that, in the rat, moderate global
HI did not influence the sensorimotor measurements assessed at 11 months. The moderate severity of
the insult and the neuroplasticity observed early in life may explain the lack of a measurable effect on
the adult survivors. More research is warranted to further confirm our results.
Highlights:
1. SSEPs are used to clinically assess the integrity of peripheral and central somatosensory pathways
after perinatal HI.
2. Childhood SSEPs are often used to predict long-term outcomes, but it is unknown if sensory
pathway deficits persist into adulthood.
3. We showed the electrophysiological and behavioral integrity of the somatosensory pathways in
adult rats subjected to moderate perinatal HI.
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Abstract: Bilirubin encephalopathy/kernicterus is relatively rare, but continues to occur despite
universal newborn screening. What is more interesting is the spectrum of clinical and even
neuropathological findings that have been reported in the literature to be associated with bilirubin
encephalopathy and kernicterus. In this review, the authors discuss the array of clinicopathological
findings reported in the context of bilirubin encephalopathy and kernicterus, as well as the types of
diagnostic testing used in patients suspected of having bilirubin encephalopathy or kernicterus.
The authors aim to raise the awareness of these features among both pediatric neurologists
and neuropathologists.
Keywords: bilirubin encephalopathy; kernicterus; neurological symptoms; diagnosis; neuropathology
1. Introduction
Bilirubin encephalopathy/kernicterus is a relatively uncommon occurrence. Although neonatal
jaundice is quite common, affecting 60%–80% of newborns overall [1], severe hyperbilirubinemia
(> 20 mg/dL) that could potentially lead to kernicterus and neurodevelopmental complications is said
to be much rarer, affecting less than 2% of newborn infants [2]. Associated risk factors can include a low
gestational age, low birth weight, hemolysis, sepsis, cephalohematoma or easy bruising, and exclusive
breast feeding. Recent literature has shed light on the wide range of clinical symptomology and
pathological findings associated with bilirubin encephalopathy/kernicterus [3,4]. Bilirubin-induced
neurological complications continue to occur in industrialized countries, but a disproportionately
increased burden is reported in low- and middle-income countries, primarily because of delays in
delivering treatments that are more readily available in high-income countries [1,5]. This review
aims to provide a comprehensive overview of the clinical, radiological, and neuropathological
features associated with bilirubin encephalopathy/kernicterus that have been reported in the
literature, as well as the string of diagnostic tests used in patients suspected of having bilirubin
encephalopathy or kernicterus. The authors hope to raise awareness of the wide spectrum of findings
that should raise the possibility of bilirubin encephalopathy or kernicterus to pediatric neurologists
and neuropathologists alike.
2. Clinical Presentation
Acute bilirubin encephalopathy encompasses the acute illness caused by severe
hyperbilirubinemia. Presenting signs and symptoms include decreased feeding, lethargy, abnormal
tone (hypotonia and/or hypertonia), high-pitched cry, retrocollis and opisthotonus, setting-sun
sign, fever, seizures, and possibly death [6,7]. Seizures usually resolve several weeks after the acute
insult. Therefore, persistent seizures in a child with kernicterus should prompt a search for another
concomitant condition.
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The so-called ‘kernicteric facies’ in acute bilirubin encephalopathy includes a combination of the
setting-sun sign (i.e., paresis of upward gaze) with eyelid retraction, which together comprise the
Collier sign, and facial dystonia. These findings make the infant appear stunned, scared, or anxious.
Some infants may also exhibit disconjugate or wondering eyes. This kernicteric facies persists for at
least two to three weeks after acute bilirubin encephalopathy [8].
Recent reviews and studies have also reported apnea in both preterm and term infants in
conjunction with other findings of acute bilirubin encephalopathy and also as an isolated early
abnormality [9–11]. Apnea may also be a sign of seizures in a newborn with jaundice, albeit
infrequently. These authors also suggested that apneic events are a common clinical sign of bilirubin
neurotoxicity in late preterm and term neonates with severe jaundice associated with bilirubin levels
greater than 25 mg/dL. Clinical findings suggestive of bilirubin-induced disturbance in control of
breathing include (1) new onset of frequent apnea, bradycardia, and desaturations concurrent with
marked hyperbilirubinemia; (2) apnea, bradycardia, and desaturation that require intubation and
assisted ventilation in an infant with marked hyperbilirubinemia; and (3) acute worsening of frequency
and severity of apnea from baseline levels in an infant with marked hyperbilirubinemia [9]. Any
noticeable change in the frequency and/or severity of apnea should prompt a measurement of total
serum bilirubin levels as it may suggest acute bilirubin encephalopathy.
Kernicterus describes the long-term outcome of acute bilirubin encephalopathy and encompasses
a tetrad of clinical features that are typically evident after one year of age: (i) abnormal motor control,
movements, and muscle tone; (ii) an auditory processing disturbance with or without hearing loss; (iii)
oculomotor impairments, especially impairment of the upward vertical gaze; and (iv) dysplasia of the
enamel of deciduous (baby) teeth [12].
Auditory complications, a disabling neurological finding in kernicterus, are typically characterized
by varying degrees of auditory neuropathy/dys-synchrony (AN/AD) ranging from central auditory
processing difficulties with normal hearing to severe AN/AD with absent auditory brainstem
responses, and possibly accompanying severe hearing loss and deafness [12]. In fact, the brainstem
cochlear nuclei are said to be one of the first structures affected by elevated total bilirubin, followed by
the auditory nerve [13,14]. Although the cochlea is not directly affected by elevated bilirubin levels, it
is thought that damage to the cochlea may occur secondary to damage to the cochlear nucleus and/or
auditory nerve [15].
Patients with so-called ‘motor predominant’ kernicterus due to lesions in the globus pallidus
(interna and externa) and subthalamic nucleus reportedly present with an athetotic or dyskinetic
form of cerebral palsy. In the most severe form of ‘motor predominant’ kernicterus, one may observe
severe dystonia/athetosis that prevents voluntary movements, including ambulation, speech, and
self-feeding, and may be accompanied by severe hypertonia and muscle cramping. Mild and moderate
forms of kernicterus may also present with motor symptoms that include dystonia with or without
athetosis and gross motor developmental delays, although patients with moderate kernicterus may
experience greater difficulty ambulating due to choreoathetoid movements [16].
Bilirubin-induced neurological dysfunction (BIND) (aka subtle kernicterus) was actually defined
by the presence of subtle developmental disabilities without the classical findings of kernicterus [12].
Patients may exhibit neurodevelopmental disabilities with a history of excessive hyperbilirubinemia
and prior signs of bilirubin encephalopathy. Subtle kernicterus spectrum disorders may also be
associated with conditions related to the findings of classical kernicterus, such as auditory imperception,
aphasia, and other neurodevelopmental disorders (e.g., central auditory processing disorders, sensory
and sensorimotor integration disorders, hypotonia, ataxia or clumsiness) [12]. An important clinical
issue of subtle kernicterus/BIND seems to be auditory neuropathy, defined as impaired auditory
brainstem reflexes with normal otoacoustic emissions or cochlear microphonic responses. Auditory
brainstem response is said to be absent or abnormal, reflecting damage to the auditory nerve and/or
auditory brainstem nuclei [7]. Le Pichon et al. (2017), however, suggested using the term Kernicterus
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Spectrum Disorders to encompass all neurological sequelae of bilirubin neurotoxicity, acknowledging
that kernicterus is symptomatically broad and diverse [17].
3. Diagnostic Testing
Infants who appear jaundiced should be evaluated with a risk score or total serum/transcutaneous
bilirubin measurement [2,18]. The transcutaneous method of measuring bilirubin has the advantage
of being less invasive, with results becoming available much more quickly compared to serum
measurement and is potentially more cost effective, but this method may not be reliable at bilirubin
levels greater than 15 to 20 mg/dL [19]. The bilirubin levels should be interpreted in relation to
the infant’s age in hours. Recommendations from the American Academy of Pediatrics state that
laboratory tests should be ordered for all infants with jaundice who require phototherapy, including
neonatal blood type, direct antibody titer/Coombs test, complete blood count, blood smear, and
direct/conjugated bilirubin level [2].
In neonates, serum unconjugated bilirubin (UCB) is usually elevated during the first two weeks
of postnatal life due to the increased breakdown of fetal erythrocytes, deficient albumin transport
to the liver, and decreased conjugation leading to physiological jaundice of the newborn, requiring
no treatment [20]. In some newborn infants however, serum levels of unconjugated bilirubin can
increase significantly due to impaired postnatal maturation of hepatic transport, impaired conjugation
of bilirubin, or augmented hemolysis. This jaundice is pathologic and may lead to death or severe
neurodevelopmental complications in survivors [20]. Unconjugated bilirubin levels close to 20 mg/dL
have been reported to be related to kernicterus [21].
Measurement of free/unbound bilirubin (i.e., bilirubin not bound to albumin) can also be an
important marker of the risk of hyperbilirubinemia. A study by Morioka et al. (2015) involving 18
preterm (<30 weeks) infants (birth weight < 1000 g) diagnosed with kernicterus between 2002 and 2012
based on clinical history, neurological examinations, and laboratory investigations, found the median
age at which total bilirubin levels peaked was 28 days after birth. The majority of these infants (16/18)
were 14 or more days of age and the latest age recorded for peak total bilirubin levels was 86 days.
The median serum total and unbound bilirubin levels in this cohort at that age were 17.0 mg/dL and
1.67 × 10−3 mg/dL, respectively. Nine of 18 infants had high total and unbound bilirubin, while seven
of eight infants with low total bilirubin had high unbound bilirubin. The results of this work suggest
that chronic high unbound bilirubin levels may help identify early low-birth weight infants at risk of
developing kernicterus [22]. Measurement of unbound bilirubin is still not feasible in most parts of
the world, but we believe the above-mentioned study emphasizes the importance of developing an
accurate method for its determination in clinical practice.
Iskander et al. (2014) performed a longitudinal observational study in which the neurologic
status and auditory impairment (automated auditory brainstem response) were evaluated (both at
admission and posttreatment) in 193 term/near-term infants that were admitted to hospital for
jaundice. Relationships of total serum bilirubin (TSB) and the bilirubin-albumin (B/A) ratio to
advancing stages of neurotoxicity were compared using receiver operating characteristic curves.
The authors found a stepwise relationship between median and threshold values of TSB and the
B/A ratio, and the progression of acute neurotoxicity. However, they concluded that the B/A
ratio did not improve the prediction of bilirubin encephalopathy over total serum bilirubin levels
alone [23]. Other authors similarly consider a high B/A ratio in preterm infants to be a risk factor and
suggest its use in conjunction with TSB for the evaluation and treatment of premature infants with
hyperbilirubinemia [24]. Elevated B/A ratios may be especially helpful to predict the risk of bilirubin
neurotoxicity in cases of so-called low bilirubin kernicterus in which bilirubin-induced neuronal
injury is said to occur at total bilirubin levels that are thought to be non-hazardous with low albumin
levels [25]. Novel methods for bilirubin quantification have been developed in recent years. A detailed
discussion of these methods is beyond the scope of this article, but the interested reader is referred to
the excellent review by Ngashangva et al. (2019) [26].
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The above-mentioned methods, although accurate, are fairly expensive, and therefore may not be
accessible in low-income countries. The Bilistick method is an in vitro point-of-care diagnostic method
for measuring TSB from capillary or venous blood samples [27]. This is a much cheaper method and
multiple studies have found it to be an accurate alternative [28,29]. The Bilistick method also has
the added advantage of having a much shorter turn-around-time (time interval between specimen
collection and reporting of TSB result) compared to serum measurement and even transcutaneous
measurement of bilirubin [27].
The bilirubin-induced neurological dysfunction (BIND) score is a nine-point scale assessing mental
status, muscle tones, and crying patterns (Table 1). A BIND score of 0 is normal, while BIND scores
1–3, 4–6, and 7–9 are meant to represent mild, moderate, and severe acute bilirubin encephalopathy,
respectively [30,31]. El Houchi et al. (2017) studied the ability of the BIND score to predict not only
neurologic and auditory disability, but also its relationship to total serum bilirubin concentration.
BIND scores of 220 term and near-term infants (117 boys, 103 girls; age range = 0.1 − 13.3 years) with
severe hyperbilirubinemia were obtained at 6- and 8-h intervals. Median highest total serum bilirubin
in this cohort was recorded at 29.7 mg/dL, with a range 17–61 mg/dL. The authors found that a BIND
score ≥4 had a specificity of 87.3% and sensitivity of 97.4% for predicting a poor neurologic outcome,
and a specificity and sensitivity of 87.3% and 92.6%, respectively, for predicting long-term hearing
impairment. It is worth noting, however, that four infants with total serum bilirubin levels ≥ 36 mg/dL
had BIND scores ≤3 and normal outcomes at follow-up, while one infant with a low BIND score
developed severe auditory neuropathy. Although a positive correlation between BIND scores and total
serum bilirubin was observed, the coefficient of determination was not very high (r2 = 0.54, p < 0.005).
However, they did demonstrate that the risk of severe acute bilirubin encephalopathy increased with
increasing total serum bilirubin, especially TSB above 30 mg/dL [30].
Table 1. BIND Score (Cited from Johnson et al. 2009 [31]).
Clinical Parameter BIND Score
Mental status
Normal 0
Sleep but arousable, decreased feeding 1
Lethargy, poor suck and/or irritable/jittery with strong suck 2
Semi-coma, unable to feed, seizures, coma 3
Muscle tone
Normal 0
Persistent mild to moderate hypotonia 1
Hypertonia alternating with hypotonia, beginning arching of
neck and trunk on stimulation 2
Persistent retrocollis and opisthotonos—bicycling or twitching
of hands and feet 3
Cry pattern
Normal 0
High pitched when aroused 1
Shrill, difficult to console 2
Inconsolable crying or cry weak or absent 3
TOTAL Sum of scores from each parameter
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4. Neuroimaging
Signal abnormalities are classically reported in the globus pallidus, hippocampus, and cerebellum,
but the nature of these signal abnormalities tends to vary with time. MRI studies of infants in
the first days to weeks following acute bilirubin encephalopathy onset (i.e., subacute phase) are
said to demonstrate an increased T1-signal in the globus pallidus and subthalamic nucleus, while
T2-weighted imaging of these regions is often unremarkable or shows subtle T2-hyperintensity [32,33].
In Wang et al.’s (2008) study involving 24 neonates (including two premature infants) who underwent
conventional MRI, the main findings were found to be an abnormal bilateral increased signal intensity
in the globus pallidus on T1-weighted images without apparent T2-signal changes for 19 of the 24
patients. Of these 19 patients, 10 of them had a high signal intensity on T1-weighted imaging, but
normal T2- signal in the subthalamic nucleus [32].
Interestingly, some authors report that the sensitivity and specificity of T1-signal changes to
predict kernicterus during the subacute phase is hindered by both the evolving nature of signal
abnormalities and confounding signal changes associated with normal myelination [34]. In infants
who later show clinical evidence of chronic bilirubin encephalopathy (i.e., kernicterus), the earliest MRI
changes tend to show a high T1-signal in the globus pallidus and subthalamic nucleus. It should be
noted that an increased T1-signal in these regions can also be seen as part of normal brain development,
such as myelination, and patients with kernicterus may also not necessarily show any abnormalities on
MRI [35]. Myelinated white matter tracts such as the internal capsule appear relatively hyperintense
on T1-weighted images, while grey matter structures such as the globus pallidus tend to be less
hyperintense on T1-weighted images because of the longer relaxation time [35]. Therefore, in infants
with incomplete myelination, the globus pallidus may appear brighter and may be confused as
pathologic increase in T1-signal intensity. Neuroimaging findings therefore need to be interpreted in
the context of obtained clinical history, neurological exam findings, and results of serum biomarkers.
The neuroimaging hallmark of kernicterus is said to be the bilateral and symmetric increase of the
T2- and/or FLAIR signal in the globus pallidus and subthalamic nucleus. An increased T2 signal may
also be seen in the substantia nigra of the midbrain and dentate nucleus of the cerebellum [33].
Data regarding findings from more advanced imaging techniques such as diffusion weighted
imaging (DWI) and MR spectroscopy (MRS) are still limited. Wisnowski et al. (2016) reported a
case of a 3400 g female neonate born at 41-weeks gestation who presented with jaundice before
24 h of life, followed by lethargy and poor feeding, and a total serum bilirubin of 28 mg/dL.
She underwent MRI, where DWI showed restricted diffusion in the superior thalamic radiations,
ventroanterior (VA), and ventrolateral (VL) nuclei of the thalamus, hippocampus, substantia nigra,
subthalamic nucleus, superior cerebellar peduncle, pontine nuclei, and dentate nucleus of the
cerebellum. Interestingly, no apparent diffusion restriction in the globus pallidus or descending
corticospinal tracts was appreciated. Apparent diffusion coefficient (ADC) images demonstrated
the acute involvement of selected white matter tracts, such as superior cerebellar peduncles and
superior thalamic radiations. In addition, 1H-MRS spectra acquired from the right thalamus revealed
elevated glutamate/glutamine concentrations [36]. These observations suggest the involvement of
cortico-ponto-cerebello-thalamo-cortical pathways. These pathways include descending projections
from the motor cortex to the pontine nuclei (i.e., cortico-pontine pathway), and ascending projections
from the dentate nucleus to the motor cortex (i.e., the dentato-thalmo-cortical pathway), with the
implication that bilirubin toxicity may target not just neurons, but white matter connections as well.
Some studies have suggested that proton (1H)-MRS studies of infants with acute bilirubin
encephalopathy and/or severe hyperbilirubinemia can demonstrate decreases in the ratios of
N-acetyl-aspartate (NAA) to choline, and NAA to creatine, as well as increases in the ratio of lactate
to NAA in the vicinity of the basal ganglia in neonates who go on to develop kernicterus [32,37,38].
Wu et al.’s (2013) study enrolled 11 patients in their neonatal bilirubin encephalopathy group, eight in
their neonatal hyperbilirubinemia group, and nine in their age-matched group, all of whom underwent
1H-MRS and conventional MRI studies using a 1.5 tesla whole body MR scanner. The authors observed
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NAA/Cr and NAA/Cho peak-area ratios in the basal ganglia to be much lower in the neonatal bilirubin
encephalopathy group than in the neonatal hyperbilirubinemia and control groups (p < 0.05). Their
study did not, however, show any statistically significant differences in the peak-ratios of NAA/Cr and
NAA/Cho in the basal ganglia between the neonatal hyperbilirubinemia and control groups (p > 0.05)
or in the thalamus between the three groups. There was also no statistically significant difference
observed in the Cho/Cr ratios in the basal ganglia and thalamus between the three groups [38]. These
findings suggest that 1H-MRS can be useful in differentiating infants who go onto develop kernicterus
versus those who have severe hyperbilirubinemia but do not go on to develop clinical sequelae. Further
research is required to formulate more concrete conclusions regarding the utility of these techniques in
the diagnosis of bilirubin encephalopathy and kernicterus.
5. Neuropathology
The most consistent abnormality reported in the literature is atrophy of the globus pallidus,
but the hippocampus, thalamus, hypothalamus, and subthalamic nucleus may also display atrophy.
Classic full-blown kernicterus typically leads to yellow discoloration of the basal ganglia, especially the
globus pallidus, and subthalamic nucleus (see Figure 1). Other susceptible areas include the thalamus,
mammillary bodies, CA2 sector of the hippocampus, subiculum, indusium griseum, and uncus.
Vulnerable areas in the brainstem include the substantia nigra, oculomotor nucleus, trochlear nucleus,
cochlear nucleus, vestibular nucleus, inferior colliculus, and superior olivary complex. Purkinje cells












Figure 1. Neuropathologic findings from a patient with kernicterus. (a) Yellowish discoloration of
subthalamic nucleus and hippocampus; (b) discoloration of medullary tegmentum, inferior olives,
and cerebellar tonsils; (c) cytoplasmic pigment in cells of choroid plexus (20× magnification); (d)
Alzheimer’s type II astrocytes (arrow) in keeping with liver failure (20× magnification).
On microscopic examination, the primary target of injury is neurons. Neuronal changes are
those of acute necrosis resembling that seen in hypoxic-ischemic encephalopathy and hypoglycemia.
Within a few days after injurious insult, these dead neurons may become encrusted with calcium
or iron. Neuronal damage can be found in the lateral and medial nucleus of the globus pallidus,
subthalamic nucleus, mammillary bodies, indusium griseum, hippocampus, nucleus of the third and
fourth cranial nerves, substantia nigra, and interstitial nucleus of Cajal. Chronic lesions, also referred
to as post-kernicteric encephalopathy, display necrosis, vacuolation of the cytoplasm, and prominent
neuronal loss, as well as gliosis in the globus pallidus, subthalamic nucleus, and hippocampus [40–42].
With regards to neuronal changes, the earliest (within the first several days of bilirubin-induced
injury) neuronal changes consist of swollen granular cytoplasm, often with microvacuolation and the
disruption of neuronal and nuclear membranes. Yellow pigment can be prominent within the neuronal
cytoplasm. By the end of the first week, dissolution of affected neurons becomes apparent, and nuclear
and plasma membranes become poorly defined. In subsequent days to weeks, neuronal loss, often
with mineralization, and astrocytosis can be observed. As in other causes of liver injury, Alzheimer’s
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type II astrocytes (Figure 1d) can be found throughout the deep grey matter structures, as well as the
neocortex, brainstem, and cerebellum [43–45].
Bilirubin staining is said to be best seen in fresh specimens or in frozen sections, especially in
infants who survive several days. The anatomic distribution of this staining includes the globus
pallidus, subthalamic nucleus, hippocampus (particularly CA2 and CA3 sectors), substantia nigra,
cranial nerve nuclei (particularly oculomotor, facial, vestibular, and cochlear nuclei), superior olivary
complex, nuclei of lateral lemniscus, inferior colliculus, reticular formation of pons, inferior olivary
nuclei, dentate nucleus of the cerebellum, and anterior horn cells of the spinal cord [43,44,46,47].
This period of prominent brain pigmentation lasts for approximately seven to 10 days, and is
accompanied by the commencement of neuronal changes that result in post-kernicteric bilirubin
encephalopathy [45,48]. We recently encountered a post-mortem case in our institution (not published)
in which pigment was found in cells of choroid plexus (Figure 1c). Brito et al. (2013), in their case
report of a 32-week old female with kernicterus, suggested that unconjugated bilirubin increases the
vascular density of brain regions associated with kernicterus, such as the hippocampus and corpus
striatum, while triggering VEGF and VEGFR-2 immunoreactivity, along with albumin extravasation
into the brain parenchyma [48].
White matter abnormalities have also been reported in premature infants with kernicterus. For
example, periventricular white matter injury in the form of periventricular leukomalacia has been
reported as a frequent occurrence in the context of kernicterus [49]. Our recent postmortem case (not
published) of kernicterus also showed evidence of chronic periventricular white matter injury typified
by the presence of gliosis, macrophages, and sparse microcalcification in the periventricular white
matter. With more diffuse periventricular white matter injury, ventriculomegaly and thinned corpus
callosum may be observed [49]. A case report from Brito et al. (2012) of a preterm (32 weeks five days,
weight = 1600 g) infant who passed away on the fourth day of life with a diagnosis of kernicterus
reported a poorer staining intensity of Luxol-fast blue-periodic acid Schiff in the cerebellar white matter
compared to an age-matched non-icteric cerebellum. This poor staining intensity indicated a decreased
density of myelinated fibres, in keeping with demyelination. Axonal integrity was further assessed
with Bodian-Luxol fast blue stain and revealed axons to be severely affected by hyperbilirubinemia
compared to the non-icteric brain [50]. Findings from in vivo and in vitro experiments seem to suggest
a decreased number of myelinated axons, decreased thickness of myelin sheaths, and less compact
axons with more debris in brains exposed to unconjugated bilirubin [51].
6. Management
Management of patients with kernicterus is directed towards neurodevelopmental sequelae,
which entails physical, occupational, speech, and audiological therapies; as well as complications
including nutritional difficulties, gastroesophageal reflux, sleep disturbances, hypertonicity, and
muscle cramps [12]. Established treatment strategies for acute bilirubin encephalopathy, on the
other hand, include phototherapy and exchange transfusion [16]. Traditionally, the decision to
start phototherapy has been based on birthweight because of the strong positive correlation that is
believed to exist between total serum bilirubin and birthweight [7,52]. Interestingly, a Japanese group
revised their treatment criteria for the treatment of preterm hyperbilirubinemic infants. The revisions
included classifying newborns based on gestational age at birth or corrected gestational age rather
than birthweight as it is gestational age at birth or corrected gestational age that is associated with
organ maturation. Additionally, the treatment options created were standard phototherapy, intensive
phototherapy, and albumin therapy and/or exchange transfusion. Finally, the decision to initiate any
of these therapies is based on the total serum bilirubin and unbound bilirubin reference values for
gestational age (in weeks) at birth for < 7 days after birth and > 7 days of age [53]. Measurement
of unbound bilirubin is still not easily achievable in other parts of the world. We believe that
further studies are necessary to accurately determine the efficacy of administering these therapies
based on bilirubin levels, as well as the bilirubin/albumin ratio. It has also been argued that the
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efficacy of treatments for acute bilirubin encephalopathy has generated overconfidence in the medical
environment about the management of severe hyperbilirubinemia [54]. This can lead to an increased
risk of neurological sequelae, even in western countries. Prevention of tragedies that can arise from
severe hyperbilirubinemia and kernicterus requires the implementation of evidence-based guidelines
for the management of neonatal jaundice [54]. What is also needed are more devices like the Bili-stick
that are relatively cheap, easy to use, and accurate for distinguishing between healthy children and
those at risk, especially for low-income countries where the prevalence of kernicterus is higher.
7. Conclusions
Herein, the authors have described the range of clinical, radiological, and neuropathological
changes features (summarized in Box 1) that can be encountered in patients with bilirubin
encephalopathy/kernicterus. Further research is required to accurately determine the efficacy
of available treatment options on various parameters, including total serum bilirubin levels and
bilirubin-albumin ratio, as well as whether other more innovative therapeutic options are possible.
Box 1. Key Concepts—Acute Bilirubin Encephalopathy (ABE) and Kernicterus.
Risk Factors:
Low gestational age, low birth weight, hemolysis, sepsis, cephalohematoma, easy bruising, exclusive
breast feeding.
Clinical Presentation:
ABE: feeding, lethargy, hypotonia and/or hypertonia, high-pitched cry, retrocollis and opisthotonus, setting sun
sign, fever, seizures, death.
Kernicterus: abnormal motor control, abnormal movements, abnormal muscle tone, oculomotor impairments,
enamel dysplasia, auditory complications.
Neuroimaging highlights:
ABE: Increased T1-signal intensity in globus pallidus and subthalamic nucleus.
Kernicterus: Increased T2/FLAIR signal intensity in globus pallidus and subthalamic nucleus; possible increased
T2-signal in substantia nigra and cerebellar dentate nucleus.
Neuropathological Findings:
- Atrophy of the globus pallidus, hippocampus, thalamus, hypothalamus, and subthalamic nucleus.
- Yellow discoloration of the basal ganglia, especially the globus pallidus and subthalamic nucleus.
- Neuronal necrosis followed by dissolution.
Management:
ABE: Phototherapy, exchange transfusion.
Kernicterus: Supportive management of neurological sequelae.
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Abstract: Sialidosis (MIM 256550) is a rare, autosomal recessive inherited disorder, caused by
α-N-acetyl neuraminidase deficiency resulting from a mutation in the neuraminidase gene (NEU1),
located on 6p21.33. This genetic alteration leads to abnormal intracellular accumulation as well as
urinary excretion of sialyloligosaccharides. A definitive diagnosis is made after the identification of a
mutation in the NEU1 gene. So far, 40 mutations of NEU1 have been reported. An association exists
between the impact of the individual mutations and the severity of clinical presentation of sialidosis.
According to the clinical symptoms, sialidosis has been divided into two subtypes with different ages
of onset and severity, including sialidosis type I (normomorphic or mild form) and sialidosis type
II (dysmorphic or severe form). Sialidosis II is further subdivided into (i) congenital; (ii) infantile;
and (iii) juvenile. Despite being uncommon, sialidosis has enormous clinical relevance due to its
debilitating character. A complete understanding of the underlying pathology remains a challenge,
which in turn limits the development of effective therapeutic strategies. Furthermore, in the last few
years, some atypical cases of sialidosis have been reported as well. We herein attempt to combine and
discuss the underlying molecular biology, the clinical features, and the morphological patterns of
sialidosis type I and II.
Keywords: sialidosis; neuraminidase; sialidosis I; sialidosis II; lysosomal storage disease; lysosomal
exocytosis
1. Introduction
Sialidosis, an autosomal recessive disorder, occurs due to a structural defect in the neuraminidase
gene and is characterized by abnormal tissue accumulation as well as urinary excretion of sialylated
oligosaccharides and glycolipids [1].
The human neuraminidase gene is located at chromosome band 6p21.3, where the HLA locus is
also reported to be located [2]. Until 1977, deficiency of Neuraminidase 1 (NEU1) was thought to be
associated with classical mucolipidosis I, a severe and rapidly progressive lysosomal storage disease
with onset at birth or shortly after birth [3,4]. In 1977, the term sialidosis was first used to describe the
syndrome of two siblings having a visual impairment and mild neurological manifestations that slowly
developed in their adolescence. Enzymatic assays in cultured fibroblasts and leukocytes from these
siblings exhibited an isolated deficiency of NEU1 [3,4]. Later, Sialidosis was classified into two types:
Sialidosis Type I (normomorphic) and Sialidosis Type II (dysmorphic) [5]. In this study, we review the
underlying genetics and molecular mechanisms of sialidosis and their correlation with clinical and
morphological findings.
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2. Background
Sialidase (neuraminidase, EC 3.2.1.18) catalyzes the hydrolysis of terminal sialic acid residues
of glycoconjugates. Sialidase has been extensively studied in viruses and bacteria. In these
microorganisms, its function is to destroy the sialic acid-containing receptors at the surface of host cells
to mobilize bacterial nutrients. In mammals, three types of sialidases have been reported, including
the lysosomal, plasma membrane, and cytosolic localized enzymes [1].
In human lysosomes, the degradation of complex macromolecular substrates requires the
synergistic action of multiple hydrolases that act synergistically to carry out the degradation process
of complex macromolecular substrates efficiently. One such efficient catalytic team is formed by
three hydrolases which are ubiquitous, but differentially expressed: the serine carboxypeptidase,
protective protein/cathepsin A (PPCA), the sialidase, Neuraminidase-1 (NEU1), and the glycosidase
β-Galactosidase (β-GAL) [6]. The different expression of three enzymes can be explained by the fact
that deficiency of each leads to three distinct lysosomal storage disorders (LSDs): galactosialidosis
(GS) or PPCA deficiency with a secondary combined deficiency of NEU1 and β-GAL, sialidosis or
NEU1 deficiency, and GM1-gangliosidosis (GM1) or β-GAL deficiency. Each disease is inherited as an
autosomal recessive trait and is distinguished by variable clinical phenotypes, ranging from congenital
forms to infantile/juvenile forms. All three present as a systemic disease, involving visceral organs,
bone, cartilage, muscle and the nervous system [6].
Catalytic activation of NEU1 is PPCA dependent: The function of NEU1 is to initiate the
catabolism glycoproteins and glycolipids, by cleaving their terminal sialic acids. For this, NEU1
depends on its interaction with the auxiliary protein protective protein/cathepsin A (PPCA). PPCA is
essential for the stability of NEU1 and acts as a molecular chaperone for the subcellular localization
and compartmentalization [7]. It can be assumed that NEU1 mutations that affect its interaction
with PPCA may also lead to disease, even if the residues forming the active site of the enzyme
remain intact [8]. In fact, researchers using the crystal structures of bacterial sialidases as templates
have investigated numerous NEU1 amino acid substitutions related to different clinical phenotypes.
Most of those substitutions appear to be located at the core surface of the molecule, demonstrating
that they may affect the interaction of NEU1 with its chaperone PPCA. Three pathogenic mutations,
F260Y, L270F, and A298V, gathered at the surface of the bacterial sialidases. These enzymes were
correctly synthesized yet degraded instantly since the resulting proteins failed to associate with
PPCA [9]. A putative region of interaction between NEU1 and PPCA was noticed after a careful study
of the hydrodynamic properties of these two proteins. This region appeared to be crucial for NEU1
binding to the precursor form of PPCA. Therefore, NEU1 mutations affecting amino acids within
this domain may affect the stability of the enzyme and subsequent PPCA-mediated transportation
to lysosomes [7–9]. It is crucial to remember that a primary defect of PPCA results in the lysosomal
disorder galactosialidosis [2]. The similarity in the clinical symptoms of these two disorders can
be attributed to the fact that the absence of functional PPCA results in a near-complete secondary
deficiency of NEU1 [10].
Mechanisms of Pathogenesis in Sialidosis explained with the help of the Mouse Model: The
Neu1−/− knockout (KO) mouse model is helpful in understanding the underlying molecular
mechanism(s) of sialidosis. Neu1−/− mice demonstrated NEU1 as a negative regulator of lysosomal
exocytosis. It was observed that in hematopoietic cells, NEU1 negatively regulates lysosomal exocytosis
by processing the sialic acids on the lysosomal membrane protein 1 (LAMP1). LAMP1 is an integral
membrane protein and plays a useful role in the docking of lysosomes at the plasma membrane (PM).
Deficiency or impaired NEU1 activity causes defective processing of the sialic acids on LAMP1, causing
accumulation of LAMP1 in an over-sialylated state with a prolonged half-life. This accumulation of
over-sialylated LAMP1 increases the number of LAMP1-marked lysosomes that dock at the PM, poised
to engage in lysosomal exocytosis upon an influx of calcium. LAMP1’s essential function in the docking
of lysosomes to the PM has been further supported by the fact that silencing LAMP1 in NEU1-deficient
cells normalize the number of lysosomes docked at the PM and thus decreased the extent of lysosomal
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exocytosis. Hence, NEU1 loss of function ultimately results in the excessive extracellular release of
lysosomal luminal contents from deficient cells of several tissues and organs (Figure 1). Excessive
lysosomal exocytosis has now been associated with various pathological manifestations which are
characteristic of sialidosis, including its role in neurodegeneration and links with Alzheimer’s disease,
hearing loss, muscle atrophy and splenomegaly [11]. Moreover, phagocytosis in macrophages, which is
regulated by NEU1, as well as NEU1-dependent regulation of insulin signaling are the other pathways
that have been considered as additional pathological mechanisms involved in the NEU1 loss of function
of the organs [12].
 
Figure 1. Schematic representation demonstrating downstream of NEU1 deficiency leads to LAMP1
accumulation causing an increased number of lysosomes at the plasmatic membrane (PM) resulting
in exacerbated lysosomal exocytosis. Lysosomal-associated membrane protein 1 (LAMP1), aka
lysosome-associated membrane glycoprotein 1 or CD107a, is a protein that in humans is determined
by the LAMP1 gene. This abnormal release of lysosomal content causes extracellular PM remodeling.
Hence changes in cell characteristics take place with subsequent organ pathogenesis.
3. Morphological and Clinical Aspects of Sialidosis and NEU1 Mutation(s)
3.1. Method of Study Selection, Criteria, and Data Extraction
Initially, an electronic search was done on Google Scholar, Scopus, and PUBMED. The search was
conducted between the time of January 1980 to January 2018. The words used were sialidosis I,
sialidosis II, congenital sialidosis, infantile sialidosis, juvenile sialidosis and combinations of
these words. In the next step, reference lists of the publications were checked to identify any
additional studies. The search was limited to studies published in English in the open literature
in peer-reviewed journals.
Cases of sialidosis I typically present later in life (second to third decade); therefore, sialidosis
I was discussed briefly in this study. However, for sialidosis II, all cases found were included in the
paper since this condition is present in the pediatric group of patients.
Sialidosis (MIM #256550) is known as an autosomal recessive inherited disease. However
numerous times, genetic alterations have been found in NEU1 of unrelated sialidosis patients. So
far, more than 40 mutations within the NEU1 gene have been identified in patients with sialidosis
types I and II. Age of onset and severity of the clinical manifestations are paralleled with NEU1
mutations and the level of residual neuraminidase activity, demonstrating the existence of significant
genotype-phenotype correlation in sialidosis.
NEU1 protein variants have been categorized into three groups based on biochemical properties.
In the first group, the mutant enzyme stays catalytically inactive and does not localize to the lysosomes;
whereas in the second group, the mutant protein localizes to the lysosomes yet is enzymatically inactive.
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Finally, in the third group, the mutant protein has residual activity and localizes to the lysosomes. An
association appears to exist between individual mutations and the clinical severity of sialidosis [7]. In
the least severe form of sialidosis, the modification is thought to cause a decrease in sialidase activity.
However, mutant sialidase has residual activity as well as localizing to the lysosomes. Hence, leading
to sialidosis I.
3.2. Sialidosis I
Also known as cherry-red spot myoclonus syndrome, type I sialidosis is the less severe,
non-neuropathic subtype of this disease. Patients typically exhibit symptoms in the second or
third decade of life. Symptoms may include gait abnormalities, decreased visual acuity, or both.
Patients usually have no physical defects. Their intelligence level may range from normal to
slightly impaired [13]. Myoclonus is an essential feature of sialidosis I, which over the course of
the disease tends to get disabling. Precipitating factors may include light touch, sound stimuli,
voluntary movements, passive joint movements, voluntary movements, and dysarthria. Action
myoclonus, intentional tremors, cerebellar ataxia, and hyperreflexia are the other commonly found
symptoms [14]. Muscle strength may remain normal. However, hypotonia can be seen. In some cases,
the patients may become wheelchair-bound as the disease progresses [7]. Laboratory tests for sialidosis
include a thin-layer chromatography test that is a useful screening test to find an abnormal urinary
oligosaccharide pattern. Peripheral blood smear or bone marrow smear may show the presence of
storage granules in lymphocytes. Deficiency of the lysosomal sialidase activity (neuraminidase) can be
demonstrated in cultured skin fibroblasts obtained from a skin biopsy and is an important diagnostic
step. Importantly, in enzymatic studies, sialidosis is differentiated from galactosialidosis by analyzing
the enzymatic activity of β-galactosidase which should be normal. The final diagnosis is made after
whole genome sequencing. As mentioned earlier, symptoms and their extent of severity are closely
associated with the type of NEU1 mutations involved and subsequently the levels of residual enzyme
activity [15].
Pathologically, cytoplasmic accumulation of sialyloligosaccharides has been observed in many
neurons in the central nervous systems (CNS) of sialidosis patients. Moreover, neuroradiological
imaging studies frequently reveal diffuse brain atrophy in the advanced stage of sialidosis type
I, particularly of the cerebellar area [16]. However, initial neuroradiological investigations can be
unremarkable in sialidosis 1. Studies also suggest that the major clinical effects seen are caused
by changes at a level above the brainstem [17–20]. Further investigation in this area will help in
understanding the underlying pathological mechanism which will consequently lead to the availability
of better therapeutic approaches.
Atypical Cases of Sialidosis I
In the last decade, one crucial observation regarding sialidosis I is the presence of isolated
instances of action myoclonus. Myoclonus, which is considered an essential feature of sialidosis I,
has been seen in patients in the absence of other classic symptoms (macular cherry-red spot and
sialyloligosacchariduria). After whole genome sequencing, mutations in NEU1 were identified. This
aspect elucidates the fact that mutations affecting NEU1 activity can exist in the absence of other
clinical signs that are characteristic of sialidosis [21]. This aspect warrants further studies in this area
to investigate if there are more cases of sialidosis I than initially predicted.
3.3. Sialidosis II
Based on the age at onset of the symptoms, type II sialidosis is further divided into three subtypes:
(i) congenital or hydropic (in utero); (ii) infantile (0–12 months); and (iii) juvenile (2–20 years) [7,22].
The congenital or hydropic subtype: Profoundly severe mutational alterations may lead to a
complete absence of lysosomal neuraminidase and are lethal during fetal development or at birth.
The congenital type of sialidosis, which is the severe form of the disease, is thought to be the result
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of such mutations. It manifests itself prenatally and is characterized by ascites and hydrops fetalis,
hepatomegaly and stillbirths or death at a very early age [7]. Table 1 summarizes the cases of congenital
sialidosis reported from 1979 until now (cases presented before 1979 can be found in a previous
review [5]). It can be observed that hydrops, ascites, and edema are the distinguishing features
of the severe, congenital group of the disease, followed by coarse features, dysostosis multiplex,
and hepatosplenomegaly. Renal involvement, cardiac anomalies, ophthalmic finding, myoclonus,
inguinal hernia, telangiectasias, petechiae, bluish to purpuric macules and hydrocephalus are the
clinical features that may infrequently manifest [9,22–46]. Studies reporting histopathological features
of congenital sialidosis are limited. In one study, light microscopy of fetal tissues (after pregnancy
was terminated at 20 weeks) exhibited vacuolation in the liver, bone marrow, kidney, and brain. In
addition, an abnormal pattern of vacuolations was also present in the endocrine organs such as the
thyroid gland, adrenal gland, hypophysis, testes as well as in the thymus. Moreover, vacuolation of
the placenta demonstrated that in congenital sialidosis abnormal storage takes place during the early
fetal period [36]. Figure 2 illustrates vacuolation of placenta, spleen, and thymus of a patient with
congenital sialidosis.
 
Figure 2. Microphotographs a–c showing the vacuolar degeneration of syncytium-trophoblast of a
placenta (Hematoxylin & Eosin staining, 400×), bone marrow (Hematoxylin & Eosin staining, 630×,
the arrow points to a cell with margination of the nucleus due to an engulfment of the cytoplasm with
undigested material), and thymus (Anti-CD68 immunostaining, 200× with the arrows highlighting the
macrophages) from a sialidosis pregnancy. The chromatogram in d shows the genetic alteration of the
sialidosis gene.
Infantile/juvenile subtype: It has been suggested that NEU1 mutations in which mutant enzymes
localize to the lysosomes yet stay enzymatically inactive lead to the infantile/juvenile subtype of
sialidosis II, which is characterized by the development of progressive mucopolysaccharidosis-like
phenotype; Patients presenting with coarse facies, visceromegaly, dysostosis multiplex, vertebral
deformities, mental retardation [7,47–55]. Table 2 summarizes the clinical features of the
infantile/juvenile subtype. Skeletal abnormalities, mainly dysostosis multiplex appear to be a
consistent feature of infantile/juvenile phenotypes, along with coarse facies, hepatosplenomegaly, and
severe mental retardation. Ocular manifestations, including cherry red spots, cataracts, nystagmus,
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strabismus, and corneal clouding are common as well while hypotonia, renal involvement, and
cardiac anomalies are relatively infrequent findings. It is noticeable that earlier onset of disease has
a fulminant course. While in late-onset, the patient may survive for more extended periods (only
four patients survived for more than two decades). Hearing loss and ataxia may present in the late
onset of infantile/juvenile form and tend to worsen with time. One case of sialidosis II was reported
in the last decade, in which the patient developed myoclonic seizures at the age of 17, followed by
dysphagia and dysphonia. There was a marked delay in motor and cognitive functions since childhood
which worsened over time. However, the patient was able to achieve an elementary school education.
At the time of diagnosis, the patient was 30 years old and bedridden, with an advanced degree of
mental deficiency. It is notable that the patient was able to achieve education demonstrates that her
cognitive delay was not as severe in childhood but progressed with age [55]. This detail seems essential
and may aid in future developing therapeutic interventions in this area. Also, it is noteworthy that
myoclonus, which is considered a characteristic of sialidosis I, is found in both Congenital as well as
Infantile/Juvenile subtypes. (Tables 1 and 2).
NEU1 knockout model Neu1−/− mice developed a systemic and neurodegenerative condition
that is comparable to the early onset of sialidosis II [10] thus helping in understanding the clinical
manifestation of this disease. Some typical clinical features that have been studied and explained are
as follows. Hepatosplenomegaly is a fairly standard feature in sialidosis II. Enlargement of the spleen
observed in Neu1−/−mice is consistent with this finding. Histological studies of spleens in mutant
mice showed a time-dependent expansion of total splenic cell counts along with an increased number
of erythroid precursors and megakaryocytes. Along with these changes in the spleen, an increased
number of hematopoietic progenitors in the peripheral blood and an overall lower number of these
cells in the bone marrow (BM) was found. Thus, indicating extramedullary hematopoiesis (EMH) as
the possible cause of splenic hypertrophy in Neu1−/−. Furthermore, immunohistochemical studies of
mutant livers showed a high number of erythroblasts, suggesting extramedullary hematopoiesis in
this organ as well. Pathological studies of livers revealed initial ballooning followed by progressive,
age-dependent filling of sinusoidal cells and hepatocytes with vacuoles [10]. Skeletal abnormalities
frequently occur in sialidosis II. According to researchers, a possible hypothesis explaining the
underlying pathogenesis is the impaired function of osteoclasts resulting in inefficient bone remodeling
and consequently leading to bone deformities [10]. Hearing loss is another feature of sialidosis II that
appears late in the disease. Studies of the (KO)model showed both conductive and neurosensory
defects contribute to hearing loss in Neu1−/− mice. It has been suggested that the absence of
NEU1 and the potential exacerbation of lysosomal exocytosis in the inner ear are responsible for
the occurrence of hearing the loss in Neu1−/− mice. Histopathological studies exhibited thickened,
cerumen occlusion in the external auditory canal, while in the middle ear infiltration of connective
tissue with signs of chronic inflammation was noticed. Also, in many cells of the extensive cochlea
vacuolization was seen [56]. In the brain, Neu1-null mice show extensive vacuolization of the epithelial
cells of the choroid plexus and the endothelial cells of the ependymal layer 31, 33. Microglia and
perivascular macrophages were among the most affected cells. This feature was prominently noticeable
in the dentate gyrus and the hippocampus, but these cells are also scattered throughout the cortex and
in the cerebellum, causing a widespread microgliosis [10]. Additionally, in the hippocampal region
of the Neu1-null mice, recent studies have suggested a link between NEU1 deficiency-exacerbated
lysosomal exocytosis and the spontaneous occurrence of Alzheimer’s disease (AD)-like amyloidogenic
process. Essentially accumulation in endo-lysosomes of an over sialylated amyloid precursor protein
(APP), which is a newly identified substrate of NEU1, initiates the process. Next Endo-lysosomal APP
is proteolytically cleaved to generate amyloid β-peptide isoforms (Aβ), which is ultimately released
extracellularly by excessive lysosomal exocytosis. The finding that intracranial injection of NEU1 in
the AD mouse model reduces the numbers of amyloid plaques and the levels of amyloid peptides is
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4. Therapeutic Interventions for Sialidosis
Due to the rarity of the disease, establishing optimum therapeutic measures remains a challenge
although many promising methods are being proposed and being investigated. One attempt of
enzyme replacement therapy (ERT) in Neu1−/− mice using a recombinant NEU1 enzyme purified
from overexpressing insect cells was made, which helped significantly in increasing levels of the NEU1
protein, and this treatment achieved subsequent correction of the underlying pathology in most of the
systemic organs. However, the recombinant protein turned out to be highly immunogenic in the mutant
mice and thus causes a severe immune response. Consequently, the therapeutic use of ERT became
restricted [58,59]. Another study investigated the efficacy of the immuno-suppressant (Celastrol) along
with a proteasomal inhibitor (MG132) as a therapeutic option for sialidosis. Researchers found that
MG132 enhances enzyme activity and its localization in cells expressing defective sialidase provided
promising results [60]. Additionally, chaperone-mediated gene therapy using a new mouse model has
been suggested. The new mouse model ubiquitously expresses a NEU1 variant, which has a V54M
amino acid substitution found in an adult patient with type I sialidosis. Mutant mice exhibited signs
of lysosomal disease after one year of age, with low residual NEU1 activity detected in most organs
and cell types. Injection of aged mutant mice with AAV-PPCA caused improvement of symptoms in
the disease phenotype, hence suggesting that some NEU1 mutations associated with type I sialidosis
may respond to PPCA-chaperone-mediated gene therapy [61]. Researchers believe that the treatment
may be useful for other NEU1 mutations, particularly those in patients with type I sialidosis [8].
5. Conclusions and Future Perspectives
Sialidosis is an autosomal recessive disease resulting due to a mutation in the neuraminidase
(NEU1) gene. Missense mutations appear to be the most commonly occurring. Among these mutations,
a significant molecular heterogeneity is present, with a mixed variety of clinical phenotypes presenting
either as sialidosis I or sialidosis II with different levels of severity. The onset of disease, the severity
of symptoms, and prognosis differ in sialidosis I and sialidosis II. Bonten et al. demonstrated that
this association between the clinical phenotype and severity of the disease is the result of the residual
activity of the mutant enzymes. Patients with type II disease have catalytic inactive neuraminidase,
while patients with the mild type I disease have active catalytic neuraminidase. In the type I disease,
there is an absence of any obvious physical defects, and life expectancy remains unaffected. However,
progressive visual loss and myoclonus, which may tend to get worse with time, can be disabling. In
type II, the congenital subtype takes a fulminant course with very low life expectancy. Ascites and
edema are the prominent features of this subgroup of the disease. In the infantile/juvenile sub type,
characteristic features include hepatosplenomegaly, dysostosis multiplex, coarse facies, cherry-red spot,
myoclonus, and severe mental retardation. Some clinical manifestations such as ataxia and hearing loss
may become progressively severe with age. In the last decade, atypical cases of sialidosis 1 have been
reported, and this aspect warrants further studies in this area to investigate if there are more cases of
sialidosis I than initially predicted. Furthermore, the possibility suggested by previous researchers that,
in addition to neuraminidase mutations, environmental factors including diet, prophylactic therapies,
or other genetic factors may have some effect on the penetrance and severity of the disease and/or
phenotype of the disease seems more plausible [7]. Perhaps in the future, a more detailed prenatal
history inquiring about the diet, medication, and different types of environmental exposure of parents
may help the researchers understand this aspect of the disease. Therapeutic options for sialidosis
remain limited. Researchers have emphasized exploring treatment options for sialidosis I [8]. In
sialidosis I, symptoms are relatively mild and appear late. Although intelligence level remains normal,
myoclonus can be debilitating. Therefore, effective therapy may improve quality of life. In sialidosis
type II patients, an early onset, systemic involvement, and a fulminant course make it more challenging
to provide treatment. Perhaps it would be worthwhile to explore the suggestion of taking an in utero
approach for therapy in the future. Alternatively, carrier detection in affected families, prenatal
molecular diagnosis, and improved genetic counseling seem to be a suitable practical approaches.
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Finally, NEU1 appears to have a crucial link with the CNS. Studies provide substantial evidence to
demonstrate the NEU1 enzyme has a correlation with Alzheimer’s disease. Further understanding of
NEU1 and its link with the CNS may provide useful information regarding genetics, pathogenesis,
and treatment of not only sialidosis, but also Alzheimer’s disease.
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